KR20220013311A - 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 - Google Patents
코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 Download PDFInfo
- Publication number
- KR20220013311A KR20220013311A KR1020210075095A KR20210075095A KR20220013311A KR 20220013311 A KR20220013311 A KR 20220013311A KR 1020210075095 A KR1020210075095 A KR 1020210075095A KR 20210075095 A KR20210075095 A KR 20210075095A KR 20220013311 A KR20220013311 A KR 20220013311A
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- gly
- coronavirus
- prt
- tyr
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 147
- 241000004176 Alphacoronavirus Species 0.000 title description 7
- 241000700605 Viruses Species 0.000 claims abstract description 148
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 112
- 241000711573 Coronaviridae Species 0.000 claims abstract description 90
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 88
- 201000010099 disease Diseases 0.000 claims abstract description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 48
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims abstract description 23
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 238000003745 diagnosis Methods 0.000 claims abstract description 6
- 101710198474 Spike protein Proteins 0.000 claims description 87
- 229940096437 Protein S Drugs 0.000 claims description 84
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 75
- 230000035772 mutation Effects 0.000 claims description 69
- 102220599672 Spindlin-1_D614G_mutation Human genes 0.000 claims description 56
- 241000315672 SARS coronavirus Species 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 50
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 38
- 208000025721 COVID-19 Diseases 0.000 claims description 30
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- 102100031673 Corneodesmosin Human genes 0.000 claims description 15
- 101710139375 Corneodesmosin Proteins 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102220599656 Spindlin-1_E484K_mutation Human genes 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 102220599422 Spindlin-1_L452R_mutation Human genes 0.000 claims description 5
- 102220599652 Spindlin-1_F490S_mutation Human genes 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229940127121 immunoconjugate Drugs 0.000 claims description 4
- 102220592182 Spindlin-1_A222V_mutation Human genes 0.000 claims description 3
- 102220599423 Spindlin-1_A475V_mutation Human genes 0.000 claims description 3
- 102220599414 Spindlin-1_N234Q_mutation Human genes 0.000 claims description 3
- 102220599655 Spindlin-1_S477N_mutation Human genes 0.000 claims description 3
- 102220599418 Spindlin-1_V1176F_mutation Human genes 0.000 claims description 3
- 102220599416 Spindlin-1_Y453F_mutation Human genes 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000012931 lyophilized formulation Substances 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229940071643 prefilled syringe Drugs 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 145
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 112
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 106
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 101
- 108010044940 alanylglutamine Proteins 0.000 description 68
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 59
- 108010073969 valyllysine Proteins 0.000 description 57
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 55
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 53
- FUKDBQGFSJUXGX-RWMBFGLXSA-N Lys-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)O FUKDBQGFSJUXGX-RWMBFGLXSA-N 0.000 description 51
- 108010003137 tyrosyltyrosine Proteins 0.000 description 51
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 50
- DPSUVAPLRQDWAO-YDHLFZDLSA-N Asn-Tyr-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)N)N DPSUVAPLRQDWAO-YDHLFZDLSA-N 0.000 description 50
- 108010068265 aspartyltyrosine Proteins 0.000 description 50
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 48
- ILKYYKRAULNYMS-JYJNAYRXSA-N Gln-Lys-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ILKYYKRAULNYMS-JYJNAYRXSA-N 0.000 description 48
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 47
- 235000001014 amino acid Nutrition 0.000 description 47
- KQFRUSHJPKXBMB-BHDSKKPTSA-N Ala-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 KQFRUSHJPKXBMB-BHDSKKPTSA-N 0.000 description 46
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 45
- PIQRHJQWEPWFJG-UWJYBYFXSA-N Ser-Tyr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PIQRHJQWEPWFJG-UWJYBYFXSA-N 0.000 description 45
- 108010027345 wheylin-1 peptide Proteins 0.000 description 45
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 43
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 41
- AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 40
- SLQVFYWBGNNOTK-BYULHYEWSA-N Ile-Gly-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N SLQVFYWBGNNOTK-BYULHYEWSA-N 0.000 description 40
- JPPLRQVZMZFOSX-UWJYBYFXSA-N Asn-Tyr-Ala Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 JPPLRQVZMZFOSX-UWJYBYFXSA-N 0.000 description 38
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 38
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 37
- VTFWAGGJDRSQFG-MELADBBJSA-N Tyr-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O VTFWAGGJDRSQFG-MELADBBJSA-N 0.000 description 37
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 description 36
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 35
- WSWWTQYHFCBKBT-DVJZZOLTSA-N Gly-Thr-Trp Chemical compound C[C@@H](O)[C@H](NC(=O)CN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O WSWWTQYHFCBKBT-DVJZZOLTSA-N 0.000 description 35
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 35
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 32
- 108010054812 diprotin A Proteins 0.000 description 32
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 32
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 31
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 31
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 31
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 30
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 30
- OVBMCNDKCWAXMZ-NAKRPEOUSA-N Val-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N OVBMCNDKCWAXMZ-NAKRPEOUSA-N 0.000 description 30
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 29
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 29
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 29
- FVKRQMQQFGBXHV-QXEWZRGKSA-N Met-Asp-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FVKRQMQQFGBXHV-QXEWZRGKSA-N 0.000 description 29
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 29
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 29
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 28
- JJGRJMKUOYXZRA-LPEHRKFASA-N Asn-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O JJGRJMKUOYXZRA-LPEHRKFASA-N 0.000 description 27
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 27
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 27
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 27
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 27
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 26
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 25
- BCNRNJWSRFDPTQ-HJWJTTGWSA-N Pro-Ile-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BCNRNJWSRFDPTQ-HJWJTTGWSA-N 0.000 description 25
- JQAWYCUUFIMTHE-WLTAIBSBSA-N Thr-Gly-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JQAWYCUUFIMTHE-WLTAIBSBSA-N 0.000 description 25
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 25
- 241000880493 Leptailurus serval Species 0.000 description 24
- NSTPFWRAIDTNGH-BZSNNMDCSA-N Tyr-Asn-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NSTPFWRAIDTNGH-BZSNNMDCSA-N 0.000 description 24
- 108010038745 tryptophylglycine Proteins 0.000 description 24
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 23
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 23
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 23
- VDCIPFYVCICPEC-FXQIFTODSA-N Asn-Arg-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O VDCIPFYVCICPEC-FXQIFTODSA-N 0.000 description 22
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 22
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 22
- 108010093581 aspartyl-proline Proteins 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 22
- YOBGUCWZPXJHTN-BQBZGAKWSA-N Gly-Ser-Arg Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YOBGUCWZPXJHTN-BQBZGAKWSA-N 0.000 description 21
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 21
- WYOBRXPIZVKNMF-IRXDYDNUSA-N Tyr-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 WYOBRXPIZVKNMF-IRXDYDNUSA-N 0.000 description 21
- DTPGSUQHUMELQB-GVARAGBVSA-N Ile-Tyr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 DTPGSUQHUMELQB-GVARAGBVSA-N 0.000 description 20
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 20
- GHAXJVNBAKGWEJ-AVGNSLFASA-N Gln-Ser-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GHAXJVNBAKGWEJ-AVGNSLFASA-N 0.000 description 19
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 19
- 125000000539 amino acid group Chemical group 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 19
- DNLQVHBBMPZUGJ-BQBZGAKWSA-N Arg-Ser-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O DNLQVHBBMPZUGJ-BQBZGAKWSA-N 0.000 description 18
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 18
- 241000282412 Homo Species 0.000 description 18
- NZOCIWKZUVUNDW-ZKWXMUAHSA-N Ile-Gly-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O NZOCIWKZUVUNDW-ZKWXMUAHSA-N 0.000 description 18
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 18
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 18
- OSFZCEQJLWCIBG-BZSNNMDCSA-N Ser-Tyr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSFZCEQJLWCIBG-BZSNNMDCSA-N 0.000 description 18
- GQEXFCQNAJHJTI-IHPCNDPISA-N Trp-Phe-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N GQEXFCQNAJHJTI-IHPCNDPISA-N 0.000 description 18
- AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 18
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 108010026333 seryl-proline Proteins 0.000 description 18
- OJNZVYSGVYLQIN-BQBZGAKWSA-N Gly-Met-Asp Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O OJNZVYSGVYLQIN-BQBZGAKWSA-N 0.000 description 17
- SVBAHOMTJRFSIC-SXTJYALSSA-N Ile-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SVBAHOMTJRFSIC-SXTJYALSSA-N 0.000 description 17
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 17
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 17
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 17
- RONJIBWTGKVKFY-HTUGSXCWSA-N Gln-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O RONJIBWTGKVKFY-HTUGSXCWSA-N 0.000 description 16
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 16
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 16
- GNNJKUYDWFIBTK-QWRGUYRKSA-N Gly-Tyr-Asp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O GNNJKUYDWFIBTK-QWRGUYRKSA-N 0.000 description 16
- PZAJPILZRFPYJJ-SRVKXCTJSA-N His-Ser-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O PZAJPILZRFPYJJ-SRVKXCTJSA-N 0.000 description 16
- VFJIWSJKZJTQII-SRVKXCTJSA-N Tyr-Asp-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O VFJIWSJKZJTQII-SRVKXCTJSA-N 0.000 description 16
- 108010087924 alanylproline Proteins 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 108010084389 glycyltryptophan Proteins 0.000 description 16
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 15
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 15
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 108010050848 glycylleucine Proteins 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 108010051242 phenylalanylserine Proteins 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 14
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 108010008355 arginyl-glutamine Proteins 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 108010016616 cysteinylglycine Proteins 0.000 description 14
- 108010087823 glycyltyrosine Proteins 0.000 description 14
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 14
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 13
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 13
- KBAPKNDWAGVGTH-IGISWZIWSA-N Ile-Ile-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KBAPKNDWAGVGTH-IGISWZIWSA-N 0.000 description 13
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 13
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 13
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 13
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 13
- QKDIHFHGHBYTKB-IHRRRGAJSA-N Pro-Ser-Phe Chemical compound N([C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 QKDIHFHGHBYTKB-IHRRRGAJSA-N 0.000 description 13
- CTLVSHXLRVEILB-UBHSHLNASA-N Ser-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N CTLVSHXLRVEILB-UBHSHLNASA-N 0.000 description 13
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 13
- NVPHRWNWTKYIST-BPNCWPANSA-N Arg-Tyr-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 NVPHRWNWTKYIST-BPNCWPANSA-N 0.000 description 12
- CXRWMMRLEMVSEH-PEFMBERDSA-N Glu-Ile-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O CXRWMMRLEMVSEH-PEFMBERDSA-N 0.000 description 12
- XUORRGAFUQIMLC-STQMWFEESA-N Gly-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O XUORRGAFUQIMLC-STQMWFEESA-N 0.000 description 12
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 12
- GXXTUIUYTWGPMV-FXQIFTODSA-N Ser-Arg-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O GXXTUIUYTWGPMV-FXQIFTODSA-N 0.000 description 12
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 12
- 108010077515 glycylproline Proteins 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108010084932 tryptophyl-proline Proteins 0.000 description 12
- LTCKTLYKRMCFOC-KKUMJFAQSA-N Asp-Phe-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LTCKTLYKRMCFOC-KKUMJFAQSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 11
- NKCZYEDZTKOFBG-GUBZILKMSA-N Gln-Gln-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NKCZYEDZTKOFBG-GUBZILKMSA-N 0.000 description 11
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 11
- GAFKBWKVXNERFA-QWRGUYRKSA-N Gly-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 GAFKBWKVXNERFA-QWRGUYRKSA-N 0.000 description 11
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 11
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 11
- ULIWFCCJIOEHMU-BQBZGAKWSA-N Pro-Gly-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 ULIWFCCJIOEHMU-BQBZGAKWSA-N 0.000 description 11
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 11
- 241001112090 Pseudovirus Species 0.000 description 11
- MQQBBLVOUUJKLH-HJPIBITLSA-N Ser-Ile-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MQQBBLVOUUJKLH-HJPIBITLSA-N 0.000 description 11
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 11
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 11
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 11
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 11
- 108010077245 asparaginyl-proline Proteins 0.000 description 11
- 108010049041 glutamylalanine Proteins 0.000 description 11
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 11
- 108010037850 glycylvaline Proteins 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- SFPRJVVDZNLUTG-OWLDWWDNSA-N Ala-Trp-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFPRJVVDZNLUTG-OWLDWWDNSA-N 0.000 description 10
- ATABBWFGOHKROJ-GUBZILKMSA-N Arg-Pro-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O ATABBWFGOHKROJ-GUBZILKMSA-N 0.000 description 10
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 10
- XLZCLJRGGMBKLR-PCBIJLKTSA-N Asn-Ile-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XLZCLJRGGMBKLR-PCBIJLKTSA-N 0.000 description 10
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 10
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 10
- ZBKUIQNCRIYVGH-SDDRHHMPSA-N Gln-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZBKUIQNCRIYVGH-SDDRHHMPSA-N 0.000 description 10
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 10
- RIPJMCFGQHGHNP-RHYQMDGZSA-N Lys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N)O RIPJMCFGQHGHNP-RHYQMDGZSA-N 0.000 description 10
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 10
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 10
- CRCHQCUINSOGFD-JBACZVJFSA-N Trp-Tyr-Glu Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N CRCHQCUINSOGFD-JBACZVJFSA-N 0.000 description 10
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 10
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 10
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 10
- 108010089804 glycyl-threonine Proteins 0.000 description 10
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 9
- PLNJUJGNLDSFOP-UWJYBYFXSA-N Asp-Tyr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PLNJUJGNLDSFOP-UWJYBYFXSA-N 0.000 description 9
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 9
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 9
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 9
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 9
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 9
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 9
- OJFFAQFRCVPHNN-JYBASQMISA-N Ser-Thr-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OJFFAQFRCVPHNN-JYBASQMISA-N 0.000 description 9
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 9
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 9
- 108010047495 alanylglycine Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- ALMIMUZAWTUNIO-BZSNNMDCSA-N Asp-Tyr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ALMIMUZAWTUNIO-BZSNNMDCSA-N 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- 238000009007 Diagnostic Kit Methods 0.000 description 8
- RBWKVOSARCFSQQ-FXQIFTODSA-N Gln-Gln-Ser Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O RBWKVOSARCFSQQ-FXQIFTODSA-N 0.000 description 8
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 8
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 8
- LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 8
- JMQFHZWESBGPFC-WDSKDSINSA-N Gly-Gln-Asp Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JMQFHZWESBGPFC-WDSKDSINSA-N 0.000 description 8
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 8
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 8
- SCJJPCQUJYPHRZ-BQBZGAKWSA-N Gly-Pro-Asn Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O SCJJPCQUJYPHRZ-BQBZGAKWSA-N 0.000 description 8
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- QLQHWWCSCLZUMA-KKUMJFAQSA-N Leu-Asp-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QLQHWWCSCLZUMA-KKUMJFAQSA-N 0.000 description 8
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 8
- 241000169446 Promethis Species 0.000 description 8
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 8
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 8
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 8
- AKLNEFNQWLHIGY-QWRGUYRKSA-N Tyr-Gly-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N)O AKLNEFNQWLHIGY-QWRGUYRKSA-N 0.000 description 8
- NOOMDULIORCDNF-IRXDYDNUSA-N Tyr-Gly-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NOOMDULIORCDNF-IRXDYDNUSA-N 0.000 description 8
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 8
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 8
- 239000003443 antiviral agent Substances 0.000 description 8
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000562 conjugate Substances 0.000 description 8
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 8
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 8
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 8
- 230000002285 radioactive effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 7
- 102100021277 Beta-secretase 2 Human genes 0.000 description 7
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 7
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 7
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 7
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 description 7
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 description 7
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 7
- FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 7
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 7
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 7
- SUZVLFWOCKHWET-CQDKDKBSSA-N Lys-Tyr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O SUZVLFWOCKHWET-CQDKDKBSSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 7
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 7
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 7
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 7
- NIEWSKWFURSECR-FOHZUACHSA-N Thr-Gly-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NIEWSKWFURSECR-FOHZUACHSA-N 0.000 description 7
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 7
- NGALWFGCOMHUSN-AVGNSLFASA-N Tyr-Gln-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NGALWFGCOMHUSN-AVGNSLFASA-N 0.000 description 7
- AGDDLOQMXUQPDY-BZSNNMDCSA-N Tyr-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O AGDDLOQMXUQPDY-BZSNNMDCSA-N 0.000 description 7
- RVGVIWNHABGIFH-IHRRRGAJSA-N Tyr-Val-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O RVGVIWNHABGIFH-IHRRRGAJSA-N 0.000 description 7
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 7
- 108010038633 aspartylglutamate Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000003449 preventive effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 108010048818 seryl-histidine Proteins 0.000 description 7
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 6
- AWPWHMVCSISSQK-QWRGUYRKSA-N Asp-Tyr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O AWPWHMVCSISSQK-QWRGUYRKSA-N 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- ZWABFSSWTSAMQN-KBIXCLLPSA-N Glu-Ile-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O ZWABFSSWTSAMQN-KBIXCLLPSA-N 0.000 description 6
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 6
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 6
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 6
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 6
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- DBVWMYGBVFCRBE-CIUDSAMLSA-N Leu-Asn-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DBVWMYGBVFCRBE-CIUDSAMLSA-N 0.000 description 6
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 6
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 6
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 6
- MQVFHOPCKNTHGT-MELADBBJSA-N Phe-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O MQVFHOPCKNTHGT-MELADBBJSA-N 0.000 description 6
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 6
- CXBFHZLODKPIJY-AAEUAGOBSA-N Ser-Gly-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N CXBFHZLODKPIJY-AAEUAGOBSA-N 0.000 description 6
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 6
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 6
- 102220590604 Spindlin-1_K417N_mutation Human genes 0.000 description 6
- 102220599406 Spindlin-1_N501Y_mutation Human genes 0.000 description 6
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 6
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 6
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 6
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 6
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 6
- 108010010147 glycylglutamine Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 238000000691 measurement method Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 229960000329 ribavirin Drugs 0.000 description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 6
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 5
- BFMIRJBURUXDRG-DLOVCJGASA-N Ala-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 BFMIRJBURUXDRG-DLOVCJGASA-N 0.000 description 5
- XKHLBBQNPSOGPI-GUBZILKMSA-N Ala-Val-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N XKHLBBQNPSOGPI-GUBZILKMSA-N 0.000 description 5
- USNSOPDIZILSJP-FXQIFTODSA-N Arg-Asn-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O USNSOPDIZILSJP-FXQIFTODSA-N 0.000 description 5
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 5
- NVWJMQNYLYWVNQ-BYULHYEWSA-N Asn-Ile-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O NVWJMQNYLYWVNQ-BYULHYEWSA-N 0.000 description 5
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 5
- DBWYWXNMZZYIRY-LPEHRKFASA-N Asp-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O DBWYWXNMZZYIRY-LPEHRKFASA-N 0.000 description 5
- MUWDILPCTSMUHI-ZLUOBGJFSA-N Asp-Asn-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)O MUWDILPCTSMUHI-ZLUOBGJFSA-N 0.000 description 5
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 5
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 5
- 101710150190 Beta-secretase 2 Proteins 0.000 description 5
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 5
- DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 description 5
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 5
- HPBKQFJXDUVNQV-FHWLQOOXSA-N Gln-Tyr-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O HPBKQFJXDUVNQV-FHWLQOOXSA-N 0.000 description 5
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 5
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 5
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 5
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 5
- FHGVHXCQMJWQPK-SRVKXCTJSA-N His-Lys-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O FHGVHXCQMJWQPK-SRVKXCTJSA-N 0.000 description 5
- 241000482741 Human coronavirus NL63 Species 0.000 description 5
- 241001428935 Human coronavirus OC43 Species 0.000 description 5
- OMDWJWGZGMCQND-CFMVVWHZSA-N Ile-Tyr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMDWJWGZGMCQND-CFMVVWHZSA-N 0.000 description 5
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108010079364 N-glycylalanine Proteins 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 5
- ICHZYBVODUVUKN-SRVKXCTJSA-N Ser-Asn-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ICHZYBVODUVUKN-SRVKXCTJSA-N 0.000 description 5
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 5
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 5
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 5
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 5
- GSCVDSBEYVGMJQ-SRVKXCTJSA-N Ser-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)O GSCVDSBEYVGMJQ-SRVKXCTJSA-N 0.000 description 5
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 5
- BIWBTRRBHIEVAH-IHPCNDPISA-N Ser-Tyr-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O BIWBTRRBHIEVAH-IHPCNDPISA-N 0.000 description 5
- JXKMXEBNZCKSDY-JIOCBJNQSA-N Thr-Asp-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O JXKMXEBNZCKSDY-JIOCBJNQSA-N 0.000 description 5
- BURPTJBFWIOHEY-UWJYBYFXSA-N Tyr-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BURPTJBFWIOHEY-UWJYBYFXSA-N 0.000 description 5
- MNMYOSZWCKYEDI-JRQIVUDYSA-N Tyr-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MNMYOSZWCKYEDI-JRQIVUDYSA-N 0.000 description 5
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 5
- USXYVSTVPHELAF-RCWTZXSCSA-N Val-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N)O USXYVSTVPHELAF-RCWTZXSCSA-N 0.000 description 5
- JSOXWWFKRJKTMT-WOPDTQHZSA-N Val-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N JSOXWWFKRJKTMT-WOPDTQHZSA-N 0.000 description 5
- 239000000611 antibody drug conjugate Substances 0.000 description 5
- 229940049595 antibody-drug conjugate Drugs 0.000 description 5
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108010018006 histidylserine Proteins 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 108010031719 prolyl-serine Proteins 0.000 description 5
- 108010053725 prolylvaline Proteins 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 5
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 4
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 4
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 4
- RCENDENBBJFJHZ-ACZMJKKPSA-N Asn-Asn-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCENDENBBJFJHZ-ACZMJKKPSA-N 0.000 description 4
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 4
- MYTHOBCLNIOFBL-SRVKXCTJSA-N Asn-Ser-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYTHOBCLNIOFBL-SRVKXCTJSA-N 0.000 description 4
- YSYTWUMRHSFODC-QWRGUYRKSA-N Asn-Tyr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O YSYTWUMRHSFODC-QWRGUYRKSA-N 0.000 description 4
- NECWUSYTYSIFNC-DLOVCJGASA-N Asp-Ala-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 NECWUSYTYSIFNC-DLOVCJGASA-N 0.000 description 4
- VAWNQIGQPUOPQW-ACZMJKKPSA-N Asp-Glu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VAWNQIGQPUOPQW-ACZMJKKPSA-N 0.000 description 4
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 4
- RVMXMLSYBTXCAV-VEVYYDQMSA-N Asp-Pro-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMXMLSYBTXCAV-VEVYYDQMSA-N 0.000 description 4
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- GPISLLFQNHELLK-DCAQKATOSA-N Gln-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N GPISLLFQNHELLK-DCAQKATOSA-N 0.000 description 4
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 4
- FTMLQFPULNGION-ZVZYQTTQSA-N Gln-Val-Trp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O FTMLQFPULNGION-ZVZYQTTQSA-N 0.000 description 4
- RSUVOPBMWMTVDI-XEGUGMAKSA-N Glu-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C)C(O)=O)=CNC2=C1 RSUVOPBMWMTVDI-XEGUGMAKSA-N 0.000 description 4
- VPKBCVUDBNINAH-GARJFASQSA-N Glu-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O VPKBCVUDBNINAH-GARJFASQSA-N 0.000 description 4
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 4
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 description 4
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 4
- IGBBXBFSLKRHJB-BZSNNMDCSA-N His-Lys-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 IGBBXBFSLKRHJB-BZSNNMDCSA-N 0.000 description 4
- 244000309467 Human Coronavirus Species 0.000 description 4
- 241001109669 Human coronavirus HKU1 Species 0.000 description 4
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- INCJJHQRZGQLFC-KBPBESRZSA-N Leu-Phe-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O INCJJHQRZGQLFC-KBPBESRZSA-N 0.000 description 4
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 4
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 4
- KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 4
- NRKNYPRRWXVELC-NQCBNZPSSA-N Phe-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)N NRKNYPRRWXVELC-NQCBNZPSSA-N 0.000 description 4
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 4
- FUVBEZJCRMHWEM-FXQIFTODSA-N Pro-Asn-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FUVBEZJCRMHWEM-FXQIFTODSA-N 0.000 description 4
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 4
- VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 4
- SPLBRAKYXGOFSO-UNQGMJICSA-N Pro-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2)O SPLBRAKYXGOFSO-UNQGMJICSA-N 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 4
- IDCKUIWEIZYVSO-WFBYXXMGSA-N Ser-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C)C(O)=O)=CNC2=C1 IDCKUIWEIZYVSO-WFBYXXMGSA-N 0.000 description 4
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 4
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 4
- MUARUIBTKQJKFY-WHFBIAKZSA-N Ser-Gly-Asp Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MUARUIBTKQJKFY-WHFBIAKZSA-N 0.000 description 4
- NBUKGEFVZJMSIS-XIRDDKMYSA-N Ser-His-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CO)N NBUKGEFVZJMSIS-XIRDDKMYSA-N 0.000 description 4
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 4
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 4
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 4
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 4
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 4
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 4
- IHAPJUHCZXBPHR-WZLNRYEVSA-N Thr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N IHAPJUHCZXBPHR-WZLNRYEVSA-N 0.000 description 4
- LXXCHJKHJYRMIY-FQPOAREZSA-N Thr-Tyr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O LXXCHJKHJYRMIY-FQPOAREZSA-N 0.000 description 4
- BKIOKSLLAAZYTC-KKHAAJSZSA-N Thr-Val-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O BKIOKSLLAAZYTC-KKHAAJSZSA-N 0.000 description 4
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 4
- AZBIIKDSDLVJAK-VHWLVUOQSA-N Trp-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N AZBIIKDSDLVJAK-VHWLVUOQSA-N 0.000 description 4
- SMLCYZYQFRTLCO-UWJYBYFXSA-N Tyr-Cys-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O SMLCYZYQFRTLCO-UWJYBYFXSA-N 0.000 description 4
- LMKKMCGTDANZTR-BZSNNMDCSA-N Tyr-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LMKKMCGTDANZTR-BZSNNMDCSA-N 0.000 description 4
- QFXVAFIHVWXXBJ-AVGNSLFASA-N Tyr-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O QFXVAFIHVWXXBJ-AVGNSLFASA-N 0.000 description 4
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 4
- GZWPQZDVTBZVEP-BZSNNMDCSA-N Tyr-Tyr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O GZWPQZDVTBZVEP-BZSNNMDCSA-N 0.000 description 4
- OJCISMMNNUNNJA-BZSNNMDCSA-N Tyr-Tyr-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 OJCISMMNNUNNJA-BZSNNMDCSA-N 0.000 description 4
- UUJHRSTVQCFDPA-UFYCRDLUSA-N Tyr-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 UUJHRSTVQCFDPA-UFYCRDLUSA-N 0.000 description 4
- ILMVQSHENUZYIZ-JYJNAYRXSA-N Val-Met-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N ILMVQSHENUZYIZ-JYJNAYRXSA-N 0.000 description 4
- JQTYTBPCSOAZHI-FXQIFTODSA-N Val-Ser-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N JQTYTBPCSOAZHI-FXQIFTODSA-N 0.000 description 4
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 4
- QHSSPPHOHJSTML-HOCLYGCPSA-N Val-Trp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N QHSSPPHOHJSTML-HOCLYGCPSA-N 0.000 description 4
- 108010041407 alanylaspartic acid Proteins 0.000 description 4
- 108010070944 alanylhistidine Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 4
- 108010085059 glutamyl-arginyl-proline Proteins 0.000 description 4
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 4
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 4
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 4
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 201000009240 nasopharyngitis Diseases 0.000 description 4
- 108010073101 phenylalanylleucine Proteins 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 238000012124 rapid diagnostic test Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010061238 threonyl-glycine Proteins 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000005723 virus inoculator Substances 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- GSCLWXDNIMNIJE-ZLUOBGJFSA-N Ala-Asp-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GSCLWXDNIMNIJE-ZLUOBGJFSA-N 0.000 description 3
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 3
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 3
- SFNFGFDRYJKZKN-XQXXSGGOSA-N Ala-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)N)O SFNFGFDRYJKZKN-XQXXSGGOSA-N 0.000 description 3
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 3
- RGQCNKIDEQJEBT-CQDKDKBSSA-N Ala-Leu-Tyr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 RGQCNKIDEQJEBT-CQDKDKBSSA-N 0.000 description 3
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 3
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 3
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 3
- MUGAESARFRGOTQ-IGNZVWTISA-N Ala-Tyr-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N MUGAESARFRGOTQ-IGNZVWTISA-N 0.000 description 3
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 3
- IIABBYGHLYWVOS-FXQIFTODSA-N Arg-Asn-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O IIABBYGHLYWVOS-FXQIFTODSA-N 0.000 description 3
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- GRRXPUAICOGISM-RWMBFGLXSA-N Arg-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O GRRXPUAICOGISM-RWMBFGLXSA-N 0.000 description 3
- PAPSMOYMQDWIOR-AVGNSLFASA-N Arg-Lys-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PAPSMOYMQDWIOR-AVGNSLFASA-N 0.000 description 3
- ADPACBMPYWJJCE-FXQIFTODSA-N Arg-Ser-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O ADPACBMPYWJJCE-FXQIFTODSA-N 0.000 description 3
- POOCJCRBHHMAOS-FXQIFTODSA-N Asn-Arg-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O POOCJCRBHHMAOS-FXQIFTODSA-N 0.000 description 3
- ACRYGQFHAQHDSF-ZLUOBGJFSA-N Asn-Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ACRYGQFHAQHDSF-ZLUOBGJFSA-N 0.000 description 3
- AITGTTNYKAWKDR-CIUDSAMLSA-N Asn-His-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O AITGTTNYKAWKDR-CIUDSAMLSA-N 0.000 description 3
- REQUGIWGOGSOEZ-ZLUOBGJFSA-N Asn-Ser-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N REQUGIWGOGSOEZ-ZLUOBGJFSA-N 0.000 description 3
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 3
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 3
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 3
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 3
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 3
- NALWOULWGHTVDA-UWVGGRQHSA-N Asp-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NALWOULWGHTVDA-UWVGGRQHSA-N 0.000 description 3
- BPAUXFVCSYQDQX-JRQIVUDYSA-N Asp-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)O)N)O BPAUXFVCSYQDQX-JRQIVUDYSA-N 0.000 description 3
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 3
- YNJBLTDKTMKEET-ZLUOBGJFSA-N Cys-Ser-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O YNJBLTDKTMKEET-ZLUOBGJFSA-N 0.000 description 3
- CLEFUAZULXANBU-MELADBBJSA-N Cys-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CS)N)C(=O)O CLEFUAZULXANBU-MELADBBJSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- RZSLYUUFFVHFRQ-FXQIFTODSA-N Gln-Ala-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O RZSLYUUFFVHFRQ-FXQIFTODSA-N 0.000 description 3
- ZFADFBPRMSBPOT-KKUMJFAQSA-N Gln-Arg-Phe Chemical compound N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O ZFADFBPRMSBPOT-KKUMJFAQSA-N 0.000 description 3
- GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 3
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 3
- FKXCBKCOSVIGCT-AVGNSLFASA-N Gln-Lys-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FKXCBKCOSVIGCT-AVGNSLFASA-N 0.000 description 3
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 3
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 3
- NTBDVNJIWCKURJ-ACZMJKKPSA-N Glu-Asp-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NTBDVNJIWCKURJ-ACZMJKKPSA-N 0.000 description 3
- FGSGPLRPQCZBSQ-AVGNSLFASA-N Glu-Phe-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O FGSGPLRPQCZBSQ-AVGNSLFASA-N 0.000 description 3
- JPXNYFOHTHSREU-UWVGGRQHSA-N Gly-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN JPXNYFOHTHSREU-UWVGGRQHSA-N 0.000 description 3
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 3
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 3
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 3
- FUTAPPOITCCWTH-WHFBIAKZSA-N Gly-Asp-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FUTAPPOITCCWTH-WHFBIAKZSA-N 0.000 description 3
- QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 3
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 3
- FQKKPCWTZZEDIC-XPUUQOCRSA-N Gly-His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 FQKKPCWTZZEDIC-XPUUQOCRSA-N 0.000 description 3
- HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 description 3
- TWTPDFFBLQEBOE-IUCAKERBSA-N Gly-Leu-Gln Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O TWTPDFFBLQEBOE-IUCAKERBSA-N 0.000 description 3
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 3
- LBDXVCBAJJNJNN-WHFBIAKZSA-N Gly-Ser-Cys Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O LBDXVCBAJJNJNN-WHFBIAKZSA-N 0.000 description 3
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 3
- FFALDIDGPLUDKV-ZDLURKLDSA-N Gly-Thr-Ser Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O FFALDIDGPLUDKV-ZDLURKLDSA-N 0.000 description 3
- PYFIQROSWQERAS-LBPRGKRZSA-N Gly-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(=O)NCC(O)=O)=CNC2=C1 PYFIQROSWQERAS-LBPRGKRZSA-N 0.000 description 3
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- DRKZDEFADVYTLU-AVGNSLFASA-N His-Val-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O DRKZDEFADVYTLU-AVGNSLFASA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 3
- FJWYJQRCVNGEAQ-ZPFDUUQYSA-N Ile-Asn-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N FJWYJQRCVNGEAQ-ZPFDUUQYSA-N 0.000 description 3
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 3
- LWWILHPVAKKLQS-QXEWZRGKSA-N Ile-Gly-Met Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N LWWILHPVAKKLQS-QXEWZRGKSA-N 0.000 description 3
- ZLFNNVATRMCAKN-ZKWXMUAHSA-N Ile-Ser-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZLFNNVATRMCAKN-ZKWXMUAHSA-N 0.000 description 3
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 3
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 3
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 3
- WUFYAPWIHCUMLL-CIUDSAMLSA-N Leu-Asn-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O WUFYAPWIHCUMLL-CIUDSAMLSA-N 0.000 description 3
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 3
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 3
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 3
- IRNSXVOWSXSULE-DCAQKATOSA-N Lys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN IRNSXVOWSXSULE-DCAQKATOSA-N 0.000 description 3
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 3
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 3
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 3
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 3
- ALEVUGKHINJNIF-QEJZJMRPSA-N Lys-Phe-Ala Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 ALEVUGKHINJNIF-QEJZJMRPSA-N 0.000 description 3
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 3
- SJDQOYTYNGZZJX-SRVKXCTJSA-N Met-Glu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SJDQOYTYNGZZJX-SRVKXCTJSA-N 0.000 description 3
- RAAVFTFEAUAVIY-DCAQKATOSA-N Met-Glu-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N RAAVFTFEAUAVIY-DCAQKATOSA-N 0.000 description 3
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- CMHTUJQZQXFNTQ-OEAJRASXSA-N Phe-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)O CMHTUJQZQXFNTQ-OEAJRASXSA-N 0.000 description 3
- GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 3
- APIAILHCTSBGLU-JYJNAYRXSA-N Pro-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@@H]2CCCN2 APIAILHCTSBGLU-JYJNAYRXSA-N 0.000 description 3
- XYAFCOJKICBRDU-JYJNAYRXSA-N Pro-Phe-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O XYAFCOJKICBRDU-JYJNAYRXSA-N 0.000 description 3
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 3
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 3
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 3
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 3
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 3
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 3
- XVAUJOAYHWWNQF-ZLUOBGJFSA-N Ser-Asn-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O XVAUJOAYHWWNQF-ZLUOBGJFSA-N 0.000 description 3
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 3
- SFZKGGOGCNQPJY-CIUDSAMLSA-N Ser-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N SFZKGGOGCNQPJY-CIUDSAMLSA-N 0.000 description 3
- JFWDJFULOLKQFY-QWRGUYRKSA-N Ser-Gly-Phe Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JFWDJFULOLKQFY-QWRGUYRKSA-N 0.000 description 3
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 3
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 3
- GZGFSPWOMUKKCV-NAKRPEOUSA-N Ser-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO GZGFSPWOMUKKCV-NAKRPEOUSA-N 0.000 description 3
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 3
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 3
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 3
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 3
- RTXKJFWHEBTABY-IHPCNDPISA-N Ser-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CO)N RTXKJFWHEBTABY-IHPCNDPISA-N 0.000 description 3
- HAUVENOGHPECML-BPUTZDHNSA-N Ser-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 HAUVENOGHPECML-BPUTZDHNSA-N 0.000 description 3
- IAOHCSQDQDWRQU-GUBZILKMSA-N Ser-Val-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IAOHCSQDQDWRQU-GUBZILKMSA-N 0.000 description 3
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 3
- GLQFKOVWXPPFTP-VEVYYDQMSA-N Thr-Arg-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GLQFKOVWXPPFTP-VEVYYDQMSA-N 0.000 description 3
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 3
- VEIKMWOMUYMMMK-FCLVOEFKSA-N Thr-Phe-Phe Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 VEIKMWOMUYMMMK-FCLVOEFKSA-N 0.000 description 3
- MUAFDCVOHYAFNG-RCWTZXSCSA-N Thr-Pro-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MUAFDCVOHYAFNG-RCWTZXSCSA-N 0.000 description 3
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 3
- OLFOOYQTTQSSRK-UNQGMJICSA-N Thr-Pro-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLFOOYQTTQSSRK-UNQGMJICSA-N 0.000 description 3
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 3
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 3
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 3
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 3
- RERIQEJUYCLJQI-QRTARXTBSA-N Trp-Asp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N RERIQEJUYCLJQI-QRTARXTBSA-N 0.000 description 3
- FEZASNVQLJQBHW-CABZTGNLSA-N Trp-Gly-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O)=CNC2=C1 FEZASNVQLJQBHW-CABZTGNLSA-N 0.000 description 3
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 3
- SAKLWFSRZTZQAJ-GQGQLFGLSA-N Trp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N SAKLWFSRZTZQAJ-GQGQLFGLSA-N 0.000 description 3
- UJGDFQRPYGJBEH-AAEUAGOBSA-N Trp-Ser-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N UJGDFQRPYGJBEH-AAEUAGOBSA-N 0.000 description 3
- ZKVANNIVSDOQMG-HKUYNNGSSA-N Trp-Tyr-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)NCC(=O)O)N ZKVANNIVSDOQMG-HKUYNNGSSA-N 0.000 description 3
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 3
- PZXUIGWOEWWFQM-SRVKXCTJSA-N Tyr-Asn-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O PZXUIGWOEWWFQM-SRVKXCTJSA-N 0.000 description 3
- WPVGRKLNHJJCEN-BZSNNMDCSA-N Tyr-Asp-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WPVGRKLNHJJCEN-BZSNNMDCSA-N 0.000 description 3
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 3
- XYNFFTNEQDWZNY-ULQDDVLXSA-N Tyr-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N XYNFFTNEQDWZNY-ULQDDVLXSA-N 0.000 description 3
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 3
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 description 3
- QRCBQDPRKMYTMB-IHPCNDPISA-N Tyr-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N QRCBQDPRKMYTMB-IHPCNDPISA-N 0.000 description 3
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 3
- WKWJJQZZZBBWKV-JYJNAYRXSA-N Val-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WKWJJQZZZBBWKV-JYJNAYRXSA-N 0.000 description 3
- OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 3
- XEYUMGGWQCIWAR-XVKPBYJWSA-N Val-Gln-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N XEYUMGGWQCIWAR-XVKPBYJWSA-N 0.000 description 3
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 3
- BZWUSZGQOILYEU-STECZYCISA-N Val-Ile-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BZWUSZGQOILYEU-STECZYCISA-N 0.000 description 3
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 3
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 3
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 3
- LZRWTJSPTJSWDN-FKBYEOEOSA-N Val-Trp-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N LZRWTJSPTJSWDN-FKBYEOEOSA-N 0.000 description 3
- CFIBZQOLUDURST-IHRRRGAJSA-N Val-Tyr-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)N CFIBZQOLUDURST-IHRRRGAJSA-N 0.000 description 3
- GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 3
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 108010085325 histidylproline Proteins 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 108010038320 lysylphenylalanine Proteins 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229940051283 regdanvimab Drugs 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 2
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 2
- SIGTYDNEPYEXGK-ZANVPECISA-N Ala-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 SIGTYDNEPYEXGK-ZANVPECISA-N 0.000 description 2
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 2
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 2
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 2
- GMGWOTQMUKYZIE-UBHSHLNASA-N Ala-Pro-Phe Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GMGWOTQMUKYZIE-UBHSHLNASA-N 0.000 description 2
- UCDOXFBTMLKASE-HERUPUMHSA-N Ala-Ser-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N UCDOXFBTMLKASE-HERUPUMHSA-N 0.000 description 2
- SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 2
- AOAKQKVICDWCLB-UWJYBYFXSA-N Ala-Tyr-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N AOAKQKVICDWCLB-UWJYBYFXSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- OCOZPTHLDVSFCZ-BPUTZDHNSA-N Arg-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N OCOZPTHLDVSFCZ-BPUTZDHNSA-N 0.000 description 2
- LKDHUGLXOHYINY-XUXIUFHCSA-N Arg-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LKDHUGLXOHYINY-XUXIUFHCSA-N 0.000 description 2
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 2
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 2
- OVQJAKFLFTZDNC-GUBZILKMSA-N Arg-Pro-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O OVQJAKFLFTZDNC-GUBZILKMSA-N 0.000 description 2
- CNBIWSCSSCAINS-UFYCRDLUSA-N Arg-Tyr-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CNBIWSCSSCAINS-UFYCRDLUSA-N 0.000 description 2
- NTXNUXPCNRDMAF-WFBYXXMGSA-N Asn-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC(N)=O)C)C(O)=O)=CNC2=C1 NTXNUXPCNRDMAF-WFBYXXMGSA-N 0.000 description 2
- ACKNRKFVYUVWAC-ZPFDUUQYSA-N Asn-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ACKNRKFVYUVWAC-ZPFDUUQYSA-N 0.000 description 2
- RBOBTTLFPRSXKZ-BZSNNMDCSA-N Asn-Phe-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RBOBTTLFPRSXKZ-BZSNNMDCSA-N 0.000 description 2
- UYCPJVYQYARFGB-YDHLFZDLSA-N Asn-Phe-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O UYCPJVYQYARFGB-YDHLFZDLSA-N 0.000 description 2
- YQPSDMUGFKJZHR-QRTARXTBSA-N Asn-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)N YQPSDMUGFKJZHR-QRTARXTBSA-N 0.000 description 2
- DXHINQUXBZNUCF-MELADBBJSA-N Asn-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O DXHINQUXBZNUCF-MELADBBJSA-N 0.000 description 2
- KNMRXHIAVXHCLW-ZLUOBGJFSA-N Asp-Asn-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O KNMRXHIAVXHCLW-ZLUOBGJFSA-N 0.000 description 2
- OMMIEVATLAGRCK-BYPYZUCNSA-N Asp-Gly-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)NCC(O)=O OMMIEVATLAGRCK-BYPYZUCNSA-N 0.000 description 2
- IVPNEDNYYYFAGI-GARJFASQSA-N Asp-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N IVPNEDNYYYFAGI-GARJFASQSA-N 0.000 description 2
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 2
- RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 description 2
- GYNUXDMCDILYIQ-QRTARXTBSA-N Asp-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N GYNUXDMCDILYIQ-QRTARXTBSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- NXQCSPVUPLUTJH-WHFBIAKZSA-N Cys-Ser-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O NXQCSPVUPLUTJH-WHFBIAKZSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 241000008920 Gammacoronavirus Species 0.000 description 2
- WLODHVXYKYHLJD-ACZMJKKPSA-N Gln-Asp-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N WLODHVXYKYHLJD-ACZMJKKPSA-N 0.000 description 2
- WVUZERSNWGUKJY-BPUTZDHNSA-N Gln-Glu-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N WVUZERSNWGUKJY-BPUTZDHNSA-N 0.000 description 2
- MLSKFHLRFVGNLL-WDCWCFNPSA-N Gln-Leu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MLSKFHLRFVGNLL-WDCWCFNPSA-N 0.000 description 2
- UESYBOXFJWJVSB-AVGNSLFASA-N Gln-Phe-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O UESYBOXFJWJVSB-AVGNSLFASA-N 0.000 description 2
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 2
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 2
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 2
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 2
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 2
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 2
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 2
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 2
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 2
- OCQUNKSFDYDXBG-QXEWZRGKSA-N Gly-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OCQUNKSFDYDXBG-QXEWZRGKSA-N 0.000 description 2
- GNBMOZPQUXTCRW-STQMWFEESA-N Gly-Asn-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)CN)C(O)=O)=CNC2=C1 GNBMOZPQUXTCRW-STQMWFEESA-N 0.000 description 2
- PDAWDNVHMUKWJR-ZETCQYMHSA-N Gly-Gly-His Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 PDAWDNVHMUKWJR-ZETCQYMHSA-N 0.000 description 2
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 2
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 2
- BMWFDYIYBAFROD-WPRPVWTQSA-N Gly-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN BMWFDYIYBAFROD-WPRPVWTQSA-N 0.000 description 2
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 2
- HUFUVTYGPOUCBN-MBLNEYKQSA-N Gly-Thr-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HUFUVTYGPOUCBN-MBLNEYKQSA-N 0.000 description 2
- FOKISINOENBSDM-WLTAIBSBSA-N Gly-Thr-Tyr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FOKISINOENBSDM-WLTAIBSBSA-N 0.000 description 2
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 2
- WTUSRDZLLWGYAT-KCTSRDHCSA-N Gly-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN WTUSRDZLLWGYAT-KCTSRDHCSA-N 0.000 description 2
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 2
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 2
- NHJKZMDIMMTVCK-QXEWZRGKSA-N Ile-Gly-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N NHJKZMDIMMTVCK-QXEWZRGKSA-N 0.000 description 2
- FXJLRZFMKGHYJP-CFMVVWHZSA-N Ile-Tyr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FXJLRZFMKGHYJP-CFMVVWHZSA-N 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 2
- LAGPXKYZCCTSGQ-JYJNAYRXSA-N Leu-Glu-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LAGPXKYZCCTSGQ-JYJNAYRXSA-N 0.000 description 2
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 2
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 2
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 2
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 2
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 2
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 2
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 101710164702 Major outer membrane protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVOKRHYSSFPHC-STECZYCISA-N Met-Ile-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFVOKRHYSSFPHC-STECZYCISA-N 0.000 description 2
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 2
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 description 2
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 2
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 2
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 2
- ZSKJPKFTPQCPIH-RCWTZXSCSA-N Pro-Arg-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSKJPKFTPQCPIH-RCWTZXSCSA-N 0.000 description 2
- RETPETNFPLNLRV-JYJNAYRXSA-N Pro-Asn-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O RETPETNFPLNLRV-JYJNAYRXSA-N 0.000 description 2
- ILMLVTGTUJPQFP-FXQIFTODSA-N Pro-Asp-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ILMLVTGTUJPQFP-FXQIFTODSA-N 0.000 description 2
- DEDANIDYQAPTFI-IHRRRGAJSA-N Pro-Asp-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DEDANIDYQAPTFI-IHRRRGAJSA-N 0.000 description 2
- LNOWDSPAYBWJOR-PEDHHIEDSA-N Pro-Ile-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LNOWDSPAYBWJOR-PEDHHIEDSA-N 0.000 description 2
- QAAYIXYLEMRULP-SRVKXCTJSA-N Pro-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 QAAYIXYLEMRULP-SRVKXCTJSA-N 0.000 description 2
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 description 2
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 2
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 2
- VVAWNPIOYXAMAL-KJEVXHAQSA-N Pro-Thr-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VVAWNPIOYXAMAL-KJEVXHAQSA-N 0.000 description 2
- HOJUNFDJDAPVBI-BZSNNMDCSA-N Pro-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3 HOJUNFDJDAPVBI-BZSNNMDCSA-N 0.000 description 2
- CWZUFLWPEFHWEI-IHRRRGAJSA-N Pro-Tyr-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O CWZUFLWPEFHWEI-IHRRRGAJSA-N 0.000 description 2
- IIRBTQHFVNGPMQ-AVGNSLFASA-N Pro-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 IIRBTQHFVNGPMQ-AVGNSLFASA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 2
- OBXVZEAMXFSGPU-FXQIFTODSA-N Ser-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)CN=C(N)N OBXVZEAMXFSGPU-FXQIFTODSA-N 0.000 description 2
- KNZQGAUEYZJUSQ-ZLUOBGJFSA-N Ser-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N KNZQGAUEYZJUSQ-ZLUOBGJFSA-N 0.000 description 2
- QKQDTEYDEIJPNK-GUBZILKMSA-N Ser-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO QKQDTEYDEIJPNK-GUBZILKMSA-N 0.000 description 2
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 2
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 2
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 2
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 2
- LPSKHZWBQONOQJ-XIRDDKMYSA-N Ser-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N LPSKHZWBQONOQJ-XIRDDKMYSA-N 0.000 description 2
- WNDUPCKKKGSKIQ-CIUDSAMLSA-N Ser-Pro-Gln Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O WNDUPCKKKGSKIQ-CIUDSAMLSA-N 0.000 description 2
- QUGRFWPMPVIAPW-IHRRRGAJSA-N Ser-Pro-Phe Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QUGRFWPMPVIAPW-IHRRRGAJSA-N 0.000 description 2
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 description 2
- BVLGVLWFIZFEAH-BPUTZDHNSA-N Ser-Pro-Trp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O BVLGVLWFIZFEAH-BPUTZDHNSA-N 0.000 description 2
- XGQKSRGHEZNWIS-IHRRRGAJSA-N Ser-Pro-Tyr Chemical compound N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O XGQKSRGHEZNWIS-IHRRRGAJSA-N 0.000 description 2
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 2
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 2
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 2
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 2
- HAYADTTXNZFUDM-IHRRRGAJSA-N Ser-Tyr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HAYADTTXNZFUDM-IHRRRGAJSA-N 0.000 description 2
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 2
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102220590605 Spindlin-1_K417T_mutation Human genes 0.000 description 2
- 102220642430 Spindlin-1_P681R_mutation Human genes 0.000 description 2
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 2
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 2
- SIMKLINEDYOTKL-MBLNEYKQSA-N Thr-His-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C)C(=O)O)N)O SIMKLINEDYOTKL-MBLNEYKQSA-N 0.000 description 2
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 2
- JWQNAFHCXKVZKZ-UVOCVTCTSA-N Thr-Lys-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWQNAFHCXKVZKZ-UVOCVTCTSA-N 0.000 description 2
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 2
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 2
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 2
- IQPWNQRRAJHOKV-KATARQTJSA-N Thr-Ser-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN IQPWNQRRAJHOKV-KATARQTJSA-N 0.000 description 2
- YRJOLUDFVAUXLI-GSSVUCPTSA-N Thr-Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O YRJOLUDFVAUXLI-GSSVUCPTSA-N 0.000 description 2
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 2
- UKINEYBQXPMOJO-UBHSHLNASA-N Trp-Asn-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N UKINEYBQXPMOJO-UBHSHLNASA-N 0.000 description 2
- XOLLWQIBBLBAHQ-WDSOQIARSA-N Trp-Pro-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O XOLLWQIBBLBAHQ-WDSOQIARSA-N 0.000 description 2
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 2
- UMXSDHPSMROQRB-YJRXYDGGSA-N Tyr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O UMXSDHPSMROQRB-YJRXYDGGSA-N 0.000 description 2
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 2
- IYHNBRUWVBIVJR-IHRRRGAJSA-N Tyr-Gln-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 IYHNBRUWVBIVJR-IHRRRGAJSA-N 0.000 description 2
- BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 2
- VYQQQIRHIFALGE-UWJYBYFXSA-N Tyr-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VYQQQIRHIFALGE-UWJYBYFXSA-N 0.000 description 2
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 2
- CVUDMNSZAIZFAE-TUAOUCFPSA-N Val-Arg-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N CVUDMNSZAIZFAE-TUAOUCFPSA-N 0.000 description 2
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 2
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 description 2
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 2
- YDVDTCJGBBJGRT-GUBZILKMSA-N Val-Met-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N YDVDTCJGBBJGRT-GUBZILKMSA-N 0.000 description 2
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 2
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 2
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 2
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 108010068380 arginylarginine Proteins 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- 108010009297 diglycyl-histidine Proteins 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 108010050343 histidyl-alanyl-glutamine Proteins 0.000 description 2
- 108010036413 histidylglycine Proteins 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003317 immunochromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 239000002923 metal particle Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010079317 prolyl-tyrosine Proteins 0.000 description 2
- 108010015796 prolylisoleucine Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- 108010077037 tyrosyl-tyrosyl-phenylalanine Proteins 0.000 description 2
- 108010078580 tyrosylleucine Proteins 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 1
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 1
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- OIUCUUXSMIJSEB-QPLCGJKRSA-N 4-[(z)-4-chloro-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC(O)=CC=1)=C(\CCCl)C1=CC=CC=C1 OIUCUUXSMIJSEB-QPLCGJKRSA-N 0.000 description 1
- 108010036211 5-HT-moduline Proteins 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- DKJPOZOEBONHFS-ZLUOBGJFSA-N Ala-Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O DKJPOZOEBONHFS-ZLUOBGJFSA-N 0.000 description 1
- SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 description 1
- KVWLTGNCJYDJET-LSJOCFKGSA-N Ala-Arg-His Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KVWLTGNCJYDJET-LSJOCFKGSA-N 0.000 description 1
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 1
- YIGLXQRFQVWFEY-NRPADANISA-N Ala-Gln-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O YIGLXQRFQVWFEY-NRPADANISA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- SHKGHIFSEAGTNL-DLOVCJGASA-N Ala-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 SHKGHIFSEAGTNL-DLOVCJGASA-N 0.000 description 1
- QJABSQFUHKHTNP-SYWGBEHUSA-N Ala-Ile-Trp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O QJABSQFUHKHTNP-SYWGBEHUSA-N 0.000 description 1
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- MAEQBGQTDWDSJQ-LSJOCFKGSA-N Ala-Met-His Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N MAEQBGQTDWDSJQ-LSJOCFKGSA-N 0.000 description 1
- HYIDEIQUCBKIPL-CQDKDKBSSA-N Ala-Phe-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N HYIDEIQUCBKIPL-CQDKDKBSSA-N 0.000 description 1
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 1
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- LTTLSZVJTDSACD-OWLDWWDNSA-N Ala-Thr-Trp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O LTTLSZVJTDSACD-OWLDWWDNSA-N 0.000 description 1
- FSXDWQGEWZQBPJ-HERUPUMHSA-N Ala-Trp-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FSXDWQGEWZQBPJ-HERUPUMHSA-N 0.000 description 1
- LFFOJBOTZUWINF-ZANVPECISA-N Ala-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O)=CNC2=C1 LFFOJBOTZUWINF-ZANVPECISA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 1
- WESHVRNMNFMVBE-FXQIFTODSA-N Arg-Asn-Asp Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)CN=C(N)N WESHVRNMNFMVBE-FXQIFTODSA-N 0.000 description 1
- OTUQSEPIIVBYEM-IHRRRGAJSA-N Arg-Asn-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OTUQSEPIIVBYEM-IHRRRGAJSA-N 0.000 description 1
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 1
- NTAZNGWBXRVEDJ-FXQIFTODSA-N Arg-Asp-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NTAZNGWBXRVEDJ-FXQIFTODSA-N 0.000 description 1
- KMSHNDWHPWXPEC-BQBZGAKWSA-N Arg-Asp-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KMSHNDWHPWXPEC-BQBZGAKWSA-N 0.000 description 1
- ZEAYJGRKRUBDOB-GARJFASQSA-N Arg-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZEAYJGRKRUBDOB-GARJFASQSA-N 0.000 description 1
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 description 1
- FFEUXEAKYRCACT-PEDHHIEDSA-N Arg-Ile-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(O)=O FFEUXEAKYRCACT-PEDHHIEDSA-N 0.000 description 1
- GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 1
- XUGATJVGQUGQKY-ULQDDVLXSA-N Arg-Lys-Phe Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XUGATJVGQUGQKY-ULQDDVLXSA-N 0.000 description 1
- NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 description 1
- FKQITMVNILRUCQ-IHRRRGAJSA-N Arg-Phe-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O FKQITMVNILRUCQ-IHRRRGAJSA-N 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- AMIQZQAAYGYKOP-FXQIFTODSA-N Arg-Ser-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O AMIQZQAAYGYKOP-FXQIFTODSA-N 0.000 description 1
- ISJWBVIYRBAXEB-CIUDSAMLSA-N Arg-Ser-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISJWBVIYRBAXEB-CIUDSAMLSA-N 0.000 description 1
- ZPWMEWYQBWSGAO-ZJDVBMNYSA-N Arg-Thr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZPWMEWYQBWSGAO-ZJDVBMNYSA-N 0.000 description 1
- WTFIFQWLQXZLIZ-UMPQAUOISA-N Arg-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O WTFIFQWLQXZLIZ-UMPQAUOISA-N 0.000 description 1
- LOVIQNMIPQVIGT-BVSLBCMMSA-N Arg-Trp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCN=C(N)N)N)C(O)=O)C1=CC=CC=C1 LOVIQNMIPQVIGT-BVSLBCMMSA-N 0.000 description 1
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
- AOJYORNRFWWEIV-IHRRRGAJSA-N Arg-Tyr-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CC=C(O)C=C1 AOJYORNRFWWEIV-IHRRRGAJSA-N 0.000 description 1
- VLIJAPRTSXSGFY-STQMWFEESA-N Arg-Tyr-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 VLIJAPRTSXSGFY-STQMWFEESA-N 0.000 description 1
- PFOYSEIHFVKHNF-FXQIFTODSA-N Asn-Ala-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PFOYSEIHFVKHNF-FXQIFTODSA-N 0.000 description 1
- ORXCYAFUCSTQGY-FXQIFTODSA-N Asn-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N ORXCYAFUCSTQGY-FXQIFTODSA-N 0.000 description 1
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 1
- QEYJFBMTSMLPKZ-ZKWXMUAHSA-N Asn-Ala-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QEYJFBMTSMLPKZ-ZKWXMUAHSA-N 0.000 description 1
- QPTAGIPWARILES-AVGNSLFASA-N Asn-Gln-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QPTAGIPWARILES-AVGNSLFASA-N 0.000 description 1
- GJFYPBDMUGGLFR-NKWVEPMBSA-N Asn-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC(=O)N)N)C(=O)O GJFYPBDMUGGLFR-NKWVEPMBSA-N 0.000 description 1
- JRCASHGTXZYSPW-XIRDDKMYSA-N Asn-His-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CC(=O)N)N JRCASHGTXZYSPW-XIRDDKMYSA-N 0.000 description 1
- SPCONPVIDFMDJI-QSFUFRPTSA-N Asn-Ile-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O SPCONPVIDFMDJI-QSFUFRPTSA-N 0.000 description 1
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
- RZNAMKZJPBQWDJ-SRVKXCTJSA-N Asn-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N RZNAMKZJPBQWDJ-SRVKXCTJSA-N 0.000 description 1
- NTWOPSIUJBMNRI-KKUMJFAQSA-N Asn-Lys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTWOPSIUJBMNRI-KKUMJFAQSA-N 0.000 description 1
- QXOPPIDJKPEKCW-GUBZILKMSA-N Asn-Pro-Arg Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O QXOPPIDJKPEKCW-GUBZILKMSA-N 0.000 description 1
- BYLSYQASFJJBCL-DCAQKATOSA-N Asn-Pro-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BYLSYQASFJJBCL-DCAQKATOSA-N 0.000 description 1
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 1
- IDUUACUJKUXKKD-VEVYYDQMSA-N Asn-Pro-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O IDUUACUJKUXKKD-VEVYYDQMSA-N 0.000 description 1
- VWADICJNCPFKJS-ZLUOBGJFSA-N Asn-Ser-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O VWADICJNCPFKJS-ZLUOBGJFSA-N 0.000 description 1
- NCXTYSVDWLAQGZ-ZKWXMUAHSA-N Asn-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O NCXTYSVDWLAQGZ-ZKWXMUAHSA-N 0.000 description 1
- XCBKBPRFACFFOO-AQZXSJQPSA-N Asn-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O XCBKBPRFACFFOO-AQZXSJQPSA-N 0.000 description 1
- KZYSHAMXEBPJBD-JRQIVUDYSA-N Asn-Thr-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KZYSHAMXEBPJBD-JRQIVUDYSA-N 0.000 description 1
- DAYDURRBMDCCFL-AAEUAGOBSA-N Asn-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N DAYDURRBMDCCFL-AAEUAGOBSA-N 0.000 description 1
- CPYHLXSGDBDULY-IHPCNDPISA-N Asn-Trp-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O CPYHLXSGDBDULY-IHPCNDPISA-N 0.000 description 1
- CGYKCTPUGXFPMG-IHPCNDPISA-N Asn-Tyr-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O CGYKCTPUGXFPMG-IHPCNDPISA-N 0.000 description 1
- LRCIOEVFVGXZKB-BZSNNMDCSA-N Asn-Tyr-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LRCIOEVFVGXZKB-BZSNNMDCSA-N 0.000 description 1
- HPNDBHLITCHRSO-WHFBIAKZSA-N Asp-Ala-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(O)=O HPNDBHLITCHRSO-WHFBIAKZSA-N 0.000 description 1
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 1
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 1
- ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- JGDBHIVECJGXJA-FXQIFTODSA-N Asp-Asp-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JGDBHIVECJGXJA-FXQIFTODSA-N 0.000 description 1
- BFOYULZBKYOKAN-OLHMAJIHSA-N Asp-Asp-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BFOYULZBKYOKAN-OLHMAJIHSA-N 0.000 description 1
- TVIZQBFURPLQDV-DJFWLOJKSA-N Asp-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N TVIZQBFURPLQDV-DJFWLOJKSA-N 0.000 description 1
- SEMWSADZTMJELF-BYULHYEWSA-N Asp-Ile-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O SEMWSADZTMJELF-BYULHYEWSA-N 0.000 description 1
- ORRJQLIATJDMQM-HJGDQZAQSA-N Asp-Leu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O ORRJQLIATJDMQM-HJGDQZAQSA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- KOWYNSKRPUWSFG-IHPCNDPISA-N Asp-Phe-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)NC(=O)[C@H](CC(=O)O)N KOWYNSKRPUWSFG-IHPCNDPISA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- ZBYLEBZCVKLPCY-FXQIFTODSA-N Asp-Ser-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZBYLEBZCVKLPCY-FXQIFTODSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 1
- VHUKCUHLFMRHOD-MELADBBJSA-N Asp-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O VHUKCUHLFMRHOD-MELADBBJSA-N 0.000 description 1
- PLOKOIJSGCISHE-BYULHYEWSA-N Asp-Val-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PLOKOIJSGCISHE-BYULHYEWSA-N 0.000 description 1
- XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 description 1
- GXIUDSXIUSTSLO-QXEWZRGKSA-N Asp-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)O)N GXIUDSXIUSTSLO-QXEWZRGKSA-N 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 241000004175 Coronavirinae Species 0.000 description 1
- CMYVIUWVYHOLRD-ZLUOBGJFSA-N Cys-Ser-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O CMYVIUWVYHOLRD-ZLUOBGJFSA-N 0.000 description 1
- VRJZMZGGAKVSIQ-SRVKXCTJSA-N Cys-Tyr-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VRJZMZGGAKVSIQ-SRVKXCTJSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229940123014 DNA polymerase inhibitor Drugs 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- SHERTACNJPYHAR-ACZMJKKPSA-N Gln-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O SHERTACNJPYHAR-ACZMJKKPSA-N 0.000 description 1
- OVQXQLWWJSNYFV-XEGUGMAKSA-N Gln-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(N)=O)C)C(O)=O)=CNC2=C1 OVQXQLWWJSNYFV-XEGUGMAKSA-N 0.000 description 1
- DLOHWQXXGMEZDW-CIUDSAMLSA-N Gln-Arg-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DLOHWQXXGMEZDW-CIUDSAMLSA-N 0.000 description 1
- JESJDAAGXULQOP-CIUDSAMLSA-N Gln-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N JESJDAAGXULQOP-CIUDSAMLSA-N 0.000 description 1
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 1
- PONUFVLSGMQFAI-AVGNSLFASA-N Gln-Asn-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PONUFVLSGMQFAI-AVGNSLFASA-N 0.000 description 1
- BTSPOOHJBYJRKO-CIUDSAMLSA-N Gln-Asp-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BTSPOOHJBYJRKO-CIUDSAMLSA-N 0.000 description 1
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 1
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 1
- OFPWCBGRYAOLMU-AVGNSLFASA-N Gln-Asp-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O OFPWCBGRYAOLMU-AVGNSLFASA-N 0.000 description 1
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- JHPFPROFOAJRFN-IHRRRGAJSA-N Gln-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O JHPFPROFOAJRFN-IHRRRGAJSA-N 0.000 description 1
- SBHVGKBYOQKAEA-SDDRHHMPSA-N Gln-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SBHVGKBYOQKAEA-SDDRHHMPSA-N 0.000 description 1
- YRWWJCDWLVXTHN-LAEOZQHASA-N Gln-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N YRWWJCDWLVXTHN-LAEOZQHASA-N 0.000 description 1
- XQDGOJPVMSWZSO-SRVKXCTJSA-N Gln-Pro-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N XQDGOJPVMSWZSO-SRVKXCTJSA-N 0.000 description 1
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 1
- JILRMFFFCHUUTJ-ACZMJKKPSA-N Gln-Ser-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O JILRMFFFCHUUTJ-ACZMJKKPSA-N 0.000 description 1
- QXQDADBVIBLBHN-FHWLQOOXSA-N Gln-Tyr-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QXQDADBVIBLBHN-FHWLQOOXSA-N 0.000 description 1
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 1
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
- RDDSZZJOKDVPAE-ACZMJKKPSA-N Glu-Asn-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDDSZZJOKDVPAE-ACZMJKKPSA-N 0.000 description 1
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 1
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 1
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- CQAHWYDHKUWYIX-YUMQZZPRSA-N Glu-Pro-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O CQAHWYDHKUWYIX-YUMQZZPRSA-N 0.000 description 1
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 1
- MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 1
- LSYFGBRDBIQYAQ-FHWLQOOXSA-N Glu-Tyr-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LSYFGBRDBIQYAQ-FHWLQOOXSA-N 0.000 description 1
- LERGJIVJIIODPZ-ZANVPECISA-N Gly-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)CN)C)C(O)=O)=CNC2=C1 LERGJIVJIIODPZ-ZANVPECISA-N 0.000 description 1
- XUDLUKYPXQDCRX-BQBZGAKWSA-N Gly-Arg-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O XUDLUKYPXQDCRX-BQBZGAKWSA-N 0.000 description 1
- VXKCPBPQEKKERH-IUCAKERBSA-N Gly-Arg-Pro Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O VXKCPBPQEKKERH-IUCAKERBSA-N 0.000 description 1
- CIMULJZTTOBOPN-WHFBIAKZSA-N Gly-Asn-Asn Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CIMULJZTTOBOPN-WHFBIAKZSA-N 0.000 description 1
- JVACNFOPSUPDTK-QWRGUYRKSA-N Gly-Asn-Phe Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JVACNFOPSUPDTK-QWRGUYRKSA-N 0.000 description 1
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 1
- JUGQPPOVWXSPKJ-RYUDHWBXSA-N Gly-Gln-Phe Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JUGQPPOVWXSPKJ-RYUDHWBXSA-N 0.000 description 1
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- UPADCCSMVOQAGF-LBPRGKRZSA-N Gly-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)CN)C(O)=O)=CNC2=C1 UPADCCSMVOQAGF-LBPRGKRZSA-N 0.000 description 1
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 1
- HPAIKDPJURGQLN-KBPBESRZSA-N Gly-His-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 HPAIKDPJURGQLN-KBPBESRZSA-N 0.000 description 1
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 1
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 1
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 1
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 1
- OQQKUTVULYLCDG-ONGXEEELSA-N Gly-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CN)C(O)=O OQQKUTVULYLCDG-ONGXEEELSA-N 0.000 description 1
- IBYOLNARKHMLBG-WHOFXGATSA-N Gly-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IBYOLNARKHMLBG-WHOFXGATSA-N 0.000 description 1
- JPVGHHQGKPQYIL-KBPBESRZSA-N Gly-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 JPVGHHQGKPQYIL-KBPBESRZSA-N 0.000 description 1
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- JNGHLWWFPGIJER-STQMWFEESA-N Gly-Pro-Tyr Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JNGHLWWFPGIJER-STQMWFEESA-N 0.000 description 1
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 1
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- IROABALAWGJQGM-OALUTQOASA-N Gly-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)CN IROABALAWGJQGM-OALUTQOASA-N 0.000 description 1
- MREVELMMFOLESM-HOCLYGCPSA-N Gly-Trp-Val Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O MREVELMMFOLESM-HOCLYGCPSA-N 0.000 description 1
- YJDALMUYJIENAG-QWRGUYRKSA-N Gly-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN)O YJDALMUYJIENAG-QWRGUYRKSA-N 0.000 description 1
- HQSKKSLNLSTONK-JTQLQIEISA-N Gly-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 HQSKKSLNLSTONK-JTQLQIEISA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- SVHKVHBPTOMLTO-DCAQKATOSA-N His-Arg-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SVHKVHBPTOMLTO-DCAQKATOSA-N 0.000 description 1
- LSQHWKPPOFDHHZ-YUMQZZPRSA-N His-Asp-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N LSQHWKPPOFDHHZ-YUMQZZPRSA-N 0.000 description 1
- FMRKUXFLLPKVPG-JYJNAYRXSA-N His-Gln-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CN=CN2)N)O FMRKUXFLLPKVPG-JYJNAYRXSA-N 0.000 description 1
- QAMFAYSMNZBNCA-UWVGGRQHSA-N His-Gly-Met Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O QAMFAYSMNZBNCA-UWVGGRQHSA-N 0.000 description 1
- BDFCIKANUNMFGB-PMVVWTBXSA-N His-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 BDFCIKANUNMFGB-PMVVWTBXSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- FHKZHRMERJUXRJ-DCAQKATOSA-N His-Ser-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 FHKZHRMERJUXRJ-DCAQKATOSA-N 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- MKWSZEHGHSLNPF-NAKRPEOUSA-N Ile-Ala-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N MKWSZEHGHSLNPF-NAKRPEOUSA-N 0.000 description 1
- TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 1
- BEWFWZRGBDVXRP-PEFMBERDSA-N Ile-Glu-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BEWFWZRGBDVXRP-PEFMBERDSA-N 0.000 description 1
- MQFGXJNSUJTXDT-QSFUFRPTSA-N Ile-Gly-Ile Chemical compound N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)O MQFGXJNSUJTXDT-QSFUFRPTSA-N 0.000 description 1
- DFFTXLCCDFYRKD-MBLNEYKQSA-N Ile-Gly-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N DFFTXLCCDFYRKD-MBLNEYKQSA-N 0.000 description 1
- JLWLMGADIQFKRD-QSFUFRPTSA-N Ile-His-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CN=CN1 JLWLMGADIQFKRD-QSFUFRPTSA-N 0.000 description 1
- KYLIZSDYWQQTFM-PEDHHIEDSA-N Ile-Ile-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N KYLIZSDYWQQTFM-PEDHHIEDSA-N 0.000 description 1
- PHRWFSFCNJPWRO-PPCPHDFISA-N Ile-Leu-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N PHRWFSFCNJPWRO-PPCPHDFISA-N 0.000 description 1
- IIWQTXMUALXGOV-PCBIJLKTSA-N Ile-Phe-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N IIWQTXMUALXGOV-PCBIJLKTSA-N 0.000 description 1
- KCTIFOCXAIUQQK-QXEWZRGKSA-N Ile-Pro-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O KCTIFOCXAIUQQK-QXEWZRGKSA-N 0.000 description 1
- YKZAMJXNJUWFIK-JBDRJPRFSA-N Ile-Ser-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)O)N YKZAMJXNJUWFIK-JBDRJPRFSA-N 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 1
- RKQAYOWLSFLJEE-SVSWQMSJSA-N Ile-Thr-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)O)N RKQAYOWLSFLJEE-SVSWQMSJSA-N 0.000 description 1
- OAQJOXZPGHTJNA-NGTWOADLSA-N Ile-Trp-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N OAQJOXZPGHTJNA-NGTWOADLSA-N 0.000 description 1
- HQLSBZFLOUHQJK-STECZYCISA-N Ile-Tyr-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HQLSBZFLOUHQJK-STECZYCISA-N 0.000 description 1
- JSLIXOUMAOUGBN-JUKXBJQTSA-N Ile-Tyr-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N JSLIXOUMAOUGBN-JUKXBJQTSA-N 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- SUPVSFFZWVOEOI-CQDKDKBSSA-N Leu-Ala-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SUPVSFFZWVOEOI-CQDKDKBSSA-N 0.000 description 1
- SUPVSFFZWVOEOI-UHFFFAOYSA-N Leu-Ala-Tyr Natural products CC(C)CC(N)C(=O)NC(C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 SUPVSFFZWVOEOI-UHFFFAOYSA-N 0.000 description 1
- JUWJEAPUNARGCF-DCAQKATOSA-N Leu-Arg-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JUWJEAPUNARGCF-DCAQKATOSA-N 0.000 description 1
- RFUBXQQFJFGJFV-GUBZILKMSA-N Leu-Asn-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RFUBXQQFJFGJFV-GUBZILKMSA-N 0.000 description 1
- WGNOPSQMIQERPK-GARJFASQSA-N Leu-Asn-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N WGNOPSQMIQERPK-GARJFASQSA-N 0.000 description 1
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 1
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 description 1
- TWQIYNGNYNJUFM-NHCYSSNCSA-N Leu-Asn-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TWQIYNGNYNJUFM-NHCYSSNCSA-N 0.000 description 1
- KTFHTMHHKXUYPW-ZPFDUUQYSA-N Leu-Asp-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KTFHTMHHKXUYPW-ZPFDUUQYSA-N 0.000 description 1
- VPKIQULSKFVCSM-SRVKXCTJSA-N Leu-Gln-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPKIQULSKFVCSM-SRVKXCTJSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- KUEVMUXNILMJTK-JYJNAYRXSA-N Leu-Gln-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KUEVMUXNILMJTK-JYJNAYRXSA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- KEVYYIMVELOXCT-KBPBESRZSA-N Leu-Gly-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KEVYYIMVELOXCT-KBPBESRZSA-N 0.000 description 1
- KOSWSHVQIVTVQF-ZPFDUUQYSA-N Leu-Ile-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KOSWSHVQIVTVQF-ZPFDUUQYSA-N 0.000 description 1
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- UCNNZELZXFXXJQ-BZSNNMDCSA-N Leu-Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCNNZELZXFXXJQ-BZSNNMDCSA-N 0.000 description 1
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 1
- KXCMQWMNYQOAKA-SRVKXCTJSA-N Leu-Met-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N KXCMQWMNYQOAKA-SRVKXCTJSA-N 0.000 description 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 1
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- HQBOMRTVKVKFMN-WDSOQIARSA-N Leu-Trp-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O HQBOMRTVKVKFMN-WDSOQIARSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 1
- FMFNIDICDKEMOE-XUXIUFHCSA-N Leu-Val-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FMFNIDICDKEMOE-XUXIUFHCSA-N 0.000 description 1
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 1
- SQRLLZAQNOQCEG-KKUMJFAQSA-N Lys-Tyr-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 SQRLLZAQNOQCEG-KKUMJFAQSA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- QWTGQXGNNMIUCW-BPUTZDHNSA-N Met-Asn-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O QWTGQXGNNMIUCW-BPUTZDHNSA-N 0.000 description 1
- UZVWDRPUTHXQAM-FXQIFTODSA-N Met-Asp-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O UZVWDRPUTHXQAM-FXQIFTODSA-N 0.000 description 1
- AEQVPPGEJJBFEE-CYDGBPFRSA-N Met-Ile-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEQVPPGEJJBFEE-CYDGBPFRSA-N 0.000 description 1
- QTMIXEQWGNIPBL-JYJNAYRXSA-N Met-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N QTMIXEQWGNIPBL-JYJNAYRXSA-N 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- CSYVXYQDIVCQNU-QWRGUYRKSA-N Phe-Asp-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O CSYVXYQDIVCQNU-QWRGUYRKSA-N 0.000 description 1
- VUYCNYVLKACHPA-KKUMJFAQSA-N Phe-Asp-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N VUYCNYVLKACHPA-KKUMJFAQSA-N 0.000 description 1
- QPQDWBAJWOGAMJ-IHPCNDPISA-N Phe-Asp-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 QPQDWBAJWOGAMJ-IHPCNDPISA-N 0.000 description 1
- WPTYDQPGBMDUBI-QWRGUYRKSA-N Phe-Gly-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O WPTYDQPGBMDUBI-QWRGUYRKSA-N 0.000 description 1
- HBGFEEQFVBWYJQ-KBPBESRZSA-N Phe-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HBGFEEQFVBWYJQ-KBPBESRZSA-N 0.000 description 1
- BEEVXUYVEHXWRQ-YESZJQIVSA-N Phe-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O BEEVXUYVEHXWRQ-YESZJQIVSA-N 0.000 description 1
- FXPZZKBHNOMLGA-HJWJTTGWSA-N Phe-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FXPZZKBHNOMLGA-HJWJTTGWSA-N 0.000 description 1
- WKTSCAXSYITIJJ-PCBIJLKTSA-N Phe-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O WKTSCAXSYITIJJ-PCBIJLKTSA-N 0.000 description 1
- XMQSOOJRRVEHRO-ULQDDVLXSA-N Phe-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 XMQSOOJRRVEHRO-ULQDDVLXSA-N 0.000 description 1
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- QTDBZORPVYTRJU-KKXDTOCCSA-N Phe-Tyr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O QTDBZORPVYTRJU-KKXDTOCCSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 1
- VPVHXWGPALPDGP-GUBZILKMSA-N Pro-Asn-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPVHXWGPALPDGP-GUBZILKMSA-N 0.000 description 1
- PULPZRAHVFBVTO-DCAQKATOSA-N Pro-Glu-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PULPZRAHVFBVTO-DCAQKATOSA-N 0.000 description 1
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 1
- ZTVCLZLGHZXLOT-ULQDDVLXSA-N Pro-Glu-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O ZTVCLZLGHZXLOT-ULQDDVLXSA-N 0.000 description 1
- QEWBZBLXDKIQPS-STQMWFEESA-N Pro-Gly-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QEWBZBLXDKIQPS-STQMWFEESA-N 0.000 description 1
- RUDOLGWDSKQQFF-DCAQKATOSA-N Pro-Leu-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O RUDOLGWDSKQQFF-DCAQKATOSA-N 0.000 description 1
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 description 1
- DRKAXLDECUGLFE-ULQDDVLXSA-N Pro-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O DRKAXLDECUGLFE-ULQDDVLXSA-N 0.000 description 1
- WCNVGGZRTNHOOS-ULQDDVLXSA-N Pro-Lys-Tyr Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O WCNVGGZRTNHOOS-ULQDDVLXSA-N 0.000 description 1
- WHNJMTHJGCEKGA-ULQDDVLXSA-N Pro-Phe-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WHNJMTHJGCEKGA-ULQDDVLXSA-N 0.000 description 1
- BUEIYHBJHCDAMI-UFYCRDLUSA-N Pro-Phe-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BUEIYHBJHCDAMI-UFYCRDLUSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 1
- ITUDDXVFGFEKPD-NAKRPEOUSA-N Pro-Ser-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ITUDDXVFGFEKPD-NAKRPEOUSA-N 0.000 description 1
- VBZXFFYOBDLLFE-HSHDSVGOSA-N Pro-Trp-Thr Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@H](O)C)C(O)=O)C(=O)[C@@H]1CCCN1 VBZXFFYOBDLLFE-HSHDSVGOSA-N 0.000 description 1
- LZHHZYDPMZEMRX-STQMWFEESA-N Pro-Tyr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O LZHHZYDPMZEMRX-STQMWFEESA-N 0.000 description 1
- QKWYXRPICJEQAJ-KJEVXHAQSA-N Pro-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2)O QKWYXRPICJEQAJ-KJEVXHAQSA-N 0.000 description 1
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 1
- VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101710193484 S-antigen protein Proteins 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- KYKKKSWGEPFUMR-NAKRPEOUSA-N Ser-Arg-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KYKKKSWGEPFUMR-NAKRPEOUSA-N 0.000 description 1
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 1
- UBRXAVQWXOWRSJ-ZLUOBGJFSA-N Ser-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)C(=O)N UBRXAVQWXOWRSJ-ZLUOBGJFSA-N 0.000 description 1
- ZXLUWXWISXIFIX-ACZMJKKPSA-N Ser-Asn-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZXLUWXWISXIFIX-ACZMJKKPSA-N 0.000 description 1
- CNIIKZQXBBQHCX-FXQIFTODSA-N Ser-Asp-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O CNIIKZQXBBQHCX-FXQIFTODSA-N 0.000 description 1
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- RJHJPZQOMKCSTP-CIUDSAMLSA-N Ser-His-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O RJHJPZQOMKCSTP-CIUDSAMLSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 1
- NQZFFLBPNDLTPO-DLOVCJGASA-N Ser-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)N NQZFFLBPNDLTPO-DLOVCJGASA-N 0.000 description 1
- UGTZYIPOBYXWRW-SRVKXCTJSA-N Ser-Phe-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O UGTZYIPOBYXWRW-SRVKXCTJSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 1
- UQGAAZXSCGWMFU-UBHSHLNASA-N Ser-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N UQGAAZXSCGWMFU-UBHSHLNASA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 101800000904 Spike protein S1 Proteins 0.000 description 1
- 102220599612 Spindlin-1_A701V_mutation Human genes 0.000 description 1
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 1
- 102220599647 Spindlin-1_E484Q_mutation Human genes 0.000 description 1
- 102220599420 Spindlin-1_N501T_mutation Human genes 0.000 description 1
- 102220599657 Spindlin-1_Q493R_mutation Human genes 0.000 description 1
- 102220599404 Spindlin-1_Q493Y_mutation Human genes 0.000 description 1
- 102220599614 Spindlin-1_Q677H_mutation Human genes 0.000 description 1
- 102220599660 Spindlin-1_T478K_mutation Human genes 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- MQCPGOZXFSYJPS-KZVJFYERSA-N Thr-Ala-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MQCPGOZXFSYJPS-KZVJFYERSA-N 0.000 description 1
- UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 description 1
- VIBXMCZWVUOZLA-OLHMAJIHSA-N Thr-Asn-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VIBXMCZWVUOZLA-OLHMAJIHSA-N 0.000 description 1
- MFEBUIFJVPNZLO-OLHMAJIHSA-N Thr-Asp-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O MFEBUIFJVPNZLO-OLHMAJIHSA-N 0.000 description 1
- YOSLMIPKOUAHKI-OLHMAJIHSA-N Thr-Asp-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O YOSLMIPKOUAHKI-OLHMAJIHSA-N 0.000 description 1
- VEWZSFGRQDUAJM-YJRXYDGGSA-N Thr-Cys-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O VEWZSFGRQDUAJM-YJRXYDGGSA-N 0.000 description 1
- DIPIPFHFLPTCLK-LOKLDPHHSA-N Thr-Gln-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O DIPIPFHFLPTCLK-LOKLDPHHSA-N 0.000 description 1
- RCEHMXVEMNXRIW-IRIUXVKKSA-N Thr-Gln-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O RCEHMXVEMNXRIW-IRIUXVKKSA-N 0.000 description 1
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 1
- XFTYVCHLARBHBQ-FOHZUACHSA-N Thr-Gly-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XFTYVCHLARBHBQ-FOHZUACHSA-N 0.000 description 1
- KRGDDWVBBDLPSJ-CUJWVEQBSA-N Thr-His-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O KRGDDWVBBDLPSJ-CUJWVEQBSA-N 0.000 description 1
- YJCVECXVYHZOBK-KNZXXDILSA-N Thr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H]([C@@H](C)O)N YJCVECXVYHZOBK-KNZXXDILSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- HOVLHEKTGVIKAP-WDCWCFNPSA-N Thr-Leu-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HOVLHEKTGVIKAP-WDCWCFNPSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- ABWNZPOIUJMNKT-IXOXFDKPSA-N Thr-Phe-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O ABWNZPOIUJMNKT-IXOXFDKPSA-N 0.000 description 1
- NDXSOKGYKCGYKT-VEVYYDQMSA-N Thr-Pro-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O NDXSOKGYKCGYKT-VEVYYDQMSA-N 0.000 description 1
- VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 1
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
- XEVHXNLPUBVQEX-DVJZZOLTSA-N Thr-Trp-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N)O XEVHXNLPUBVQEX-DVJZZOLTSA-N 0.000 description 1
- NDLHSJWPCXKOGG-VLCNGCBASA-N Thr-Trp-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N)O NDLHSJWPCXKOGG-VLCNGCBASA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- AVYVKJMBNLPWRX-WFBYXXMGSA-N Trp-Ala-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 AVYVKJMBNLPWRX-WFBYXXMGSA-N 0.000 description 1
- VEYXZZGMIBKXCN-UBHSHLNASA-N Trp-Asp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VEYXZZGMIBKXCN-UBHSHLNASA-N 0.000 description 1
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
- HJWLQSFTGDQSRX-BPUTZDHNSA-N Trp-Met-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O HJWLQSFTGDQSRX-BPUTZDHNSA-N 0.000 description 1
- MICFJCRQBFSKPA-UMPQAUOISA-N Trp-Met-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)=CNC2=C1 MICFJCRQBFSKPA-UMPQAUOISA-N 0.000 description 1
- UIRVSEPRMWDVEW-RNXOBYDBSA-N Trp-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N UIRVSEPRMWDVEW-RNXOBYDBSA-N 0.000 description 1
- ZJPSMXCFEKMZFE-IHPCNDPISA-N Trp-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O ZJPSMXCFEKMZFE-IHPCNDPISA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- AKFLVKKWVZMFOT-IHRRRGAJSA-N Tyr-Arg-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O AKFLVKKWVZMFOT-IHRRRGAJSA-N 0.000 description 1
- CRWOSTCODDFEKZ-HRCADAONSA-N Tyr-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O CRWOSTCODDFEKZ-HRCADAONSA-N 0.000 description 1
- CKKFTIQYURNSEI-IHRRRGAJSA-N Tyr-Asn-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CKKFTIQYURNSEI-IHRRRGAJSA-N 0.000 description 1
- AYHSJESDFKREAR-KKUMJFAQSA-N Tyr-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AYHSJESDFKREAR-KKUMJFAQSA-N 0.000 description 1
- AYPAIRCDLARHLM-KKUMJFAQSA-N Tyr-Asn-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O AYPAIRCDLARHLM-KKUMJFAQSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- NLMXVDDEQFKQQU-CFMVVWHZSA-N Tyr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLMXVDDEQFKQQU-CFMVVWHZSA-N 0.000 description 1
- TZXFLDNBYYGLKA-BZSNNMDCSA-N Tyr-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 TZXFLDNBYYGLKA-BZSNNMDCSA-N 0.000 description 1
- YLRLHDFMMWDYTK-KKUMJFAQSA-N Tyr-Cys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLRLHDFMMWDYTK-KKUMJFAQSA-N 0.000 description 1
- PMDWYLVWHRTJIW-STQMWFEESA-N Tyr-Gly-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PMDWYLVWHRTJIW-STQMWFEESA-N 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- QAYSODICXVZUIA-WLTAIBSBSA-N Tyr-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QAYSODICXVZUIA-WLTAIBSBSA-N 0.000 description 1
- CVXURBLRELTJKO-BWAGICSOSA-N Tyr-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O CVXURBLRELTJKO-BWAGICSOSA-N 0.000 description 1
- YMUQBRQQCPQEQN-CXTHYWKRSA-N Tyr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N YMUQBRQQCPQEQN-CXTHYWKRSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- PYJKETPLFITNKS-IHRRRGAJSA-N Tyr-Pro-Asn Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O PYJKETPLFITNKS-IHRRRGAJSA-N 0.000 description 1
- SOEGLGLDSUHWTI-STECZYCISA-N Tyr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=C(O)C=C1 SOEGLGLDSUHWTI-STECZYCISA-N 0.000 description 1
- BIWVVOHTKDLRMP-ULQDDVLXSA-N Tyr-Pro-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BIWVVOHTKDLRMP-ULQDDVLXSA-N 0.000 description 1
- SOAUMCDLIUGXJJ-SRVKXCTJSA-N Tyr-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O SOAUMCDLIUGXJJ-SRVKXCTJSA-N 0.000 description 1
- BCOBSVIZMQXKFY-KKUMJFAQSA-N Tyr-Ser-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O BCOBSVIZMQXKFY-KKUMJFAQSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- KLQPIEVIKOQRAW-IZPVPAKOSA-N Tyr-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KLQPIEVIKOQRAW-IZPVPAKOSA-N 0.000 description 1
- ZYVAAYAOTVJBSS-GMVOTWDCSA-N Tyr-Trp-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O ZYVAAYAOTVJBSS-GMVOTWDCSA-N 0.000 description 1
- JRMCISZDVLOTLR-BVSLBCMMSA-N Tyr-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=C(C=C3)O)N JRMCISZDVLOTLR-BVSLBCMMSA-N 0.000 description 1
- DJSYPCWZPNHQQE-FHWLQOOXSA-N Tyr-Tyr-Gln Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CC=C(O)C=C1 DJSYPCWZPNHQQE-FHWLQOOXSA-N 0.000 description 1
- TYGHOWWWMTWVKM-HJOGWXRNSA-N Tyr-Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 TYGHOWWWMTWVKM-HJOGWXRNSA-N 0.000 description 1
- KSGKJSFPWSMJHK-JNPHEJMOSA-N Tyr-Tyr-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KSGKJSFPWSMJHK-JNPHEJMOSA-N 0.000 description 1
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- IQQYYFPCWKWUHW-YDHLFZDLSA-N Val-Asn-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N IQQYYFPCWKWUHW-YDHLFZDLSA-N 0.000 description 1
- XKVXSCHXGJOQND-ZOBUZTSGSA-N Val-Asp-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N XKVXSCHXGJOQND-ZOBUZTSGSA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- NXRAUQGGHPCJIB-RCOVLWMOSA-N Val-Gly-Asn Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O NXRAUQGGHPCJIB-RCOVLWMOSA-N 0.000 description 1
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 1
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 1
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 1
- MJXNDRCLGDSBBE-FHWLQOOXSA-N Val-His-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N MJXNDRCLGDSBBE-FHWLQOOXSA-N 0.000 description 1
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- MJOUSKQHAIARKI-JYJNAYRXSA-N Val-Phe-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 MJOUSKQHAIARKI-JYJNAYRXSA-N 0.000 description 1
- ZXYPHBKIZLAQTL-QXEWZRGKSA-N Val-Pro-Asp Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N ZXYPHBKIZLAQTL-QXEWZRGKSA-N 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- UQMPYVLTQCGRSK-IFFSRLJSSA-N Val-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N)O UQMPYVLTQCGRSK-IFFSRLJSSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- OHDRQQURAXLVGJ-AXMZSLBLSA-N azane;(2z)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-AXMZSLBLSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229950002031 galidesivir Drugs 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- HPAIKDPJURGQLN-UHFFFAOYSA-N glycyl-L-histidyl-L-phenylalanine Natural products C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(NC(=O)CN)CC1=CN=CN1 HPAIKDPJURGQLN-UHFFFAOYSA-N 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 1
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 1
- 108010008671 glycyl-tryptophyl-methionine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 229940112586 kaletra Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 108010051673 leucyl-glycyl-phenylalanine Proteins 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 1
- 108010012988 lysyl-glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010029384 tryptophyl-histidine Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 108010005834 tyrosyl-alanyl-glycine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Abstract
본 발명은 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자에 관한 것이다. 보다 구체적으로는, 본 발명의 결합 분자는 사스-코로나바이러스-2(SARS-CoV-2) 야생형 및 향후 발생 가능한 변이 바이러스뿐만 아니라, 인간에게 감염되어 치명적인 질병을 유발하는 사스-코로나바이러스(SARS-CoV), 중동호흡기증후군 코로나바이러스 (MERS-CoV) 등을 포함한 인간에게 감염 가능성이 있는 다양한 코로나바이러스 종에 대한 우수한 결합 능력을 가지고, 우수한 중화 효과를 나타내므로, 코로나바이러스로 인하여 발생하는 질환에 대한 진단, 예방 또는 치료에 매우 유용하다.
Description
본 발명은 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자에 관한 것으로, 보다 구체적으로는, 사스-코로나바이러스-2(SARS-CoV-2) 야생형 및 향후 발생 가능한 변이 바이러스뿐만 아니라, 인간에게 감염되어 치명적인 질병을 유발하는 사스-코로나바이러스(SARS-CoV), 중동호흡기증후군 코로나바이러스 (MERS-CoV) 등을 포함한 인간에게 감염 가능성이 있는 다양한 코로나바이러스 종에 대한 우수한 결합 능력 및 중화 효과를 가진 결합 분자에 관한 것이다.
코로나바이러스(Coronavirus)는 코로나바이러스 과(Family Coronaviridae)에 속하는 바이러스들을 지칭하며 일반적으로 조류뿐만 아니라 사람을 포함한 다양한 포유류에서도 발견된다. 코로나바이러스는 그 종이 다양하고, 바이러스의 특성과 숙주에 따라서 호흡기와 소화기 감염병을 모두 유발하는 것으로 알려져 있으며, 일반 감기부터 치명적인 폐렴에 이르기까지 다양한 중증도의 호흡기 질환을 유발하는 바이러스이다. 코로나바이러스 과에 속하는 바이러스는 일반적으로 27~32kb 길이를 가진 단일 가닥의 감염성 있는 양성 (positive sense) RNA 게놈을 가지며 게놈의 5번 말단에 cap, 3번 말단에 poly A tail이 존재한다. 코로나바이러스는 피막(Envelope)을 가지고 있으며 스파이크 (Spike, S) 단백질과 피막 (Envelope, E) 단백질과 같은 주요 외막(outer membrane) 단백질들이 존재한다. 스파이크 단백질은 중화 항체 유도, 수용체 결합, 막 융합 등 바이러스의 감염과 병원성에 관여하고 피막 (E) 단백질은 바이러스 입자의 형태 형성과 바이러스가 감염 후 세포 밖으로 방출할 때에 관여한다.
코로나바이러스 중 7개 유형은 인간에게 질병을 유발하는 것으로 알려져 있고, 이중 3개 유형의 감염은 인간에게 훨씬 더 중증 혹은 치명적인 폐렴의 원인이 될 수 있다. 인간에게 치명적인 3가지 유형은 전 세계적으로 문제시 되었던 2003년 중증 급성 호흡기 증후군 (Severe acute respiratory syndrome)의 발병 원인으로 확인된 사스-코로나바이러스 (SARS-CoV), 2012년에 중동 호흡기 증후군 (Middle East Respiratory Syndrome)의 원인으로 확인된 메르스-코로나바이러스 (MERS-CoV), 2019년 후반에 중국 우한 지역에서 처음 확인되어 코로나바이러스 감염증 2019 (코로나-19, COVID-19)의 원인으로 밝혀진 신종 코로나바이러스, 사스-코로나바이러스-2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)가 있다.
사스-코로나바이러스(severe acute respiratory syndrome coronavirus, SARS-CoV)는 다른 코로나바이러스처럼 원형구조의 외피에 둘러싸여 있고 표면에 왕관 모양의 돌기 (스파이크 단백질)을 가지고 있는 구조다. 사스-코로나바이러스로 인해 발병한 중증 급성 호흡기 증후군은 중국에서 처음 발견되었고, 2003년 중반까지 세계적으로 8,000건 이상의 사례와 800건 이상의 사망을 초래하였다. 현재까지 사스-코로나바이러스의 인체감염증을 치료할 수 있는 항바이러스 약제는 없다. 다만 발병 초기에는 ribavirin을 사용하며, 감염 조직에서 면역 매개 손상을 억제하기위해 고농도 스테로이드를 사용할 수 있다.
메르스-코로나바이러스 (Middle East Respiratory syndrome coronavirus, MERS-CoV)는 단일 양성 가닥 RNA 유전체를 가지고있으며, 유전자는 RNA 중합 유전자, 구조단백질 유전자, 외피단백질, 막단밸질, 뉴클레오캡시드 단백질 순으로 배열되어 있다. 중동 호흡기 증후군 (MERS) 유발하는 바이러스는 중증 급성 호흡기 증후군 (SARS)을 유발하는 바이러스와 유사한 코로나바이러스다. 메르스에 대해서도 특정한 치료는 없고, 발열과 근육통 완화를 위해 아세트아미노펜 또는 이부프로펜과 같은 비스테로이드성 항염증제 (NSAID)를 투여한다.
사스-코로나바이러스-2(severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)는 유전적 배열(DNA sequencing)상 전도 기능(Positive sense) 단일 가닥 RNA(single-stranded RNA) 코로나바이러스로서, 인간에게 전염성이 있고 코로나바이러스감염증-19(coronavirus disease 2019, COVID-19)의 원인이다. COVID-19의 최초 발생지는 중국 후베이성의 우한시이다.
SARS-CoV-2에 감염된 사람들은 열, 기침, 호흡 곤란, 설사와 같이 경증에서 중증의 증상을 보일 수 있다. 합병증이나 병을 가진 사람들, 노인은 사망할 가능성이 크다.
특히 심장질환 및 당뇨병 등의 기저질환 보유자가 감염에 더 취약하며, 합병증이나 장기 손상 등을 겪기 때문에 조기 발견과 치료가 매우 중요하다. 2019년 12월 8일부터 2020년 3월 20일 현재까지 245,550명의 환자가 발생하였고, 그 중 10,049명이 사망하여 치사율은 4.09%에 달한다(WHO). 현재까지 한국을 포함한 177개국에서 발생하였다.
현재 코로나바이러스감염증-19(coronavirus disease 2019, COVID-19)의 치료제는 없고, 기존 치료제로 환자에게 투여하여 치료 효과를 기대하고 있는 실정이다. 에볼라 치료제 혹은 치료 후보 물질인 항바이러스제 파비피라비르 (favipiravir), 렘데시비르 (remdesivir), 갈리데시비어 (galidesivir)와 C형 간염 치료제인 리바비린 (ribavirin)을 코로나19 치료제로 사용하고 있다. 에볼라 치료제로 쓰이는 약물에 비해 C형 간염 치료제인 리바비린은 빈혈과 같은 부작용이 심할 수 있고, 항바이러스제인 인터페론 (interferon)도 여러 가지 부작용을 우려하여 주의해서 사용할 것을 권고하고 있다. 말라리아치료제 클로로퀸 (Chloroquine)도 코로나19에 효과를 보이는 것으로 나타나 공개 임상시험 진행 중에 있다.
그러나 이러한 약물들이 코로나19 환자 치료에 활용되어 효과를 보고 있지만 아직 어떠한 근거에서 효과를 내는지는 아직 명확히 입증되지 않았다. 중국에서 코로나19 회복 환자의 현장을 주입하는 혈장 요법을 시행하여 중증 환자의 치료에 효과를 보였다고 발표하였으나 치료 효과가 불분명하고 불확실성이 크기 때문에 신중해야 한다.
국내의 경우, 코로나19 중앙임상 TF(테스크포스)가 2020년 2월 13일 코로나19의 치료 원칙을 마련하여, 1차 치료제로 에이즈 치료제인 칼레트라 (Kaletra), 말라리아치료제인 클로로퀸과 하이드록시클로로퀸(Hydroxychloroquine)을 권하며, 리바비린과 인터페론은 부작용을 우려해 1차 치료제로 권하지 않기로 발표했다. 경증이거나 젊은 환자, 발병 10일이 지난 경우에는 항바이러스제를 투여하지 않아도 증상이 호전된다고 판단하고, 고령자, 기저질환자, 중증 환자에게는 항바이러스 치료제를 투여하기로 합의했다.
미국 CDC는 i) 코로나19가 계절성 유행 바이러스가 아닌 메르스처럼 토착화되어 감염을 일으킬 수 있다고 발표하였고, ii) 바이러스가 올해 또는 내년 어느 시점에 커뮤니티로 전파, 코로나 바이러스가 실제 커뮤니티에 잠복되어 있다는 증거는 없으나, 데이터 기반으로 결론을 내릴 수 있도록 감시강화 필요성을 언급하였다(2020.2.13).
한국 질병관리본부는 i) 코로나19도 인플루엔자처럼 장기적으로 유행할 수 있다고 판단하여, 인플루엔자와 같이 감시 체계에 포함하겠다고 발표하였고, ii) 사람 사이에 유행하는 코로나바이러스(4종)도 겨울~봄에 유행하고 있어서 코로나19도 토착화될 수 있다는 가능성을 열어두고 있다(2020.2.17).
사스나 메르스와는 다르게 코로나19의 세계적 유행 (pandemic) 현실화에 대한 우려가 있지만 봄 이후 (4월) 소강 상태가 될 가능성도 있어, 추이를 보며 신중하게 접근하는 전문가들이 많다. 아직 코로나19에 대한 정보 부족으로 전문가들도 추후 전개 양상에 대해서는 의견이 분분하나, 단시일 내에 해결되리라 전망하는 전문가는 거의 없다. 코로나19의 유행 양상과 특징이 정확히 분석되고 이번 코로나19로 인한 위기 상황이 얼마나 지속되는지에 영향을 받겠지만, 무증상 감염자가 전세계에 퍼지게 될 경우 풍토병화 될 가능성에 대한 우려가 있다. 중국 및 국내에서의 토착화를 통한 국내 코로나19 재발병 가능성에 대한 대응책 마련이 시급하다.
또한, 최근 코로나19 확진자가 미국에서만하루 5만명 넘게 발생되고 있으며, 전 세계에서는 하루 20만명 정도의 확진자가 발생하고 있는 것은 바이러스의 변이때문이라는 것이 학계의 의견이다. 코로나 바이러스가 전염성이 강한 쪽으로 변이하고, 스파이크 단백질에서 변이가 일어나고 있다는 연구 결과들이 나오면서 우려를 증폭시키고 있으며, 스파이크 단백질과 같은 바이러스 감염에 중요한 부분에서 변이가 일어난다면 이는 백신 및 치료제 개발에도 영향을 줄 수 있다. SARS-CoV-2 에 대한 다양한 변이 바이러스가 보고됨에 따라서 야생형뿐만 아니라 변이 바이러스에 대응할 수 있는 방법 마련이 시급하다.
신속진단검사(Rapid diagnostic test, RDT)는 면역크로마토그래피 분석, 래피드 키트 분석 등 다양한 명칭으로 불리며, 주된 구성이 지지체, 검체패드, 컨쥬게이트 패드, 신호검출패드, 및 흡수패드를 포함하는 면역 크로마토그래피 스트립에 의한 분석방법으로서, 사용자가 생물학적 또는 화학적 샘플로부터 분석 물질을 특별한 기술이나 장비 없이 1-100 마이크로 리터의 샘플로 2-30분 사이에서 간단하게 검출할 수 있다. 신속진단검사는 생물학적 물질 또는 화학적 물질이 서로 특이적으로 부착하는 성질을 이용하여 분석 물질을 단시간에 정성 및 정량적으로 검사할 수 있는 방법으로, 신속진단검사는 단순히 면역 크로마토그래피 스트립을 사용하거나, 이와 같은 면역 크로마토그래피 스트립을 플라스틱 하우징 내부에 장착한 형태의 면역 크로마토그래피 키트가 사용된다. 단순히 면역 크로마토그래피 스트립을 사용할 때는 시료를 담은 용기가 별도로 필요하지만 하우징에 내장된 면역 크로마토그래피 키트는 하우징에 준비된 투입구에 시료를 직접 투입함으로서 별도의 실험용기가 필요 없어 사용하기 간편하다.
신속진단검사는 간편성 및 신속성 측면에서 최근까지 개발된 검출 방법 중 가장 진보된 분석 키트 중 하나로서 감염성 병원체의 항원 또는 항체, 암 인자, 심장 마커 등 다양한 질병원인 물질을 진단하는데 유용하게 사용한다.
이와 같은 면역크로마토그래피 스트립 또는 이를 포함하는 면역크로마토그래피 키트를 이용한 분석을 통해, 사람 또는 동물의 전혈, 혈장, 혈청, 눈물, 침, 소변, 콧물, 체액 등의 검체를 이용하여, 사스, 메르스, 인플루엔자바이러스, 조류독감 바이러스, 로타 바이러스, A형 간염, B형 간염, C형 간염, 에이즈, 매독, 클라미디아, 말라리아, 장티프스, 위궤양 원인균, 결핵, 뎅기열, 나병 등의 원인 병원체 및 항체의 유무 등을 신속하게 검사 및 진단할 수 있다.
SARS-CoV-2 또는 재유행 가능성이 있는 SARS-CoV, MERS-CoV 를 포함한 코로나바이러스에 대해 특이적인 예방제, 치료제, 또는 진단용 키트가 없기때문에 이에 따라, 본 발명자들은 추후 발생 가능성이 있는 변이 바이러스 및 코로나바이러스에 대응 가능한 치료 항체를 개발하고자 하였다.
이에, 본 출원인은 연구를 거듭한 결과 코로나19 야생형과 변이형 바이러스뿐만 아니라, 사스 혹은 메르스 등 코로나바이러스에 속하는 바이러스를 중화시킬 수 있는 항체를 개발하여, 본 발명을 완성하였다.
본 발명자들은 상기 문제점을 해결하고자 사스-코로나바이러스-2(SARS-CoV-2) 야생형 및 향후 발생 가능한 변이 바이러스뿐만 아니라, 인간에게 감염되어 치명적인 질병을 유발하는 사스-코로나바이러스(SARS-CoV), 중동호흡기증후군 코로나바이러스 (MERS-CoV) 등을 포함한 인간에게 감염 가능성이 있는 다양한 코로나바이러스 종에 대한 결합 능력을 갖는 결합 분자를 개발하였고, 이 결합 분자가 우수한 결합력 및/또는 중화 효력을 가짐을 확인함으로써 본 발명을 완성하였다.
본 발명이 해결하고자 하는 과제는 코로나바이러스(Coronavirus) 표면의 스파이크 단백질(Spike protein, S protein)에 결합하는 중화 결합 분자를 제공하는 것이다.
또한, 본 발명이 해결하고자 하는 다른 과제는 상기 결합 분자를 포함하는, 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료용 조성물을 제공하는 것이다.
또한, 본 발명이 해결하고자 하는 다른 과제는 상기 결합 분자를 포함하는 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료용 키트를 제공하는 것이다.
또한, 본 발명이 해결하고자 하는 다른 과제는 코로나바이러스로 인하여 발생하는 질환을 가진 대상에 상기 조성물을 투여하여, 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료 방법을 제공하는 것이다.
상기 과제를 해결하고자, 본 발명은 코로나바이러스(Coronavirus) 표면의 스파이크 단백질(Spike protein, S protein)에 결합하는 중화 결합 분자를 제공한다.
또한, 본 발명은 상기 결합 분자에 추가적으로 하나 이상의 태그가 결합된 이뮤노컨쥬게이트를 제공한다.
또한, 본 발명은 상기 결합 분자를 암호화하는 핵산 분자를 제공한다.
또한, 본 발명은 상기 핵산 분자가 삽입된 발현 벡터를 제공한다.
또한, 본 발명은 상기 발현 벡터로 형질전환된 세포주를 제공한다.
또한, 본 발명은 상기 결합 분자를 포함하는, 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료용 조성물을 제공한다.
또한, 본 발명은 상기 결합 분자를 포함하는 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료용 키트를 제공한다.
또한, 본 발명은 코로나바이러스로 인하여 발생하는 질환을 가진 대상에 상기 조성물을 치료학적으로 유효한 양으로 투여하는 단계를 포함하는, 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료 방법을 제공한다.
또한, 본 발명은 상기 결합 분자를 포함하는 면역크로마토그래피 분석용 스트립을 제공한다.
또한, 본 발명은 상기 면역크로마토그래피 분석용 스트립을 포함하는, 코로나바이러스로 인하여 발생하는 질환의 진단용 키트를 제공한다.
또한, 본 발명은 상기 진단용 키트를 이용하여 코로나바이러스로 인하여 발생하는 질환을 검출하는 방법을 제공한다.
또한, 본 발명은 상기 진단용 키트를 이용하여 코로나바이러스로 인하여 발생하는 질환을 진단하는 방법을 제공한다.
이하 본 발명을 더욱 상세히 설명한다.
본 발명은 코로나바이러스(Coronavirus) 표면의 스파이크 단백질(Spike protein, S protein)에 결합하는 중화 결합 분자에 관한 것이다. 상기 코로나바이러스는 사스-코로나바이러스-2(SARS-CoV-2), 사스-코로나바이러스(SARS-CoV) 및 중동호흡기증후군 코로나바이러스(MERS-CoV)로 이루어진 군으로부터 선택되는 어느 하나 이상일 수 있다.
본 발명의 일 구체예에서, 상기 코로나바이러스는
i)
사스-코로나바이러스-2(SARS-CoV-2) 및 사스-코로나바이러스(SARS-CoV);
ii)
사스-코로나바이러스-2(SARS-CoV-2) 및 중동호흡기증후군 코로나바이러스(MERS-CoV); 또는
iii)
사스-코로나바이러스-2(SARS-CoV-2), 사스-코로나바이러스(SARS-CoV) 및 중동호흡기증후군 코로나바이러스(MERS-CoV)
일 수 있다.
상기 결합 분자는 사스-코로나바이러스-2(SARS-CoV-2) 표면의 스파이크 단백질의 RBD(Receptor binding domain), S1, S2; 및/또는 사스-코로나바이러스(SARS-CoV) 스파이크 단백질; 및/또는 메르스-코로나바이러스(MERS-CoV) 스파이크 단백질 영역에 결합할 수 있다.
본 발명의 일 구체예에서, 본 발명의 중화 결합 분자는 사스-코로나바이러스-2(SARS-CoV-2)의 스파이크 단백질에 우수한 결합능을 가지면서 우수한 중화능을 나타낼 수 있다. 본 발명의 중화 결합 분자는 사스-코로나바이러스-2(SARS-CoV-2)의 스파이크 단백질에 우수한 결합능을 가지면서 사스-코로나바이러스-2(SARS-CoV-2) 야생형에 우수한 중화능을 나타낼 수 있다. 또한, 본 발명의 중화 결합 분자는 사스-코로나바이러스-2(SARS-CoV-2)의 스파이크 단백질에 돌연변이가 생긴 변이 바이러스에도 우수한 중화능을 나타낼 수 있다. 일 예로, 본 발명의 중화 결합 분자는 코로나바이러스-2(SARS-CoV-2)의 스파이크 단백질 RBD 영역 이외의 S 단백질 다른 부위의 변이 바이러스에도 중화능을 나타낼 수 있으나, 이에 한정되는 것은 아니다.
본 발명의 일 구체예에서, 본 발명의 중화 결합 분자는 사스-코로나바이러스-2(SARS-CoV-2)의 스파이크 단백질의 RBD(Receptor binding domain), S1, S2; 및/또는 사스-코로나바이러스(SARS-CoV) 스파이크 단백질; 및/또는 메르스-코로나바이러스(MERS-CoV) 스파이크 단백질 영역에 결합하여, 사스-코로나바이러스-2(SARS-CoV-2) 및/또는 사스-코로나바이러스(SARS-CoV) 및/또는 메르스-코로나바이러스(MERS-CoV)를 포함한 다양한 코로나바이러스 종에 중화능을 나타낼 수 있다.
코로나바이러스는 코로나바이러스과 (Coronaviridae)의 코로나바이러스아과 (Coronavirinae)에 속하는 RNA 바이러스로, 숙주에 따라 Alpha-, Beta-, Delta-, Gamma-coronavirus 속으로 나누어진다. 인간 코로나바이러스뿐만 아니라 고양이, 돼지, 소, 박쥐 등에서 발견되는 포유동물의 코로나바이러스는 주로 Alpha-, Beta-coronavirus 속에 속하며, 조류에 감염되는 바이러스들은 대부분 Gamma-coronavirus 속으로 분류된다. 코로나바이러스는 그 종이 다양하고, 바이러스의 특성과 숙주에 따라서 호흡기와 소화기 감염병을 모두 유발하는 것으로 알려져 있으며, 일반 감기부터 치명적인 폐렴에 이르기까지 다양한 중증도의 호흡기 질환을 유발하는 바이러스이다. 코로나바이러스 과에 속하는 바이러스는 일반적으로 27~32kb 길이를 가진 단일 가닥의 감염성 있는 양성 (positive sense) RNA 게놈을 가지며 게놈의 5번 말단에 cap, 3번 말단에 poly A tail이 존재한다. 코로나바이러스는 피막(Envelope)을 가지고 있으며 스파이크 (Spike) 단백질과 Envelope 단백질과 같은 주요 외막(outer membrane) 단백질들이 존재한다. 스파이크 단백질은 중화 항체 유도, 수용체 결합, 막 융합 등 바이러스의 감염과 병원성에 관여하고 Envelop(E) 단백질은 바이러스 입자의 형태 형성과 바이러스가 감염 후 세포 밖으로 방출할 때에 관여한다.
7개 유형의 코로나바이러스는 인간에게 질병을 유발하는 것으로 알려져 있고, 이중 3개 유형의 감염은 인간에게 훨씬 더 중증 혹은 치명적인 폐렴의 원인이 될 수 있다. 인간에게 치명적인 3가지 유형은 전 세계적으로 문제시되었던 사스-코로나바이러스 (SARS-CoV)는 2002년 중증 급성 호흡기 증후군 (SARS)의 발병 원인으로 확인되었고, 메르스-코로나바이러스 (MERS-CoV)는 2012년에 중동 호흡기 증후군 (MERS)의 원인으로 확인되었다. 사스-코로나바이러스-2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)는 코로나바이러스 감염증 2019 (코로나-19, COVID-19)의 원인으로, 2019년 후반에 중국 우한 지역에서 처음 확인된 신종 코로나바이러스이다.
사스-코로나바이러스는 2002년 겨울 중국에서 발생이 시작된 이래 수 개월 만에 홍콩, 싱가포르, 캐나다 등 전 세계적으로 확산되었던 신종 전염병으로, 사스의 원인 병원체는 사스 코로나바이러스이다. SARS-CoV 는 동물 숙주 코로나 바이러스 변종에 의해 동물로부터 사람으로 종간의 벽을 넘어 감염이 일어난 것으로 추정하고 있다. 주된 증상으로 발열과 기침, 혈중산소포화도의 급격한 감소, 호흡곤란, 폐렴 등이며, 환자의 대부분은 회복이 되지만 노인이나 소아에게 있어서는 치명적인 사인이 될 수 있는 것으로 알려져 있다. 예방을 위한 백신이나 치료제가 없기 때문에 독감치료제, 항바이러스제 등을 처방하는 것을 권고한 바 있다.
메르스-코로나바이러스는 2012년에 요르단과 사우디아라비아에서 처음 발견되었고, 대부분은 사우디아라비아에서 발생했으며, 중동 지역 밖 국가들에서 중동을 여행하거나 중동에서 일한 사람들에게 발생하였다. 메르스-코로나바이러스는 메르스 환자들과의 긴밀한 접촉을 통해 또는 감염자가 기침 또는 재채기로 방출한 공기 중 비말을 통해 전파되고, 대부분의 사람들은 발열, 오한, 근육통, 기침을 겪는다. 현재까지 국내외적으로 허가된 메르스 백신과 치료제는 전무한 상황이다. 메르스-코로나바이러스에 대한 치료는 면역 조절 인자인 인터페론과 항바이러스제인 리바비린 (Ribarvirin) 혹은 로피나비어 (lopinavir)와 같은 약물을 사용하는 것이 일반적인 권고사항이다. 그러나 인터페론과 리바비린의 경우, 골수 기능 저하, 빈혈, 바이러스 돌연변이 등 부작용을 일으켜 안전성을 우려하는 보고가 있다. 또한 원숭이 모델에서는 인터페론과 리바비린의 병용투여가 메르스 치료 효과를 보였지만, 실제 임상에서는 메르스 환자들에게 큰 효과를 보이지 못하여 보다 안전하면서 효과적인 메르스 치료제 개발이 요구되고 있다. 국내에서는 메르스-코로나바이러스 감염이 종식 된 이후 추가 발생은 없지만, 중동 국가에서는 지속적으로 발생하고 있어 메르스-코로나바이러스 재유입에 대비를 할 필요성이 있다.
사스-코로나바이러스-2는 세계보건기구(WHO)는 유전자 염기서열 차이로 인한 아미노산 변화를 기준으로 코로나 바이러스를 6개 유형으로 분류하고 있다. 먼저 S, L 유형으로 분류되었다가 다시 L, V, G 유형으로 나뉘고 G가 GH와 GR로 나뉘면서 S, L, V, G, GH, GR 의 총 6개 유형으로 분류하고 있다. 코로나19 발생 초기에 중국 우한을 비롯한 아시아 지역에는 S와 V 유형이 유행하였고, 이후 대륙별로 서로 다른 유형이 발견되었다. 이 중 GH 유형이 전파력이 높게 나타날 가능성이 있다고 보고된 바 있다. 국내의 경우 코로나바이러스 감염증 환자에서 채취한 유전자를 분류한 결과, 대부분은 유럽과 미국에서 유행한 G형의 변종인 GH형인 것으로 나타났고, 이 유형은 바이러스 전파력이 높은 것으로 알려져 있다. 이 중 바이러스의 세포 내 침입 시 중요한 역할을 하는 스파이크 단백질의 614번 아미노산을 아스파트산 (D)에서 글리신 (G)로 바뀐 G형의 바이러스는 3월 이후 유럽과 미국에서 급격히 증가해 현재는 거의 대부분 지역에서 나타나고 있다. 최근 보고된 바에 따르면 70여개 넘는 코로나바이러스 변이가 발생한 것으로 확인되었고, 전파력이 증가된 변이가 8개 (D614G 등), 중화 항체를 회피하는 변이가 10개 (A841V 등), 혈장치료 효과가 낮은 변이 17개 (I472V 등)가 확인되었다.
일 구체예로, 본 발명의 중화 결합 분자는 SARS-CoV-2 바이러스 아미노산 변이 기준으로 S형(S 단백질의 614번 위치의 아미노산이 D), L형, V형, G형(S 단백질의 614번 위치의 아미노산이 G), GH형 또는 GR형 등의 strain에 중화능을 나타낼 수 있으나, 이 strain에 한정되는 것은 아니다. 상기 SARS-CoV-2 바이러스 S형의 일 예로는 BetaCoV/Korea/KCDC03/2020 균주가 있으나, 이 균주에 한정되는 것은 아니다. 상기 SARS-CoV-2 바이러스 G형의 일 예로는 hCoV-19/South Korea/KUMC17/2020 균주가 있으나, 이 균주에 한정되는 것은 아니다. 일 예로, 본 발명의 중화 결합 분자는 사스-코로나바이러스-2(SARS-CoV-2)의 스파이크 단백질 S1 부위의 614번 아미노산 위치에서 D614G 변이가 일어난 변이 바이러스에도 중화 효과가 있을 수 있다.
본 발명의 일 구체예에서, 본 발명의 중화 결합 분자는 하기 1) 내지 20)으로 이루어진 군으로부터 선택되는 어느 하나 이상의 변이 바이러스에 중화능이 있을 수 있으나, 이 변이 바이러스에 한정되는 것은 아니다.
1)
사스-코로나바이러스-2의 스파이크 단백질의 614번 아미노산 위치에서 변이가 생긴 변이 바이러스;
2)
사스-코로나바이러스-2의 스파이크 단백질의 234번 아미노산 위치에서 변이가 생긴 변이 바이러스;
3)
사스-코로나바이러스-2의 스파이크 단백질의 406번 아미노산 위치에서 변이가 생긴 변이 바이러스;
4)
사스-코로나바이러스-2의 스파이크 단백질의 439번 아미노산 위치에서 변이가 생긴 변이 바이러스;
5)
사스-코로나바이러스-2의 스파이크 단백질의 444번 아미노산 위치에서 변이가 생긴 변이 바이러스;
6)
사스-코로나바이러스-2의 스파이크 단백질의 445번 아미노산 위치에서 변이가 생긴 변이 바이러스;
7)
사스-코로나바이러스-2의 스파이크 단백질의 449번 아미노산 위치에서 변이가 생긴 변이 바이러스;
8)
사스-코로나바이러스-2의 스파이크 단백질의 452번 아미노산 위치에서 변이가 생긴 변이 바이러스;
9)
사스-코로나바이러스-2의 스파이크 단백질의 453번 아미노산 위치에서 변이가 생긴 변이 바이러스;
10)
사스-코로나바이러스-2의 스파이크 단백질의 455번 아미노산 위치에서 변이가 생긴 변이 바이러스;
11)
사스-코로나바이러스-2의 스파이크 단백질의 456번 아미노산 위치에서 변이가 생긴 변이 바이러스;
12)
사스-코로나바이러스-2의 스파이크 단백질의 475번 아미노산 위치에서 변이가 생긴 변이 바이러스;
13)
사스-코로나바이러스-2의 스파이크 단백질의 477번 아미노산 위치에서 변이가 생긴 변이 바이러스;
14)
사스-코로나바이러스-2의 스파이크 단백질의 484번 아미노산 위치에서 변이가 생긴 변이 바이러스;
15)
사스-코로나바이러스-2의 스파이크 단백질의 490번 아미노산 위치에서 변이가 생긴 변이 바이러스;
16)
사스-코로나바이러스-2의 스파이크 단백질의 493번 아미노산 위치에서 변이가 생긴 변이 바이러스;
17)
사스-코로나바이러스-2의 스파이크 단백질의 494번 아미노산 위치에서 변이가 생긴 변이 바이러스;
18)
사스-코로나바이러스-2의 스파이크 단백질의 614번 아미노산 위치에서 변이가 생긴 변이 바이러스;
19)
사스-코로나바이러스-2의 스파이크 단백질의 685번 아미노산 위치에서 변이가 생긴 변이 바이러스; 및
20)
사스-코로나바이러스-2의 스파이크 단백질의 1176번 아미노산 위치에서 변이가 생긴 변이 바이러스.
본 발명의 일 구체예에서, 본 발명의 중화 결합 분자는 하기 1) 내지 20)으로 이루어진 군으로부터 선택되는 어느 하나 이상의 변이 바이러스에 중화능이 있으나, 이 변이 바이러스에 한정되는 아니다.
1)
사스-코로나바이러스-2의 스파이크 단백질의 614번 아미노산 위치에서 A222V 변이가 생긴 변이 바이러스;
2)
사스-코로나바이러스-2의 스파이크 단백질의 234번 아미노산 위치에서 N234Q 변이가 생긴 변이 바이러스;
3)
사스-코로나바이러스-2의 스파이크 단백질의 406번 아미노산 위치에서 E406Q 변이가 생긴 변이 바이러스;
4)
사스-코로나바이러스-2의 스파이크 단백질의 439번 아미노산 위치에서 N439K 변이가 생긴 변이 바이러스;
5)
사스-코로나바이러스-2의 스파이크 단백질의 444번 아미노산 위치에서 K444Q 변이가 생긴 변이 바이러스;
6)
사스-코로나바이러스-2의 스파이크 단백질의 445번 아미노산 위치에서 V445A 변이가 생긴 변이 바이러스;
7)
사스-코로나바이러스-2의 스파이크 단백질의 449번 아미노산 위치에서 Y449N 변이가 생긴 변이 바이러스;
8)
사스-코로나바이러스-2의 스파이크 단백질의 452번 아미노산 위치에서 L452R 변이가 생긴 변이 바이러스;
9)
사스-코로나바이러스-2의 스파이크 단백질의 453번 아미노산 위치에서 Y453F 변이가 생긴 변이 바이러스;
10)
사스-코로나바이러스-2의 스파이크 단백질의 455번 아미노산 위치에서 L455F 변이가 생긴 변이 바이러스;
11)
사스-코로나바이러스-2의 스파이크 단백질의 456번 아미노산 위치에서 F456L 변이가 생긴 변이 바이러스;
12)
사스-코로나바이러스-2의 스파이크 단백질의 475번 아미노산 위치에서 A475V 변이가 생긴 변이 바이러스;
13)
사스-코로나바이러스-2의 스파이크 단백질의 477번 아미노산 위치에서 S477N 변이가 생긴 변이 바이러스;
14)
사스-코로나바이러스-2의 스파이크 단백질의 484번 아미노산 위치에서 E484K 변이가 생긴 변이 바이러스;
15)
사스-코로나바이러스-2의 스파이크 단백질의 490번 아미노산 위치에서 F490S 변이가 생긴 변이 바이러스;
16)
사스-코로나바이러스-2의 스파이크 단백질의 493번 아미노산 위치에서 Q493K 변이가 생긴 변이 바이러스;
17)
사스-코로나바이러스-2의 스파이크 단백질의 494번 아미노산 위치에서 S494P 변이가 생긴 변이 바이러스;
18)
사스-코로나바이러스-2의 스파이크 단백질의 614번 아미노산 위치에서 D614G 변이가 생긴 변이 바이러스;
19)
사스-코로나바이러스-2의 스파이크 단백질의 685번 아미노산 위치에서 R685H 변이가 생긴 변이 바이러스; 및
20)
사스-코로나바이러스-2의 스파이크 단백질의 1176번 아미노산 위치에서 V1176F 변이가 생긴 변이 바이러스.
일 구체예로, 본 발명의 중화 결합 분자는 현재까지 단리된 사스-코로나바이러스-2 균주, 예를 들어 단리 일시와 장소를 알 수 없는 UNKNOWN-LR757996 균주(Strain), SARS-CoV-2/Hu/DP/Kng/19-027 균주; 2019년 12월 중국에서 단리된 Wuhan-Hu-1 균주; 2019년 12월 23일 최초로 중국에서 단리된 BetaCoV/Wuhan/IPBCAMS-WH-01/2019 균주; 2019년 12월 30일 중국에서 단리된 BetaCoV/Wuhan/IPBCAMS-WH-02/2019 균주, BetaCoV/Wuhan/IPBCAMS-WH-03/2019 균주, BetaCoV/Wuhan/IPBCAMS-WH-04/2019 균주, WIV02 균주, WIV04 균주, WIV05 균주, WIV06 균주, WIV07 균주; 2020년 1월 일본에서 단리된 2019-nCoV/Japan/TY/WK-521/2020 균주, 2019-nCoV/Japan/TY/WK-501/2020 균주, 2019-nCoV/Japan/TY/WK-012/2020 균주, 2019-nCoV/Japan/KY/V-029/2020 균주; 2020년 1월 대한민국에서 단리된 SNU01 균주; 대한민국에서 단리된 BetaCoV/Korea/KCDC03/2020 균주; 2020년 1월 1일 중국에서 단리된 BetaCoV/Wuhan/IPBCAMS-WH-05/2020 균주; 2020년 1월 2일 중국에서 단리된 2019-nCoV WHU02 균주, 2019-nCoV WHU01 균주; 2020년 1월 8일 중국에서 단리된 SARS-CoV-2/WH-09/human/2020/CHN 균주; 2020년 1월 10일 중국에서 단리된 2019-nCoV_HKU-SZ-002a_2020 균주; 2020년 1월 11일 중국에서 단리된 2019-nCoV_HKU-SZ-005b_2020 균주; 2020년 1월 17일 중국에서 단리된 SARS-CoV-2/Yunnan-01/human/2020/CHN 균주; 2020년 1월 19일 미국에서 단리된 2019-nCoV/USA-WA1/2020 균주; 2020년 1월 20일 중국에서 단리된 HZ-1 균주; 2020년 1월 21일 미국에서 단리된 2019-nCoV/USA-IL1/2020 균주; 2020년 1월 22일 미국에서 단리된 2019-nCoV/USA-CA2/2020 균주, 2019-nCoV/USA-AZ1/2020 균주; 2020년 1월 23일 미국에서 단리된 2019-nCoV/USA-CA1/2020 균주; 2020년 1월 25일 호주에서 단리된 Australia/VIC01/2020 균주; 2020년 1월 25일 미국에서 단리된 2019-nCoV/USA-WA1-F6/2020 균주, 2019-nCoV/USA-WA1-A12/2020 균주; 2020년 1월 27일 미국에서 단리된 2019-nCoV/USA-CA6/2020 균주; 2020년 1월 28일 미국에서 단리된 2019-nCoV/USA-IL2/2020 균주; 2020년 1월 29일 미국에서 단리된 2019-nCoV/USA-MA1/2020 균주, 2019-nCoV/USA-CA5/2020 균주, 2019-nCoV/USA-CA4/2020 균주, 2019-nCoV/USA-CA3/2020 균주; 2020년 1월 29일 핀란드에서 단리된 nCoV-FIN-29-Jan-2020 균주; 2020년 1월 29일 중국에서 단리된 SARS-CoV-2/IQTC02/human/2020/CHN 균주; 2020년 1월 31일 미국에서 단리된 2019-nCoV/USA-WI1/2020 균주; 2020년 1월 31일 타이완에서 단리된 SARS-CoV-2/NTU01/2020/TWN 균주; 2020년 2월 5일 타이완에서 단리된 SARS-CoV-2/NTU02/2020/TWN 균주; 2020년 2월 6일 미국에서 단리된 2019-nCoV/USA-CA7/2020 균주; 2020년 2월 7일 스웨덴에서 단리된 SARS-CoV-2/01/human/2020/SWE 균주; 2020년 2월 10일 미국에서 단리된 2019-nCoV/USA-CA8/2020 균주; 2020년 2월 11일 미국에서 단리된 2019-nCoV/USA-TX1/2020 균주; 2020년 2월 23일 미국에서 단리된 2019-nCoV/USA-CA9/2020 균주; 2020년 2월 28일 브라질에서 단리된 SARS-CoV-2/SP02/human/2020/BRA 균주; 단리 일시와 장소를 알 수 없는 UNKNOWN-LR757995, UNKNOWN-LR757997, UNKNOWN-LR757998, SARS-CoV-2/Hu/DP/Kng/19-020; 2020년 1월 일본에서 단리된 2019-nCoV/Japan/AI/I-004/2020; 2020년 1월 13일 네팔에서 단리된 SARS0CoV-2/61-TW/human/2020/ NPL; 2020년 2월 5일 중국에서 단리된 SARS-CoV-2/IQTC01/human/2020/CHN 균주; 대한민국에서 단리된 hCoV-19/South Korea/KUMC17/2020 균주와 향후 단리될 사스-코로나바이러스-2 균주에 대하여 중화 가능하나, 이들 균주에 한정되는 것은 아니다.
일 구체예로, 본 발명의 중화 결합 분자는 사스-코로나바이러스(SARS-CoV) 균주, 예를 들어 싱가폴에서 단리된 SIN2500, SIN2677, SIN2679, SIN2748, SIN2744 균주; 하노이에서 단리된 icSARS-CoV (SARS-CoV Urbani strain) 균주; Urbani v2163 균주; TW-1 균주; 캐나다에서 단리된 TOR-2 균주; 홍콩에서 단리된 CUHK-W1 와 HKU-39849 균주; 광저우에서 단리된 GZ01 균주; 베이징에서 단리된 BJ01, BJ02, BJ03, BJ04 균주에 대하여 중화 가능하나, 이들 균주에 한정되는 것은 아니다.
일 구체예로, 본 발명의 중화 결합 분자는 중동호흡기증후군 코로나바이러스 (MERS-CoV) 균주, 예를 들어 사우디아라비아에서 단리된 EMC/2012 균주; 요르단에서 단리된 MERS-HCoV/Jordan/01 균주; 영국에서 단리된 2c England-Qatar/2012 균주; 한국에서 단리된 MERS-CoV/Korea/KNIH/002_05_2015, KOREA/Seoul/168-2-2015 균주; Jeddah_C9313/KSA/2014 균주; 사우디아라비아에서 단리된 Florida/USA-2_Saudi Arabia_2014 균주; icMERS-CoV-T1015N 균주에 대하여 중화 가능하나, 이들 균주에 한정되는 것은 아니다.
코로나바이러스는 인간에게 유발되는 일반적인 감기뿐만 아니라 직접적인 바이러스성 기관지염이나 2차적인 세균성 기관지염도 일으킬 수 있다. 인간 코로나바이러스는 인간 코로나바이러스 299E (HCoV-229E), 인간 코로나바이러스 OC43 (HCoV-OC43), 인간 코로나바이러스 NL63 (HCoV-NL63), 인간 코로나바이러스 HKU1 (HCoV-HKU1), 중동호흡기증후군 코로나바이러스 (Middle East respiratory syndrome coronavirus, MERS-CoV), 중증급성호흡기증후군 코로나바이러스 (Severe Acute Respiratory Syndrome coronavirus, SARS-CoV), 사스코로나바이러스-2 (SARS-CoV-2)와 같이 7가지가 보고되어 있다. 4개 유형 (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1)에 감염되면 일반 감기의 증상을 일으키는 경증의 상기도 질환이 발생하지만 3개 유형 (SARS-CoV, MERS-CoV, SARS-CoV-2)은 중증일 수 있고 치명적인 폐렴을 일으킬 수 있다. 2002년 겨울 중국에서 발생이 시작된 인간 코로나 바이러스는 중증급성호흡기증후군을 일으키는 중증급성호흡기증후군 코로나바이러스 (Severe Acute Respiratory Syndrome coronavirus, SARS-CoV)로, 주요 증상은 발열, 권태감, 근육통, 두통, 오한 등이며 기침, 호흡곤란이 나타나기도 하고 상부 및 하부 호흡기 감염을 유발한다. 현재 근본적인 치료방법은 없으며, 흔한 폐렴의 원인균에 대한 항균제를 투여한다. 2012년 발견된 중동호흡기증후군 코로나바이러스 (Middle East respiratory syndrome coronavirus, MERS-CoV)의 주요 임상 증상은 발열, 기침, 호흡곤란 등이며, 대부분 환자가 중증급성하기도질환 (폐렴)이지만 일부 경한 급성상기도질환을 나타내거나 무증상인 경우도 있다. 특히, 기저 질환 (당뇨, 신부전, 만성 폐질환, 면역결핍질환)을 가진 사람에서 감염률이 높고 예후도 불량하다. 2020년 현재, MERS-CoV의 발생은 약 27여개국에서 보고되고 있다. 현재 전 세계적으로 감염 예방을 위한 백신이 개발되지 않았으며, 질병에 대한 정보가 제한적이어서 치료제도 개발되어 있지 않은 상황이다.
본 발명의 일 구체예로서, 본 발명은 현재까지 예방 및 치료제가 없는 코로나바이러스 슈퍼패밀리에 결합하여 중화능을 가지는 결합 분자들에 대한 것이며, 본 발명의 결합 분자는 SARS-CoV-2 야생형과 변이형, 및/또는 SARS-CoV, 및/또는 MERS-CoV 등 코로나바이러스에도 중화능을 가질 수 있다.
본 발명의 일 구체예로서, 상기 결합 분자는 하기 표 1의 결합 분자들로 이루어진 군으로부터 선택되는 어느 하나의 결합 분자일 수 있다. 하기 표 1에서 No.는 각 결합 분자의 번호를 의미한다.
본 발명에 있어서, 가변영역의 CDR은 Kabat 등에 의해 고안된 시스템에 따라 통상적인 방법으로 결정되었다(문헌[Kabat et al., Sequences of Proteins of Immunological Interest(5th), National Institutes of Health, Bethesda, MD. (1991)] 참조). 본 발명에 사용된 CDR 넘버링은 Kabat 방법을 사용했지만, 이외에 IMGT 방법, Chothia 방법, AbM 방법 등 다른 방법에 따라 결정된 CDR을 포함하는 결합 분자도 본 발명에 포함된다.
본 발명의 일 구체예로서, 상기 결합 분자는 하기 표 2의 결합 분자들로 이루어진 군으로부터 선택되는 어느 하나의 결합 분자일 수 있다. 하기 표 2에서 No.는 각 결합 분자의 번호를 의미한다.
본 발명의 일 구체예에서, 상기 결합 분자는 scFv 절편, scFv-Fc 절편, Fab 절편, Fv 절편, 디아바디(diabody), 키메라 항체, 인간화 항체 또는 인간 항체일 수 있으나, 이에 한정되지 않는다. 본 발명의 일 실시예는 SARS-CoV-2 S 단백질에 결합하는 scFv-Fc를 제공한다. 또한, 본 발명의 다른 일 실시예는 SARS-CoV-2 S 단백질에 결합하는 완전한 인간 항체(Full IgG)를 제공한다. 본 발명의 일 실시예는 SARS-CoV S 단백질에 결합하는 scFv-Fc를 제공한다. 또한, 본 발명의 다른 일 실시예는 SARS-CoV S 단백질에 결합하는 완전한 인간 항체(Full IgG)를 제공한다. 본 발명의 일 실시예는 MERS-CoV S 단백질에 결합하는 scFv-Fc를 제공한다. 또한, 본 발명의 다른 일 실시예는 MERS-CoV S 단백질에 결합하는 완전한 인간 항체(Full IgG)를 제공한다.
본 명세서에서 '항체'는 최대한 넓은 의미로 사용되며, 구체적으로 무손상(intact) 단일클론 항체, 다클론 항체, 2종 이상의 무손상 항체로부터 형성된 다중특이성 항체(예를 들어, 이중특이성 항체), 및 목적하는 생물학적 활성을 나타내는 항체 단편을 포함한다. 항체는 특이적인 항원을 인식하고 결합할 수 있는 면역계에 의하여 생성되는 단백질이다. 그 구조적인 면에서, 항체는 통상적으로 4개의 아미노산 쇄(2개의 중쇄 및 2개의 경쇄)로 이루어진 Y-형상의 단백질을 가진다. 각각의 항체는 주로 가변 영역 및 불변 영역의 2개의 영역을 가진다. Y의 팔의 말단 부분에 위치한 가변 영역은 표적 항원에 결합하고 상호작용한다. 상기 가변 영역은 특정 항원 상의 특이적 결합 부위를 인식하고 결합하는 상보성 결정 영역(CDR)을 포함한다. Y의 꼬리 부분에 위치한 불변 영역은 면역계에 의하여 인식되고 상호작용한다. 표적 항원은 일반적으로 다수의 항체 상의 CDR에 의하여 인식되는, 에피토프라고 하는 다수의 결합 부위를 가지고 있다. 상이한 에피토프에 특이적으로 결합하는 각각의 항체는 상이한 구조를 가진다. 그러므로 한 항원은 하나 이상의 상응하는 항체를 가질 수 있다.
아울러 본 발명은 상기 결합 분자의 기능적 변이체를 포함한다. 결합 분자들은 변이체들이 코로나바이러스 또는 이것의 S 단백질에 특이적으로 결합하기 위해 본 발명의 결합 분자와 경쟁할 수 있고, 코로나바이러스에 중화 능력을 보유한다면 본 발명의 결합 분자의 기능적 변이체로 간주된다. 기능적 변이체는 1차 구조적 서열이 실질적으로 유사한 유도체를 포함하지만, 이에 제한되는 것은 아니며, 예를 들면, 생체외(in vitro) 또는 생체내(in vivo) 변형, 화학약품 및/또는 생화학 약품을 포함하며, 이들은 본원 발명의 부모 단일클론 항체에서는 발견되지 않는다. 이와 같은 변형으로는 예를 들어 아세틸화, 아실화, 뉴클레오티드 또는 뉴클레오티드 유도체의 공유 결합, 지질 또는 지질 유도체의 공유 결합, 가교, 이황화 결합 형성, 글리코실화, 수산화, 메틸화, 산화, 페길화, 단백질 분해 및 인산화 등이 포함된다. 기능적 변이체는 선택적으로 부모 항체의 아미노산 서열과 비교하여 하나 이상의 아미노산의 치환, 삽입, 결실 또는 그들의 조합을 함유하는 아미노산 서열을 포함하는 항체일 수 있다. 더욱이 기능적 변이체는 아미노 말단 또는 카르복시 말단 중 하나 또는 모두에서 아미노산 서열의 절단체(truncated form)를 포함할 수 있다. 본 발명의 기능적 변이체는 본 발명의 부모 항체와 비교하여 동일하거나 다르거나, 더 높거나 낮은 결합 친화력을 가질 수 있지만, 여전히 코로나바이러스 또는 이것의 S 단백질에 결합할 수 있다. 일 예로, 골격구조, 초가변(Hypervariable) 영역, 특히 경쇄 또는 중쇄의 상보성 결정 영역(Complementarity-determining region, CDR)을 포함하나 이에 한정되지 않는 가변 영역의 아미노산 서열이 변형될 수 있다. 일반적으로 경쇄 또는 중쇄 영역은 3개의 CDR 영역을 포함하는, 3개의 초가변 영역 및 더욱 보존된 영역, 즉 골격 영역(FR)을 포함한다. 초가변 영역은 CDR로부터의 아미노산 잔기와 초가변 루프로부터의 아미노산 잔기를 포함한다. 본 발명의 범위에 속하는 기능적 변이체는 본 명세서의 부모 항체와 약 50%~99%, 약 60%~99%, 약 80%~99%, 약 90%~99%, 약 95%~99%, 또는 약 97%~99% 아미노산 서열 동질성을 가질 수 있다. 비교될 아미노산 서열을 최적으로 배열하고 유사하거나 또는 동일한 아미노산 잔기를 정의하기 위해 컴퓨터 알고리즘 중 당업자에게 알려진 Gap 또는 Bestfit를 사용할 수 있다. 기능적 변이체는 부모 항체 또는 그것의 일부를 PCR 방법, 올리고머 뉴클레오티드를 이용한 돌연변이 생성 및 부분 돌연변이 생성을 포함하는 공지의 일반 분자생물학적 방법에 의해 변화시키거나 유기합성 방법으로 얻을 수 있으나 이에 제한되는 것은 아니다.
또한, 본 발명은 상기 결합 분자에 추가적으로 하나 이상의 태그가 결합된 이뮤노컨쥬게이트를 제공한다. 일 구체예에서, 상기 결합 분자에 약물이 추가로 부착될 수 있다. 즉, 본 발명에 따른 결합 분자는 약제가 결합된 항체-약물 접합체(conjugate)의 형태로 사용될 수 있다. 약물을 국소 전달하기 위해 항체-약물 접합체(ADC), 즉 면역접합체를 사용하게 되면 상기 약물 모이어티를 감염된 세포에 표적화 전달할 수 있는데, 상기 약물 작용제를 접합시키지 않은 채로 투여하게 되면, 정상 세포에 대해서도 허용될 수 없는 수준의 독성이 야기될 수 있기 때문이다. 약물-연결성 및 약물-방출성 뿐만 아니라 폴리클로날 및 모노클로날 항체(mAb)의 선택성을 높임으로써 ADC의 최대 효능과 최소 독성을 개선할 수 있다.
약물 모이어티를 항체에 부착시키는, 즉 공유 결합을 통하여 연결시키는 통상적인 수단으로는, 일반적으로 약물 모이어티가 항체 상의 수 많은 부위에 부착되는 불균질한 분자 혼합물이 유발된다. 예를 들어, 세포독성 약물을 전형적으로, 종종 항체의 수 많은 리신 잔기를 통하여 항체와 접합시켜 불균질한 항체-약물 접합체 혼합물을 생성킬 수 있다. 반응 조건에 따라서, 이러한 불균질한 혼합물은 전형적으로, 약물 모이어티에 부착된 항체 분포도가 0 내지 약 8 이상이다. 또한, 특별한 정수 비의 약물 모이어티 대 항체를 수반한 접합체의 각 아군은, 약물 모이어티가 항체 상의 각종 부위에 부착되는 잠재적으로 불균질한 혼합물이다. 항체는 크고, 복잡하며 구조적으로 다양한 생체 분자이고, 종종 많은 반응성 관능기를 갖고 있다. 링커 시약 및 약물-링커 중간체와의 반응성은 pH, 농도, 염 농도 및 조용매와 같은 요인들에 의해 좌우된다.
또한, 본 발명의 다른 일 구체예는 상기 결합 분자를 암호화하는 핵산 분자를 제공한다.
본 발명의 핵산 분자는 본 발명에서 제공하는 항체의 아미노산 서열을 당업자에게 알려진 바와 같이 폴리뉴클레오티드 서열로 번역된 핵산 분자 모두를 포함한다. 그러므로 ORF(open reading frame)에 의한 다양한 폴리뉴클레오티드 서열이 제조될 수 있으며 이 또한 모두 본 발명의 핵산 분자에 포함된다.
또한, 본 발명의 다른 일 구체예는 상기 핵산 분자가 삽입된 발현 벡터를 제공한다.
상기 발현 벡터로는 셀트리온 고유의 발현 벡터인 MarEx 벡터(한국특허등록 제10-1076602호 참조) 및 상업적으로 널리 사용되는 pCDNA 벡터, F, R1, RP1, Col, pBR322, ToL, Ti 벡터; 코스미드; 람다, 람도이드(lambdoid), M13, Mu, p1 P22, Qμ, T-even, T2, T3, T7 등의 파아지; 식물 바이러스로 이루어진 군으로부터 선택된 어느 하나에서 선택된 발현 벡터를 이용할 수 있으나 이에 한정되지 않으며, 당업자에게 발현 벡터로 알려진 모든 발현 벡터는 본 발명에 사용 가능하며, 발현 벡터를 선택할 때에는 목적으로 하는 숙주 세포의 성질에 따른다. 숙주세포로의 벡터 도입시 인산칼슘 트랜스펙션, 바이러스 감염, DEAE-덱스트란 조절 트랜스펙션, 리포펙타민 트랜스펙션 또는 전기천공법에 의해 수행될 수 있으나 이에 한정되지 않으며 당업자는 사용하는 발현 벡터 및 숙주 세포에 알맞은 도입 방법을 선택하여 이용할 수 있다. 예를 들어, 벡터는 하나 이상의 선별 마커를 함유하나 이에 한정되지 않으며, 선별 마커를 포함하지 않은 벡터도 이용하여 생산물 생산 여부에 따라 선별이 가능하다. 선별 마커의 선택은 목적하는 숙주 세포에 의해 선택되며, 이는 이미 당업자에게 알려진 방법을 이용하므로 본 발명은 이에 제한을 두지 않는다.
본 발명의 결합 분자의 정제를 용이하게 하기 위하여 태그 서열을 발현 벡터 상에 삽입하여 융합시킬 수 있다. 상기 태그로는 헥사-히스티딘 태그, 헤마글루티닌 태그, myc 태그 또는 flag 태그를 포함하나 이에 한정되지 않으며 당업자에게 알려진 정제를 용이하게 하는 태그는 모두 본 발명에서 이용 가능하다.
또한, 본 발명은 상기 발현 벡터로 형질전환된 세포주를 제공한다. 본 발명의 일 구체예로서, 상기 발현 벡터가 숙주 세포에 형질전환되어, 코로나바이러스에 결합하여 중화 능력을 가지는 결합 분자를 생산하는 세포주를 제공한다.
본 발명에 있어서, 상기 세포주는 포유동물, 식물, 곤충, 균류 또는 세포성 기원의 세포를 포함할 수 있지만, 이에 한정되지 않는다. 상기 포유동물 세포로는 CHO 세포, F2N 세포, COS 세포, BHK 세포, 바우스(Bowes) 흑색종 세포, HeLa 세포, 911 세포, HT1080 세포, A549 세포, HEK 293 세포 및 HEK293T 세포로 이루어진 군에서 선택된 어느 하나를 사용할 수 있으나 이에 한정되지 않으며, 당업자에게 알려진 포유동물 숙주세포로 사용 가능한 세포는 모두 이용 가능하다.
또한, 본 발명은 상기 결합 분자를 포함하는, 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료용 조성물을 제공한다. 여기서, 상기 코로나바이러스로 인하여 발생하는 질환은 코로나바이러스 감염증 2019 (COVID-19), 중증 급성 호흡기 증후군 (Severe acute respiratory syndrome), 또는 중동 호흡기 증후군 (Middle East Respiratory Syndrome)일 수 있으나, 이에 한정되지 않는다. 본 발명의 조성물은 상기 결합 분자 이외에 약제학적으로 허용 가능한 부형제를 포함할 수 있다. 약제학적으로 허용 가능한 부형제는 당업자에게 이미 잘 알려져 있다.
본 발명의 조성물은 추가로 적어도 하나의 다른 치료제 또는 진단제를 포함할 수 있다. 예를 들어, 상기 결합 분자와 함께 인터페론, 항-S 단백질 단일클론 항체, 항-S 단백질 폴리클로날 항체, 뉴클레오시드 유사체, DNA 폴리머라제 저해제, siRNA 제제 또는 치료백신을 항바이러스 약물로서 추가로 포함할 수 있다.
본 발명의 결합 분자를 포함하는 조성물은, 각각 통상의 방법에 따라 멸균 주사용액, 동결건조(lyophilized) 제형, 사전 충전식 주사(pre-filled syringe) 용액제, 경구형 제형, 외용제 또는 좌제 등의 형태로 제형화할 수 있으나, 이에 한정되지 않는다.
또한 본 발명의 결합 분자를 포함하는 조성물은, 투여 방법은 경구 및 비경구로 나뉠 수 있으며, 일 예로 투여 경로는 정맥 내일 수 있으나, 이에 한정되지 않는다.
본 발명의 조성물을 인간을 포함하는 포유동물에게 투여함으로써 코로나바이러스 감염 및 코로나바이러스 감염에 의해 유발되는 질병을 예방 또는 치료할 수 있다. 이때, 상기 결합 분자(예, 항체)의 투여량은 처리되는 대상, 질병 또는 상태의 심각도, 투여의 속도 및 처방 의사의 판단에 따른다.
또한, 본 발명은 상기 결합 분자를 포함하는 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료용 키트를 제공한다.
본 발명의 일 구체예에서, 진단용 키트에 사용되는 본 발명의 결합 분자는 검출 가능하게 표식될 수 있다. 생분자들을 표식시키는데 사용 가능한 다양한 방법들이 당업자에게 잘 알려져 있고, 본 발명의 범주 내에서 고려된다. 본 발명에서 사용될 수 있는 표식 종류의 예로는 효소, 방사성 동위원소, 콜로이드금속, 형광 화합물, 화학발광 화합물 및 생발광 화합물이 있다. 통상적으로 사용되는 표식들은 형광물질(가령, 플루레신, 로다민, 텍사스 레드 등), 효소(가령, 고추냉이 퍼옥시다아제, β-갈락토시다아제, 알칼리포스파타 아제), 방사성 동위원소(가령, 32P 또는 125I), 바이오틴, 디곡시게닌, 콜로이드 금속, 화학발광 또는 생발광 화합물(가령, 디옥세탄, 루미놀 또는 아크리디늄)을 포함한다. 효소 또는 바이오티닐기의 공유 결합법, 요오드화법, 인산화법, 바이오틴화법 등과 같은 표식 방법들이 당 분야에 잘 알려져 있다. 검출 방법들로는 오토라디오그래피, 형광 현미경, 직접 및 간접 효소반응 등이 있으며, 이에 제한되지는 않는다. 통상적으로 사용되는 검출 분석법으로는 방사성 동위원소 또는 비-방사성 동위원소 방법이 있다. 이들은 그 중에서도 웨스턴블롯팅, 오버레이-분석법, RIA(Radioimmuno Assay) 및 IRMA(ImmuneRadioimmunometric Assay), EIA(Enzyme Immuno Assay), ELISA(Enzyme Linked Immuno Sorbent Assay), FIA(Fluorescent Immuno Assay) 및 CLIA(Chemioluminescent Immune Assay)이 있다.
본 발명의 진단용 키트는 샘플과 상기 결합 분자를 접촉시킨 후, 반응을 확인하여 SARS-CoV-2, SARS-CoV, MERS-CoV 등 코로나바이러스의 존재 여부를 검출하는 데 사용될 수 있다. 상기 샘플은 대상의 가래, 침, 혈액, 땀, 폐 세포, 폐 조직의 점액, 호흡기 조직 및 타액으로 이루어진 군으로부터 선택된 어느 하나일 수 있으나, 이에 한정되지 않으며 당업자에게 알려진 통상적인 방법으로 샘플 준비가 가능하다.
또한, 본 발명의 다른 일 구체예는
a) 상기 결합 분자; 및
b) 용기
를 포함하는 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료용 키트를 제공한다.
여기서, 상기 코로나바이러스로 인하여 발생하는 질환은 코로나바이러스 감염증 2019 (COVID-19), 중증 급성 호흡기 증후군 (Severe acute respiratory syndrome), 또는 중동 호흡기 증후군 (Middle East Respiratory Syndrome)일 수 있으나, 이에 한정되지 않는다.
본 발명의 진단, 예방 또는 치료용 키트에 있어서, 키트 용기에는 고체 담체가 포함될 수 있다. 본 발명의 항체는 고체 담체에 부착될 수 있고, 이와 같은 고체 담체는 다공성 또는 비다공성, 평면 또는 비평면일 수 있다.
또한, 본 발명은 코로나바이러스로 인하여 발생하는 질환을 가진 대상에 상기 조성물을 치료학적으로 유효한 양으로 투여하는 단계를 포함하는, 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료 방법을 제공한다. 여기서, 상기 코로나바이러스로 인하여 발생하는 질환은 코로나바이러스 감염증 2019 (COVID-19), 중증 급성 호흡기 증후군 (Severe acute respiratory syndrome), 또는 중동 호흡기 증후군 (Middle East Respiratory Syndrome)일 수 있으나, 이에 한정되지 않는다. 본 발명의 일 구체예에서, 상기 진단, 예방, 또는 치료 방법은 항-바이러스 약물, 바이러스 진입 억제제 또는 바이러스 부착 억제제를 투여하는 단계를 추가로 포함할 수 있다.
또한, 본 발명은 상기 결합 분자를 포함하는 코로나바이러스로 인하여 발생하는 질환의 진단용 조성물을 제공한다. 여기서, 상기 코로나바이러스로 인하여 발생하는 질환은 코로나바이러스 감염증 2019 (COVID-19), 중증 급성 호흡기 증후군 (Severe acute respiratory syndrome), 또는 중동 호흡기 증후군 (Middle East Respiratory Syndrome)일 수 있으나, 이에 한정되지 않는다. 본 발명의 진단용 조성물은 상기 결합 분자 이외에 약제학적으로 허용 가능한 부형제를 포함할 수 있다. 약제학적으로 허용 가능한 부형제는 당업자에게 이미 잘 알려져 있다.
본 발명의 진단용 조성물은 추가로 적어도 하나의 다른 진단제를 포함할 수 있다. 예를 들어, 상기 결합 분자와 함께 사스-코로나바이러스-2(SARS-CoV-2) 표면의 N 단백질(Nucleocapsid protein, N protein)에 결합하는 결합 분자를 추가로 포함할 수 있다.
또한, 본 발명의 다른 일 구체예로, 본 발명은 코로나바이러스 표면의 스파이크 단백질(Spike protein, S protein)에 결합하는 결합 분자를 포함하는 면역크로마토그래피 분석용 스트립을 제공한다. 상기 면역크로마토그래피 분석용 스트립은 코로나바이러스의 뉴클레오캡시드 단백질(Nucleocapsid protein, N protein)에 결합하는 결합 분자를 추가로 포함할 수 있다. 상기 코로나바이러스는 사스-코로나바이러스-2(SARS-CoV-2), 인간 코로나바이러스 229E (HCoV-229E), 인간 코로나바이러스 OC43 (HCoV-OC43), 중증급성호흡기증후군 코로나바이러스 (SARS-CoV), 인간 코로나바이러스 NL63 (HCoV-NL63), 인간 코로나바이러스 HKU1 및 중동호흡기증후군 코로나바이러스 (MERS-CoV)로 구성된 군으로부터 선택된 어느 하나일 수 있으나, 이에 한정되는 것은 아니다.
상기 면역크로마토그래피 분석용 스트립은
i) 지지체;
ii) 분석하고자 하는 검체를 수용하고 버퍼 투입부 및 검체 투입부를 구비하는 검체 패드;
iii) 상기 검체 패드에서 유입된 검체에 함유되어 있는 코로나바이러스와 특이적으로 결합하는 결합 분자를 함유하는, 컨쥬게이트 패드;
iv) 상기 검체에 코로나바이러스가 존재하는지 여부를 검출하는 신호검출부와 분석 물질의 존재 유무와 관계없이 검체가 흡수 패드로 이동하였는지 여부를 확인하는 대조부를 포함하는 신호 검출 패드; 및
v) 신호 검출 반응이 종료된 검체를 흡수하는 흡수 패드
를 포함할 수 있다.
상기 스트립은 코로나바이러스 표면의 스파이크 단백질(Spike protein, S protein)에 결합하는 결합 분자를 컨쥬게이트 패드 및 신호 검출 패드에 각각 포함할 수 있다. 상기 컨쥬게이트 패드와 신호 검출 패드에 포함된 코로나바이러스 S 단백질 결합 분자는 동일하거나, 다를 수 있다. 또한, 상기 컨쥬게이트 패드와 신호 검출 패드에 포함된 코로나바이러스 S 단백질 결합 분자는 앞서 상술한 서열을 포함하는 결합 분자일 수 있다.
상기 면역크로마토그래피 분석용 스트립에 있어서, 상기 컨쥬게이트 패드에 함유된 결합 분자는 금속 입자, 라텍스 입자, 형광물질 또는 효소로 라벨링될 수 있다. 일 예로서, 상기 금속 입자는 금 입자일 수 있다. 상기 금 입자는 금 콜로이드 입자 일 수 있으나, 이에 한정되는 것은 아니다.
보다 자세히 설명하면, 상기 면역크로마토그래피 분석용 스트립의 컨쥬게이트 패드에 본 발명의 결합 분자는 검출 가능하게 표식될 수 있다. 생분자들을 표식시키는데 사용 가능한 다양한 방법들이 당업자에게 잘 알려져 있고, 본 발명의 범주 내에서 고려된다. 본 발명에서 사용될 수 있는 표식 종류의 예로는 효소, 방사성 동위원소, 콜로이드금속, 형광 화합물, 화학발광 화합물 및 생발광 화합물이 있다. 통상적으로 사용되는 표식들은 형광물질(가령, 플루레신, 로다민, 텍사스 레드 등), 효소(가령, 고추냉이 퍼옥시다아제, β-갈락토시다아제, 알칼리포스파타 아제), 방사성 동위원소(가령, 32P 또는 125I), 바이오틴, 디곡시게닌, 콜로이드 금속, 화학발광 또는 생발광 화합물(가령, 디옥세탄, 루미놀 또는 아크리디늄)을 포함한다. 효소 또는 바이오티닐기의 공유 결합법, 요오드화법, 인산화법, 바이오틴화법 등과 같은 표식 방법들이 당 분야에 잘 알려져 있다. 검출 방법들로는 오토라디오그래피, 형광 현미경, 직접 및 간접 효소반응 등이 있으며, 이에 제한되지는 않는다. 통상적으로 사용되는 검출 분석법으로는 방사성 동위원소 또는 비-방사성 동위원소 방법이 있다. 이들은 그 중에서도 웨스턴블롯팅, 오버레이-분석법, RIA(Radioimmuno Assay) 및 IRMA(ImmuneRadioimmunometric Assay), EIA(Enzyme Immuno Assay), ELISA(Enzyme Linked Immuno Sorbent Assay), FIA(Fluorescent Immuno Assay) 및 CLIA(Chemioluminescent Immune Assay)이 있다.
상기 면역크로마토그래피 분석용 스트립에 있어서, 상기 검출은 육안, 광학, 전기화학, 또는 전기전도도에 의해 판독할 수 있으나, 이에 한정되는 것은 아니다.
또한, 본 발명의 다른 일 구체예로, 본 발명은 상기 면역크로마토그래피 분석용 스트립을 포함하는, 코로나바이러스로 인하여 발생하는 질환의 진단용 키트를 제공한다.
본 발명의 진단용 키트는 샘플과 상기 결합 분자를 접촉시킨 후, 반응을 확인하여 코로나바이러스의 존재 여부를 검출하는 데 사용될 수 있다. 상기 샘플은 대상의 가래, 침, 혈액, 땀, 폐 세포, 폐 조직의 점액, 호흡기 조직 및 타액으로 이루어진 군으로부터 선택된 어느 하나일 수 있으나, 이에 한정되지 않으며 당업자에게 알려진 통상적인 방법으로 샘플 준비가 가능하다.
또한, 본 발명의 다른 일 구체예로, 본 발명은 상기 진단용 키트를 이용하여 코로나바이러스-2를 검출하는 방법을 제공한다.
또한, 본 발명의 다른 일 구체예로, 본 발명은 상기 진단용 키트를 이용하여 코로나바이러스로 인하여 발생하는 질환을 진단하는 방법을 제공한다.
이하 본 발명에서 사용되는 용어를 다음과 같이 정의한다.
본 발명에서 사용되는 용어 "결합 분자"는 키메라, 인간화 또는 인간 단일클론 항체와 같은 단일클론 항체를 포함하는 온전한(intact)이뮤노글로블린(immunoglobulin), 또는 항원에 결합하는 이뮤노글로블린인 항원-결합 단편을 포함한다. 예를 들면 SARS-CoV-2의 스파이크 단백질(spike protein)과 결합에 있어서, 온전한(intact) 이뮤노글로블린과 경쟁하는 이뮤노글로블린 단편을 포함하는 가변성 도메인, 효소, 수용체, 단백질을 뜻한다. 구조와는 상관없이 항원-결합 단편은 온전한(intact) 이뮤노글로블린에 의해 인식된 동일한 항원과 결합된다. 항원-결합 단편은 항체의 아미노산 서열의 2개 이상의 연속기, 20개 이상의 연속 아미노산 잔기, 25개 이상의 연속 아미노산 잔기, 30개 이상의 연속 아미노산 잔기, 35개 이상의 연속 아미노산 잔기, 40개 이상의 연속 아미노산 잔기, 50개 이상의 연속 아미노산 잔기, 60개 이상의 연속 아미노산 잔기, 70개 이상의 연속 아미노산 잔기, 80개 이상의 연속 아미노산 잔기, 90개 이상의 연속 아미노산 잔기, 100개 이상의 연속 아미노산 잔기, 125개 이상의 연속 아미노산 잔기, 150개 이상의 연속 아미노산 잔기, 175개 이상 연속 아미노산 잔기, 200개 이상의 연속 아미노산 잔기, 또는 250개 이상의 연속 아미노산 잔기의 아미노산 서열을 포함하는 펩티드 또는 폴리펩티드를 포함할 수 있다.
"항원-결합 단편"은 특히 Fab, F(ab'), F(ab')2, Fv, dAb, Fd, 상보성 결정 영역(CDR) 단편, 단일-쇄 항체(scFv), 2가(bivalent) 단일-쇄 항체, 단일-쇄 파지 항체, 디아바디(diabody), 트리아바디, 테트라바디, 폴리펩티드로의 특정 항원에 결합하기에 충분한 이뮤노글로브린의 하나 이상의 단편을 함유하는 폴리펩티드 등을 포함한다. 상기 단편은 합성으로 또는 완전한 이뮤노글로블린의 효소적 또는 화학적 분해에 의해 생성되거나, 재조합 DNA 기술에 의해 유전공학적으로 생성될 수 있다. 생성 방법은 당업계에 잘 알려져 있다.
본 발명에서 사용되는 "약제학적으로 허용 가능한 부형제"라는 용어는 용인 가능한 또는 편리한 투약 형태를 제조하기 위한 약물, 제제 또는 항체와 같은 활성 분자로 조합되는 불활성 물질을 의미한다. 약제학적으로 허용 가능한 부형제는 비독성이거나, 적어도 독성이 사용된 용량 및 농도에서 수용자에게 이의 의도된 용도를 위해 허용될 수 있는 부형제이고, 약물, 제제 또는 결합 분제를 포함하는 제형화의 다른 성분과 양립할 수 있다.
본 발명에서 사용되는 "치료학적으로 유효한 양"이라는 용어는 코로나바이러스의 노출 전 또는 노출 후에 예방 또는 치료에 유효한 본 발명의 결합 분자의 양을 나타낸다.
본원에 기재된 상기 각 특징들은 조합되어 사용될 수 있으며, 상기 각 특징들이 특허청구범위의 서로 다른 종속항에 기재된다는 사실은 이들이 조합되어 사용될 수 없음을 나타내는 것은 아니다.
본 발명의 결합 분자는 사스-코로나바이러스-2(SARS-CoV-2) 야생형 및 향후 발생 가능한 변이 바이러스뿐만 아니라, 인간에게 감염되어 치명적인 질병을 유발하는 사스-코로나바이러스(SARS-CoV), 중동호흡기증후군 코로나바이러스 (MERS-CoV) 등을 포함한 인간에게 감염 가능성이 있는 다양한 코로나바이러스 종에 대한 우수한 결합 능력을 가지고, 우수한 중화 효과를 나타내므로, 코로나바이러스로 인하여 발생하는 질환에 대한 진단, 예방 또는 치료에 매우 유용하다.
도 1은 본 발명의 일 실시예에 따른 No. 32 항체의 작용 기전 (mechanism of action)을 Octet을 이용하여 Biolayer interference (BLI) 분석을 진행하여 평가한 결과를 나타낸 것이다.
도 2a는 본 발명의 결합 분자를 이용한 마우스 동물 실험 중 SARS-CoV-2 바이러스 감염 전 및 후 6일 동안 매일 각 군의 평균 체중을 평가한 결과이다.
도 2b는 본 발명의 결합 분자를 이용한 마우스 동물 실험 중 SARS-CoV-2 바이러스 접종 후 Vero 세포를 이용하여 마우스의 폐 조직의 바이러스 역가를 측정한 결과이다.
도 2c는 본 발명의 결합 분자를 이용한 마우스 동물 실험 중 SARS-CoV-2 바이러스 접종 후 Vero 세포를 이용하여 마우스의 비강세척액의 바이러스 역가를 측정한 결과이다.
도 2a는 본 발명의 결합 분자를 이용한 마우스 동물 실험 중 SARS-CoV-2 바이러스 감염 전 및 후 6일 동안 매일 각 군의 평균 체중을 평가한 결과이다.
도 2b는 본 발명의 결합 분자를 이용한 마우스 동물 실험 중 SARS-CoV-2 바이러스 접종 후 Vero 세포를 이용하여 마우스의 폐 조직의 바이러스 역가를 측정한 결과이다.
도 2c는 본 발명의 결합 분자를 이용한 마우스 동물 실험 중 SARS-CoV-2 바이러스 접종 후 Vero 세포를 이용하여 마우스의 비강세척액의 바이러스 역가를 측정한 결과이다.
이하 본 발명을 실시예를 통해 상세히 설명한다. 그러나 하기 실시예들은 본 발명의 내용을 예시하는 것일 뿐 발명의 범위가 실시예에 의해 한정되지 않는다. 본 발명에서 인용된 문헌은 본 발명의 명세서에 참조로서 통합된다.
실시예 1: SARS-CoV-2 회복 환자의 혈액으로부터 PBMC 분리
혈액의 공여자는 2020년 SARS-CoV-2에 감염되었음을 확진 받고 치료를 통하여 더 이상 바이러스가 검출되지 않은 사람들을 대상으로 하였으며 공여자 선정과 채혈 과정은 임상시험심사 위원회(IRB)의 승인을 받고 이루어졌다. 공여자 선정 후 약 30㎖의 전혈을 채혈하여 Ficoll-PaqueTM PLUS(GE Healthcare) 방법을 사용하여 PBMC(peripheral blood mononuclear cell)를 분리하였다. 분리된 PBMC는 인산 완충용액으로 2회 세척한 후, 냉동 배지(RPMI:FBS:DMSO = 5:4:1)로 1x107cells/㎖ 농도로 맞추어 액체 질소 탱크(Liquid Nitrogen Tank)에 보관하였다.
실시예 2: 항체 디스플레이된 파아지 라이브러리(phage library) 제작
실시예 1 에서 분리한 PBMC에서 Trizol Reagent(Invitrogen)를 이용하여 전체 RNA를 추출한 후 the SuperScriptTM III First-Strand cDNA synthesis system(Invitrogen, USA)을 이용하여 cDNA를 합성하였다.
합성된 cDNA로부터 항체 라이브러리의 제작은 선행문헌을 참고하였다(Barbas C. et. al. Phage display a laboratory manual. 2001. CSHL Press). 간단히 기술하면 합성된 cDNA로부터 High fidelity Taq polymerase(Roche)와 디제너레이티브 프라이머 세트(degenerative primer set)(IDT)을 이용하여 항체의 경쇄와 중쇄의 가변 영역을 PCR(polymerase chain reaction) 방법으로 증폭하였다. 분리된 경쇄와 중쇄의 가변영역 절편들이 무작위 조합으로 하나의 서열로서 연결되도록 overlap PCR 방법으로 scFv 형태의 유전자로 만들어 증폭한 후 제한 효소로 절단하고 1% 아가로스 겔 전기영동(agarose gel electrophoresis)과 gel extraction kit(Qiagen) 방법을 사용하여 scFv를 분리하였다. 파아지 벡터도 동일한 제한 효소로 절단하고 분리한 뒤 상기 scFv 유전자와 섞고 T4 DNA ligase(New England Biolab)를 넣은 후 16℃에서 12시간 이상 반응하였다. 반응액을 ER2738 수용성 세포(competent cell)과 섞고 전기천공(electroporation) 방법으로 형질 전환하였다. 형질 전환된 ER2738은 진탕 배양 후 VCSM13 helper phage(Agilent Technologies)를 넣고 12시간 이상 배양하였다.
실시예 3: 파아지 효소 면역분석을 이용한 선별
실시예 2 에서 제작한 파아지 라이브러리 배양액을 원심 분리하여 숙주세포를 제거한 뒤 4% PEG와 0.5M NaCl을 넣고 원심 분리하여 파아지를 침강 시키고 상층액을 제거하였다. 침강된 파아지를 1% BSA/TBS 에 희석하여 파아지 라이브러리를 얻고, 이후 다양한 SARS-CoV-2 Spike 단백질 (S1, S2, S1+S2), SARS-CoV spike 단백질 혹은 MERS-CoV spike 단백질들에 대한 결합 및 해리 반응으로 패닝(panning)을 독립적으로 진행하여 SARS-CoV-2, SARS-CoV 혹은 MERS-CoV spike 단백질에 대한 결합 능력을 갖는 scFv-파아지를 분리하였다. 예를 들어, SARS-CoV-2 S 단백질의 한 부분인 S2 (S2 domain) 영역(residues S686 to P1213 on S glycoprotein)이 결합된 ELISA 플레이트(plate)에 파아지 라이브러리를 넣고 상온에서 2시간 동안 반응시켰다. 반응액을 제거한 뒤 ELISA 플레이트를 0.05% tween 20이 포함된 PBS로 세척한 뒤 60㎕ 의 0.1M glycine-HCl(pH 2.2)를 넣어 항원에 결합한 scFv-파아지를 떼어내고 2M Tris(pH 9.1)를 이용하여 중화 하였다. 중화된 scFv-파아지는 ER2738에 감염시킨 뒤 보조(helper) 파아지를 넣고 배양하여 다음 번 패닝에 사용하였다. 감염시킨 ER2738의 일부는 보조 파아지를 넣기 전에 LB 플레이트에 도말하여 다음날 콜로니(colony)를 얻었다.
각 패닝 마다 형성된 콜로니는 96-well deep well plate(Axygen)에 담긴 배양액에 넣어 진탕 배양하고 OD600이 0.7 이상의 값이 되었을 때 보조 파아지를 넣은 후 37℃에서 12시간 이상 진탕 배양하였다. 배양액을 원심 분리하여 숙주세포를 제거하고 scFv-파아지를 포함하는 상등액을 준비하였다.
준비된 scFv-파아지 상등액을 6% BSA/PBS 와 1:1 희석한 뒤 SARS-CoV-2 S 단백질들을 흡착 후 블로킹(blocking)한 96-웰 마이크로타이터 플레이트의 각 웰에 넣고 37℃에서 2시간 동안 정치하였다. 각 웰을 0.05% Tween 20가 포함된 PBS로 3회 세척한 뒤 HRP(겨자무과산화효소, horseradish peroxidase)가 표지 된 항 M13 항체를 넣고 37℃에서 1시간 동안 정치하였다. 각 웰을 0.05% Tween 20가 포함된 PBS로 3회 세척한 뒤 ABTS(2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt)를 넣고 405nm 에서의 흡광도를 측정하여 SARS-CoV-2 S 항원 단백질에 대한 결합력을 갖는 scFv-파아지를 선별하였다.
실시예 4: scFv-Fc 항체 분절의 SARS-CoV-2 중화능 평가
실시예 3에서 선별된 scFv-파아지는 이후 콜로니를 진탕 배양하여 DNA를 얻은 다음 항체 가변영역에 대한 서열을 분석하였다. 이 중에서 아미노산 서열로서 중복된 클론을 제외하고 선정된 scFv-파아지를 후보 항체 동물 세포 주에서의 발현 능력을 평가하기 위하여 scFv 항체 분절(scFv-Fc) 형태로 벡터에 클로닝하였다. 형질도입 시약(Transfection reagent)을 이용하여 CHO 세포에 형질 감염시켜 발현시킨 후 그 배양액을 이용하여 scFv-Fc 항체 분절을 한국 분리종 SARS-CoV-2 바이러스 (betaCoV/Korea/KCDC/2020 NCCP43326)에 대하여 CPE(Cytopathic effect)측정법으로 평가하였다.
CPE 측정법은 항체 시료를 희석한 뒤 각각 동량의 100TCID50 바이러스와 혼합하여 37℃에서 30분 동안 반응시킨 뒤 VERO.E6 세포주에 감염시켜 살아있는 세포를 확인하는 방법으로 수행하였다. 37℃, 5% CO2 인큐베이터(incubator)에서 4일간 배양한 뒤 살아있는 세포를 분석하여 항체 분절 시료의 중화능을 평가하였다. 항체 중화능 (%)는 하나의 농도에 독립적으로 두 well을 분석한 결과 세포가 모두 살아 있으면 100%로 표기하였으며, 50%는 한 well만 살아 있을 경우, 0%는 두 well 모두 살아 있지 않음을 나타낸다.
분석 결과, [표 3]에서와 같이 중화능을 갖는 항체 분절이 확인 되었다. 하기 표 3에서의 No.는 표 1,2 에 기재된 각 결합 분자의 No.와 동일한 결합 분자를 지칭한다. 하기 [표 3]에서 양성 대조군 항체는 셀트리온의 CT-P59 코로나19 중화항체이다.
No. | scFv-Fc 희석 농도 μg/ml | ||||
2 | 1 | 0.5 | 0.25 | 0.125 | |
2 | 0 | 0 | 50 | 0 | 0 |
3 | 50 | 0 | 0 | 0 | 0 |
12 | 50 | 0 | 0 | 0 | 0 |
15 | 0 | 0 | 0 | 50 | 0 |
16 | 50 | 0 | 0 | 0 | 0 |
18 | 50 | 0 | 0 | 0 | 0 |
19 | 50 | 0 | 0 | 0 | 0 |
20 | 100 | 100 | 100 | 100 | 100 |
22 | 0 | 50 | 0 | 0 | 0 |
23 | 50 | 0 | 0 | 0 | 0 |
24 | 100 | 100 | 100 | 0 | 0 |
26 | 0 | 0 | 50 | 50 | 0 |
31 | 50 | 0 | 0 | 0 | 0 |
32 | 100 | 100 | 100 | 100 | 100 |
33 | 50 | 50 | 0 | 0 | 0 |
34 | 100 | 100 | 100 | 50 | 0 |
37 | 50 | 50 | 50 | 50 | 0 |
43 | 100 | 0 | 0 | 0 | 0 |
45 | 100 | 50 | 50 | 50 | 0 |
48 | 100 | 100 | 100 | 100 | 100 |
50 | 0 | 50 | 0 | 0 | 0 |
51 | 50 | 0 | 0 | 0 | 0 |
53 | 50 | 50 | 50 | 0 | 0 |
54 | 100 | 100 | 100 | 100 | 100 |
55 | 0 | 0 | 50 | 0 | 0 |
56 | 0 | 0 | 50 | 50 | 0 |
59 | 50 | 50 | 0 | 0 | 0 |
60 | 50 | 50 | 0 | 0 | 0 |
61 | 100 | 100 | 100 | 50 | 0 |
66 | 50 | 50 | 50 | 0 | 0 |
69 | 50 | 0 | 0 | 0 | 0 |
74 | 50 | 0 | 0 | 0 | 0 |
75 | 50 | 50 | 0 | 0 | 0 |
76 | 100 | 50 | 0 | 0 | 0 |
81 | 100 | 100 | 100 | 100 | 100 |
82 | 50 | 0 | 0 | 0 | 0 |
83 | 50 | 0 | 0 | 0 | 0 |
85 | 50 | 0 | 0 | 0 | 0 |
86 | 50 | 0 | 0 | 0 | 0 |
87 | 50 | 50 | 50 | 0 | 0 |
93 | 50 | 50 | 50 | 0 | 0 |
94 | 100 | 0 | 0 | 0 | 0 |
95 | 100 | 0 | 0 | 0 | 0 |
96 | 100 | 0 | 0 | 0 | 0 |
98 | 50 | 50 | 0 | 0 | 0 |
102 | 100 | 0 | 0 | 0 | 0 |
103 | 0 | 0 | 100 | 100 | 50 |
104 | 100 | 100 | 50 | 0 | 0 |
108 | 0 | 50 | 0 | 0 | 0 |
양성 대조군 항체 | 100 | 100 | 100 | 100 | 100 |
실시예 5: 완전 인간 항체(Full IgG)로 전환 후 항체의 결합력 평가
실시예 4에서 항체 분절(scFv-Fc)로 확인된 중화능으로 선정된 항체들을 완전 인간 항체(Full IgG)로 변환하고, 실시예 4의 방법으로 항체 배양액을 준비하여, 완전 인간 항체에서의 SARS-CoV-2 RBD와의 결합력을 평가하였다. Octet을 이용하여 Biolayer interference (BLI) 분석을 진행하여 평가하였다. 분석 결과, 완전 인간 항체 11종은 하기 [표 4]와 같이 SARS-CoV-2 바이러스 표면 단백질 (RBD)에 대해서 우수한 결합력을 가지는 것이 확인 되었다. 하기 [표 4]에서의 No.는 표 1, 표 2에 기재된 각 결합 분자의 No.와 동일한 결합 분자를 지칭한다.
No. | KD (M) |
32 | 1.47E-10 |
33 | 4.31E-11 |
34 | 1.85E-10 |
37 | 5.70E-11 |
45 | 7.08E-11 |
48 | 1.84E-10 |
53 | 3.39E-09 |
54 | 3.13E-11 |
59 | 4.96E-11 |
61 | 2.26E-11 |
81 | 4.28E-11 |
실시예 6 : 완전 인간 항체(Full IgG)의 중화능 평가
6-1. 완전 인간 항체(Full IgG)의 중화능 평가(1)
실시예 5에서 SARS-CoV-2 S (RBD) 단백질에 대한 결합 및 발현량으로 선별된 11종의 완전 인간 항체 (Full IgG)를 한국 분리종 SARS-CoV-2 바이러스 GR형 (hCoV-19/South Korea/KUMC17/2020)에 대하여 PRNT 측정법 (plaque reduction neutralization test)으로 중화능을 평가하였다.
PRNT 측정법은 항체 시료를 희석 (1 ng/ul부터 1/4단계 희석하여 10개 농도, 0.5 ng/ul부터 1/2단계 희석하여 11개 농도)한 뒤 각각 동량의 0.05 MOI 바이러스와 혼합하여 37℃에서 2시간 동안 반응시킨 뒤 VERO.E6 세포주에 감염시켜 플라크 측정(plaque assay)를 수행하였다. 37℃, 5% CO2 인큐베이터(incubator)에서 60시간 배양한 뒤, 크리스털 바이올렛(crystal violet)을 이용하여 염색하고 형성된 플라크의 수를 비교, 분석하여 항체 시료의 중화능을 평가하였다. 항체 중화능(ng/ml)은 2회 수행한 중화능 평가 결과로부터 얻은 평균값으로서 항체 처리군의 IC50 값 (항체가 바이러스에 대해 중화 활성의 50% 를 나타내는 항체 농도)으로 표시하였으며, 표 5에서 표기값이 낮을수록 중화능이 우수한 것을 나타낸다.
분석 결과, 하기 [표 5]에서와 같이 우수한 중화능을 갖는 완전 인간 항체(Full IgG)가 확인되었다. 하기 [표 5]에서 No.는 표 1, 표 2에 기재된 각 결합 분자의 No.와 동일한 결합 분자를 지칭한다.
No. | ng/ml |
32 | 92.17 |
33 | >1000 |
34 | 448.9 |
37 | 542.8 |
45 | 434.5 |
48 | 155.8 |
53 | 381.4 |
54 | 63.8 |
59 | >1000 |
61 | 798.6 |
81 | 669.9 |
6-2. 완전 인간 항체(Full IgG)의 중화능 평가(2)
항체 발현율 등 항체 특성을 반영하여 선별된 항체 6종에 대하여 SARS-CoV-2 GR형 바이러스에 대하여 중화능을 추가 평가 진행하였다.
분석 결과, 하기 [표 6]에서와 같이 중화능이 확인 되었다. 하기 [표 6]에서 No.는 표 1, 표 2에 기재된 각 결합 분자의 No.와 동일한 결합 분자를 지칭한다. 하기 [표 6]에서 양성 대조군 항체는 셀트리온의 CT-P59 코로나19 중화항체이다.
No. | ng/ml |
32 | 21.1 |
34 | 499.4 |
37 | 1082.4 |
45 | 521.9 |
54 | 16.0 |
32+54 | 11.1 |
양성대조군 | 2.0 |
6-3. 완전 인간 항체(Full IgG)의 중화능 평가(3)
항체 발현율 등 항체 특성을 반영하여 선별된 항체 No. 32에 대하여 상기 6-1.과 같은 분석 방법으로 대조군으로 한국 분리종 GR형(hCoV-19/South Korea/KUMC17/2020), GH형(hCoV-19/Korea/KCDC10847/2020), 영국변이바이러스주(hCoV-19/South Korea/KDCA0838/2020)과 남아공변이바이러스주 (hCoV-19/South Korea/KDCA0463/2020)에 대하여 PRNT측정법(plaque reduction neutralization test)으로 추가 평가 진행하였다.
분석 결과, 각 해당 바이러스주에 대해 [표 7]과 같이 중화능이 확인 되었다.
Type | IC50 (ng/ml) |
GR | 71.1 |
GH | 176.2 |
영국변이 | 31.73 |
남아공변이 | 27.62 |
6-4. 완전 인간 항체(Full IgG)의 중화능 평가(4)
항체 발현율 등 항체 특성을 반영하여 선별된 항체에 대하여 SARS-CoV-1과 MERS-CoV 바이러스에 대하여 중화능을 추가 평가 진행하였다.
분석 결과, 하기 [표 8]에서와 같이 중화능이 확인 되었다. 하기 [표 8]에서 No.는 표 1, 표 2에 기재된 각 결합 분자의 No.와 동일한 결합 분자를 지칭한다. 하기 [표 8]에서 SARS-CoV-1 분석의 양성 대조군 항체는 CR3022이며(Xiaolong Tian et al., Emerg Microbes Infect. 2020 Feb 17;9(1):382-385), MERS-CoV 양성 대조군 항체는 셀트리온의 CT-P38 메르스 중화항체이다(한국공개특허공보 제10-2019-0093114호).
No. | MERS-CoV | SARS-CoV-1 |
IC50(ng/ml) | IC50 (ng/ml) | |
2 | 6682.3 | 4001.4 |
59 | >10000 | 6729.5 |
95 | 9690.8 | >10000 |
102 | >10000 | 2314.7 |
103 | 8132.8 | >10000 |
32 | 8377.7 | >10000 |
CT-P59 | 8125.1 | >10000 |
CR3022 | >10000 | 6843.6 |
CT-P38 | 51.8 | >10000 |
실시예 6-5. 완전 인간 항체(Full IgG)의 SARS-CoV-2 슈도변이바이러스에 대한 중화능 평가(1)
SARS-CoV-2 spike D614와 D614G 그리고 제작한 20종의 SARS-CoV-2 spike 변이 슈도바이러스에 대해 No.32 + No.54 항체 칵테일의 중화능 여부를 확인하는 시험을 진행하였다. 여기서, No. 32, No. 54 항체는 표 1, 표 2에 기재된 No. 32, No. 54 결합 분자를 각각 지칭한다. 상기 SARS-CoV-2 spike 변이 슈도바이러스는 CT-P59(Regdanvimab) 항체의 에피토프 중 일부 위치와 논문(A. Baum et al.,Science, 2020 Aug 21;369(6506):1014-1018, Korber et al., 2020, Cell 182, 812-827)에 발표된 변이 바이러스를 참고하여 제작하였다. 변이 슈도바이러스의 양을 1.73ⅹ107 copies로 고정하고, 항체 1000 ng/mL 최고 농도로 3배씩 10단계로 희석하여 변이바이러스에 대한 중화능 시험을 수행한 결과, 하기 [표 9]와 같이 중화능이 확인 되었다.
No. | SARS-CoV-2 변이 pseudovirus | Backbone Vector |
IC50
(ng/mL) |
1 | D614 | - | 5.229 |
2 | S494P | D614 | 13.42 |
3 | R685H | D614 | 5.046 |
4 | S494P+R685H | D614 | 2.676 |
5 | E484K | D614 | 13.63 |
6 | Q493K | D614 | 10.15 |
7 | F490S | D614 | 13.25 |
8 | Y449N | D614 | 12.55 |
9 | L455F | D614 | 6.989 |
10 | F456L | D614 | 3.056 |
11 | L452R | D614 | 25.73 |
12 | E406Q | D614 | 15.11 |
13 | K444Q | D614 | 8.646 |
14 | V445A | D614 | 7.124 |
15 | N234Q | D614 | 70.01 |
16 | A475V | D614 | 7.35 |
17 | D614G | - | 6.723 |
18 | S477N | D614G | 4.659 |
19 | A222V | D614G | 6.404 |
20 | V1176F | D614G | 9.035 |
21 | N439K | D614G | 6.225 |
22 | Y453F | D614G | 8.515 |
6-6. 완전 인간 항체(Full IgG)의 SARS-CoV-2 슈도변이바이러스에 대한 중화능 평가(2)
SARS-CoV-2의 변이 슈도 바이러스 15종에 대해 No.32, No.54 항체의 중화능 여부를 확인하는 시험을 진행하였다. 여기서, No. 32, No. 54 항체는 표 1, 표 2에 기재된 No. 32, No. 54 결합 분자를 각각 지칭한다. 상기 SARS-CoV-2 spike 변이 슈도바이러스는 CT-P59(Regdanvimab) 항체의 에피토프 중 일부 위치와 논문(A. Baum et al.,Science, 2020 Aug 21;369(6506):1014-1018, Korber et al., 2020, Cell 182, 812-827)에 발표된 변이 바이러스를 참고하여 제작하였다. 슈도변이바이러스의 양을 1.73ⅹ107 copies로 고정하고, 항체 1000 ng/mL 최고 농도로 3배씩 10단계로 희석하여 변이바이러스에 대한 중화능 시험을 수행한 결과, 하기 [표 10]과 같이 중화능이 확인 되었다.
No. | SARS-CoV-2 변이 pseudovirus | IC50 (ng/ml) | |
No.32 | No.54 | ||
1 | D614G | 7 | 100 |
2 | K417N+E484K+N501Y | 10 | 2870 |
3 | 501Y.V2 | 60 | 2180 |
4 | D614 or G614 | 3.25 | 12.84 |
5 | K417N | 1 | 4.817 |
6 | E484K | 5.9 | >1000 |
7 | L452R | 3.39 | >1000 |
8 | Y449N | 2.14 | 21.9 |
9 | L455F | 7.52 | 8.87 |
10 | F456L | 2.4 | 2.15 |
11 | Q493K | 5.62 | 9.92 |
12 | S494P | 6.29 | 5.85 |
13 | E406Q | 3.26 | 1.71 |
14 | F490S | 6.08 | 12 |
15 | K417T | 0.91 | 7.08 |
6-7. No. 32 항체의 중화능 평가
SARS-CoV-2 S (RBD) 단백질에 대한 결합 및 발현량과 SARS-CoV-2 야생형 바이러스에 대한 중화능으로 선별된 완전 인간 항체 (Full IgG)인 No. 32 항체(표 1 및 표 2 기준)를 남아공변이바이러스주 (hCoV-19/South Korea/KDCA0463/2020)에 PRNT 측정법 (plaque reduction neutralization test)으로 중화능을 평가하였다.
PRNT 측정법은 항체 시료를 희석 (1ug/ul부터 1/2단계 희석하여 11개 농도)한 뒤 각각 동량의 0.05 MOI 바이러스와 혼합하여 37℃에서 2시간 동안 반응시킨 뒤 VERO.E6 세포주에 감염시켜 플라크 측정(plaque assay)를 수행하였다. 37℃, 5% CO2 인큐베이터(incubator)에서 60시간 배양한 뒤, 크리스털 바이올렛(crystal violet)을 이용하여 염색하고 형성된 플라크의 수를 비교, 분석하여 항체 시료의 중화능을 평가하였다. 항체 중화능(ng/ml)은 2회 수행한 중화능 평가 결과로부터 얻은 평균값으로서 항체 처리군의 IC50 값 (항체가 바이러스에 대해 중화 활성의 50% 를 나타내는 항체 농도)과 IC90 값 (항체가 바이러스에 대해 중화 활성의 90%를 나타내는 항체 농도)으로 표시하였으며, [표 11]에서 표기값이 낮을수록 중화능이 우수한 것을 나타낸다.
분석 결과, 남아공변이바이러스주에 대해 No. 32 항체로 분석 진행 시 하기 [표 11]과 같은 중화능이 확인 되었다.
항체 | IC50 (ng/ml) | IC90 (ng/ml) |
No. 32 | 24.45 | 59.78 |
6-8. No.32 항체의 SARS-CoV-2 슈도변이바이러스에 대한 중화능 평가
SARS-CoV-2 spike D614G 그리고 제작한 42종의 SARS-CoV-2 spike 변이 슈도바이러스에 대해 No.32 항체의 중화능 여부를 확인하는 시험을 진행하였다. 상기 SARS-CoV-2 spike 변이 슈도 바이러스는 CT-P59(Regdanvimab)의 에피토프 중 일부 위치와 논문(A. Baum et al., Science, 2020 Aug 21;369(6506):1014-1018., Korber et al., 2020, Cell 182, 812-827., Wang et al.,2021, doi: 10.1038/s41586-021-03398-2.)에 발표된 변이 바이러스를 참고하여 제작하였다. 변이슈도바이러스의 양을 1.73ⅹ107 copies로 고정하고, 항체 100 ng/mL 최고 농도로 3배씩 10단계로 희석하여 변이바이러스에 대한 중화능 시험을 수행한 결과, 하기 [표 12]와 같이 중화능이 확인 되었다.
No. | SARS-CoV-2 변이 pseudovirus | Backbone Vector | IC50 (ng/ml) |
1 | D614G | - | 4.113 |
2 | Q493R | D614G | 5.594 |
3 | K417E | D614G | 1.133 |
4 | G446V | D614G | 5.019 |
5 | G476S | D614G | 4.576 |
6 | F486V | D614G | 3.736 |
7 | E406W | D614G | 7.836 |
8 | N440D | D614G | 4.238 |
9 | P681H | D614G | 3.011 |
10 | K417N | D614G | 1.344 |
11 | A701V | D614G | 4.139 |
12 | D80A | D614G | 2.657 |
13 | K417N+E484K+N501Y | D614G | 2.135 |
14 | Q493M | D614G | 4.785 |
15 | F486I | D614G | 4.392 |
16 | Y489H | D614G | 6.489 |
17 | N501Y | D614G | 5.217 |
18 | HV69-70 del | D614G | 4.156 |
19 | HV69-70del + N501Y | D614G | 4.633 |
20 | N501T | D614G | 7.619 |
21 | N501F | D614G | 7.149 |
22 | Q677H | D614G | 4.84 |
23 | Q498H | D614G | 2.558 |
24 | N460T | D614G | 11.73 |
25 | F486S | D614G | 2.275 |
26 | F486L | D614G | 2.366 |
27 | T478K | D614G | 2.575 |
28 | K417T | D614G | 0.977 |
29 | Q493Y | D614G | 1.124 |
30 | Q493A | D614G | 5.745 |
31 | A372V | D614G | 2.441 |
32 | P384L | D614G | 4.404 |
33 | S494L | D614G | 4.638 |
34 | 501Y.V3 (P.1) | D614G | 1.552 |
35 | 501Y.V2 (B.1.351) | D614G | 3.727 |
36 | B.1.526 NY | D614G | 3.53 |
37 | E484Q+L452R+P681R | D614G | 7.356 |
38 | B.1.1.7 영국 | D614G | 5.413 |
39 | B.1.429 캘리포니아 | D614G | 6.723 |
40 | B.1.525 뉴욕 | D614G | 5.569 |
41 | G477R | D614G | 8.772 |
42 | D420N | D614G | - |
43 | Y473F | D614G | 5.248 |
6-9. No.32 항체의 SARS-CoV-2 미국, 남아프리카 변이바이러스에 대한 중화능 평가
항체 발현율 등 항체 특성을 반영하여 선별된 No.32 에 대하여 상기와 마찬가지로 미국 캘리포니아 변이 바이러스주 (hCoV-19/Korea/KDCA49671/2021 (B.1.427), hCoV-19/Korea/KDCA59777/2021 (B.1.429)), 남아프리카 변이 바이러스주 (hCoV-19/South Korea/KDCA0463/2020, B.1.351)에 대하여 PRNT측정법(plaque reduction neutralization test)으로 추가 평가 진행하였다. 분석 결과, 하기 [표 13]과 같이 중화능이 확인되었다.
No. | 변이바이러스 | IC50 (ng/ml) |
1 | 미국캘리포니아 (B.1.427) | 55.7 |
2 | 미국캘리포니아 (B.1.429) | 40.18 |
3 | 남아공변이주 (B.1.351) | 29.17 |
6-10. No.32 항체의 SARS-CoV-2 뉴욕, 나이지리아 변이바이러스에 대한 중화능 평가
항체 발현율 등 항체 특성을 반영하여 선별된 항체 No.32 에 대하여 상기와 마찬가지로 대조군으로 한국 분리종 GR형(B.1.1.119), 미국 뉴욕 변이 바이러스주 (hCoV-19/Korea/KDCA82438/2021, B.1.526), 영국/나이지리아 변이 바이러스주 (B.1.525)에 대하여 PRNT측정법(plaque reduction neutralization test)으로 추가 평가 진행하였다. 분석 결과, 하기 [표 14]와 같이 중화능이 확인되었다.
No. | 변이바이러스 | IC50 (ng/ml) |
No.32 | ||
1 | 미국 뉴욕 (B.1.526) | 47.59 |
2 | 영국/나이지리아 (B.1.525) | 15.77 |
3 | GR (B.1.1.119) | 72.36 |
6-11. No.32 항체의 SARS-CoV-2 브라질(P.1) 변이바이러스에 대한 중화능 평가
항체 발현율 등 항체 특성을 반영하여 선별된 항체 No.32 에 대하여 상기와 마찬가지로 브라질 변이 바이러스주 (P.1)에 대하여 PRNT측정법(plaque reduction neutralization test)으로 추가 평가 진행하였다. 분석 결과, 하기 [표 15]와 같이 중화능이 확인되었다.
No. | 변이바이러스 | IC50 (ng/ml) |
1 | 브라질 (P.1) | 7.21 |
실시예 7. 완전 인간 항체(Full IgG)의 항체 결합 특성 및 작용 기전 평가
실시예 5, 6를 통하여 선정된 항체 (full IgG)의 SARS-CoV-2 RBD 변이 단백질에 대한 결합 (No.32와 No.54 항체)및 작용 기전 (No.32 항체)을 Octet 분석을 진행하여 평가하였다.
SARS-CoV-2 바이러스는 표면 단백질 (RBD)를 인간 수용체 (ACE2)에 결합시켜 인체 세포에의 감염을 시작할 수 있다. 따라서, No. 32 항체(Full IgG)의 작용 기전 (mechanism of action)을 Octet을 이용하여 Biolayer interference (BLI) 분석을 진행하여 평가하였다. 분석 결과, [표 16]과 같이 SARS-CoV-2 바이러스 표면 단백질 (RBD)의 변이 단백질에 대해서도 우수한 결합력을 가지며, [도 1]과 같이 SARS-CoV-2 표면 단백질 (RBD)와 인간 수용체 (ACE2)의 결합이 No. 32 항체(Full IgG)에 의해 완전하게 억제되는 것이 확인되었다.
No. | RBD type | KD (M) | kon(1/Ms) | kdis(1/s) |
32 | WT | 3.05E-10 | 6.33E+05 | 1.93E-04 |
54 | 1.33E-10 | 8.15E+05 | 1.08E-04 | |
32 | S494P | 1.61E-10 | 5.48E+05 | 8.82E-05 |
54 | 1.84E-11 | 8.22E+05 | 1.51E-05 | |
32 | K417N | 3.13E-10 | 4.74E+05 | 1.48E-04 |
54 | 6.63E-11 | 1.06E+06 | 7.04E-05 | |
32 | E484K | 2.90E-10 | 6.63E+05 | 1.92E-04 |
54 | 1.73E-09 | 2.32E+05 | 4.01E-04 | |
32 | N501Y | 3.79E-10 | 4.72E+05 | 1.79E-04 |
54 | 1.18E-10 | 8.13E+05 | 9.56E-05 | |
32+54 | WT | 2.74E-10 | 3.72E+05 | 1.02E-04 |
32+54 | S494P | 1.99E-10 | 4.14E+05 | 8.22E-05 |
32+54 | K417N | 1.60E-10 | 4.62E+05 | 7.39E-05 |
32+54 | E484K | 6.90E-10 | 2.48E+05 | 1.71E-04 |
32+54 | N501Y | 2.35E-10 | 4.13E+05 | 9.68E-05 |
실시예 8. 동물실험을 통한 완전 인간 항체(Full IgG)의 SARS-CoV-2 바이러스 중화능 평가
8-1. 마우스 예방능 평가 실험
SARS-CoV-2 바이러스에 자연 감염되며 인간과 유사한 임상 증상 및 병변을 보이는 동물 모델인 TG마우스(B6.Cg-Tg(K18-ACE2)2Prlmn/J [Stock No: 034860 | K18-hACE2] from The Jackson Laboratory)를 이용하여, No. 32 및 No. 54 항체의 생체 내 예방능을 평가하기 위하여 다음과 같이 실험을 진행하였다.
군 구성은 비감염군, 감염군 및 투여군 (CT-P59 1 mg/kg 또는 10 mg/kg, No. 32 항체 1 mg/kg 또는 10 mg/kg, No. 54 항체 1 mg/kg 또는 10 mg/kg, No. 32 항체와 No. 54 항체 칵테일 1 mg/kg 또는 10 mg/kg) 총 10군으로 구성하였으며, 비감염군은 3마리, 감염군 및 투여군은 군당 6마리로 구성하였다. 각 군은 DPBS 혹은 각 투여 항체 1 mg/kg 또는 10 mg/kg 투여 후 24시간 뒤 SARS-CoV-2 바이러스(NMC-nCoV02) 1 x 105 PFU/ 50 μL를 비강에 접종하여 최대 6일간 관찰하였다. 추가적으로, 바이러스 접종 전 및 후 6일 동안 매일 각 군의 개체 별 체중을 평가하였다. 조직 내 바이러스 역가를 측정하기 위해 바이러스 접종 후 3일째와 6일째 마우스를 희생시켜 폐조직과 비강세척액을 확보하였고, Vero 세포를 이용한 플라크 분석 (Plaque assay)을 하여 각 조직의 바이러스 역가를 측정하였다.
그 결과, No. 32 항체 (1, 10 mg/kg)와 No. 54 항체 (10 mg/kg)는 CT-P59 대비 체중 변화상 열등하지 않은 결과를 보였다. No. 54 항체 저용량 (1 mg/kg)은 CT-P59와 No. 32 항체 대비 체중 변화 상 유의적으로 낮은 결과를 보였다. (도 2a)
플라크 분석으로 측정한 폐의 바이러스 역가 결과는 다음과 같다. No. 32 항체 고용량 (10 mg/kg)과 No. 32 항체와 No. 54 항체 칵테일 고용량 (10 mg/kg)은 3일째부터 바이러스가 검출되지 않아 가장 좋은 예방능을 보였고, 6일째에서는 모든 항체 투여군에서 예방능 효과를 보였다. (도 2b)
또한, 플라크 분석으로 측정한 비강세척액의 바이러스 역가는 다음과 같다. 3일째에서는 저용량 (1 mg/kg) 군들 간의 예방능 차이가 보이지 않았다. No. 32 항체와 No. 54 항체 칵테일 그룹만이 6일째에 바이러스가 검출이 되지 않아 낮은 투여 용량 (1 mg/kg) 비교에서 가장 좋은 예방능을 보였고, 고용량 (10 mg/kg)은 6일 째 모든 투여 그룹에서 예방 효과를 확인하였다. (도 2c)
<110> CELLTRION, INC.
<120> A Binding Molecules Able To Neutralize Coronavirus Superfamily
<130> CPD2021041KR
<150> KR 10-2020-0092285
<151> 2020-07-24
<150> KR 10-2020-0116817
<151> 2020-09-11
<150> KR 10-2020-0152158
<151> 2020-11-13
<150> KR 10-2020-0171999
<151> 2020-12-10
<150> KR 10-2021-0019481
<151> 2021-02-10
<150> KR 10-2021-0036902
<151> 2021-03-22
<150> KR 10-2021-0041251
<151> 2021-03-30
<160> 1520
<170> KoPatentIn 3.0
<210> 1
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 1 LC CDR1
<400> 1
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 2
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 1 LC CDR2
<400> 2
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 1 LC CDR3
<400> 3
Ala Ser Trp Asp Asp Arg Leu Ser Ala Leu Val
1 5 10
<210> 4
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 1 HC CDR1
<400> 4
Gly Tyr Tyr Trp Ser
1 5
<210> 5
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 1 HC CDR2
<400> 5
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 1 HC CDR3
<400> 6
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 7
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 2 LC CDR1
<400> 7
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 8
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 2 LC CDR2
<400> 8
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 9
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 2 LC CDR3
<400> 9
Gly Thr Trp Asp Ser Ser Leu Ser Gly Trp Val
1 5 10
<210> 10
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 2 HC CDR1
<400> 10
Ser Tyr Tyr Met His
1 5
<210> 11
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 2 HC CDR2
<400> 11
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 2 HC CDR3
<400> 12
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 13
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 3 LC CDR1
<400> 13
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 3 LC CDR2
<400> 14
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 15
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.3 LC CDR3
<400> 15
Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val
1 5 10
<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 3 HC CDR1
<400> 16
Ser Tyr Ala Met Ser
1 5
<210> 17
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 3 HC CDR2
<400> 17
Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 18
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 3 HC CDR3
<400> 18
Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp Val
1 5 10 15
<210> 19
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 4 LC CDR1
<400> 19
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 20
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 4 LC CDR2
<400> 20
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 21
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.4 LC CDR3
<400> 21
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 22
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 4 HC CDR1
<400> 22
Ser Tyr Tyr Met His
1 5
<210> 23
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 4 HC CDR2
<400> 23
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 24
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 4 HC CDR3
<400> 24
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 25
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 5 LC CDR1
<400> 25
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 26
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 5 LC CDR2
<400> 26
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 27
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.5 LC CDR3
<400> 27
Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val
1 5 10
<210> 28
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No.5 HC CDR1
<400> 28
Arg Tyr Ala Met Ser
1 5
<210> 29
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 5 HC CDR2
<400> 29
Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 30
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 5 HC CDR3
<400> 30
Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr
1 5 10 15
<210> 31
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 6 LC CDR1
<400> 31
Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 32
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 6 LC CDR2
<400> 32
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 33
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.6 LC CDR3
<400> 33
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 34
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No.6 HC CDR1
<400> 34
Ser Tyr Tyr Met His
1 5
<210> 35
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 6 HC CDR2
<400> 35
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 36
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 6 HC CDR3
<400> 36
Gly Gly Arg His Ser Leu Asp Ala
1 5
<210> 37
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 7 LC CDR1
<400> 37
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 38
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 7 LC CDR2
<400> 38
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 39
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.7 LC CDR3
<400> 39
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 40
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 7 HC CDR1
<400> 40
Arg Lys Val Ile Ala
1 5
<210> 41
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 7 HC CDR2
<400> 41
Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 42
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 7 HC CDR3
<400> 42
Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Asn
1 5 10
<210> 43
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 8 LC CDR1
<400> 43
Arg Ala Ser Gln Gly Ile Ser Asn Ser Leu Ala
1 5 10
<210> 44
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 8 LC CDR2
<400> 44
Ala Ala Ser Arg Leu Glu Ser
1 5
<210> 45
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No.8 LC CDR3
<400> 45
Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr
1 5
<210> 46
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 8 HC CDR1
<400> 46
Asn Ala Trp Met Thr
1 5
<210> 47
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 8 HC CDR2
<400> 47
Arg Ile Lys Thr Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro
1 5 10 15
Val Lys Gly
<210> 48
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 8 HC CDR3
<400> 48
His Ser Arg Pro Asp Tyr
1 5
<210> 49
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 9 LC CDR1
<400> 49
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 50
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 9 LC CDR2
<400> 50
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 51
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.9 LC CDR3
<400> 51
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 52
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 9 HC CDR1
<400> 52
Arg Lys Val Ile Ala
1 5
<210> 53
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 9 HC CDR2
<400> 53
Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 54
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 9 HC CDR3
<400> 54
Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Thr
1 5 10
<210> 55
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 10 LC CDR1
<400> 55
Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala
1 5 10
<210> 56
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 10 LC CDR2
<400> 56
Trp Ala Ser Thr Arg Glu Ser
1 5
<210> 57
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No.10 LC CDR3
<400> 57
Leu Gln Tyr Phe Thr Ile Pro Trp Thr
1 5
<210> 58
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 10 HC CDR1
<400> 58
Asn Ala Trp Met Ser
1 5
<210> 59
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No.10 HC CDR2
<400> 59
Arg Ile Lys Thr Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro
1 5 10 15
Val Lys Gly
<210> 60
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 10 HC CDR3
<400> 60
Phe Ser Thr Pro Asp Tyr
1 5
<210> 61
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 11 LC CDR1
<400> 61
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 62
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 11 LC CDR2
<400> 62
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 63
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No.11 LC CDR3
<400> 63
Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val
1 5 10
<210> 64
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 11 HC CDR1
<400> 64
Arg Tyr Ala Ile Ser
1 5
<210> 65
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No.11 HC CDR2
<400> 65
Gly Ile Ile Pro Ile Phe Gly Lys Val Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Asp
<210> 66
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 11 HC CDR3
<400> 66
Gly Gly Ser Thr Trp Tyr Gly Gly Asn Trp Phe Asp Pro
1 5 10
<210> 67
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 12 LC CDR1
<400> 67
Ser Gly Asp Val Leu Ala Lys Lys Tyr Ala Arg
1 5 10
<210> 68
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 12 LC CDR2
<400> 68
Lys Asp Ser Glu Arg Pro Ser
1 5
<210> 69
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No.12 LC CDR3
<400> 69
Tyr Ser Ala Ala Asp Asn Asn Gly Val
1 5
<210> 70
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 12 HC CDR1
<400> 70
Ser Asp Ala Met His
1 5
<210> 71
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No.12 HC CDR2
<400> 71
Val Ile Ser Tyr Asp Gly Ser Asn Glu Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 72
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 12 HC CDR3
<400> 72
Glu Ala Thr Tyr Asp Ser Ser Gly Arg Pro Thr Gly Asp Tyr Gly Met
1 5 10 15
Asp Val
<210> 73
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 13 LC CDR1
<400> 73
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 74
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 13 LC CDR2
<400> 74
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 75
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.13 LC CDR3
<400> 75
Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val
1 5 10
<210> 76
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 13 HC CDR1
<400> 76
Gly Tyr Tyr Trp Ser
1 5
<210> 77
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No.13 HC CDR2
<400> 77
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 78
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 13 HC CDR3
<400> 78
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 79
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 14 LC CDR1
<400> 79
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 80
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 14 LC CDR2
<400> 80
Asp Val Ser Asn Arg Pro Ser
1 5
<210> 81
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No.14 LC CDR3
<400> 81
Ser Ser Tyr Thr Ser Ser Ser Thr Ser His Val Val
1 5 10
<210> 82
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 14 HC CDR1
<400> 82
Ser Tyr Ala Met Asn
1 5
<210> 83
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No.14 HC CDR2
<400> 83
Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 84
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 14 HC CDR3
<400> 84
Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr
1 5 10 15
Tyr Phe Asp Tyr
20
<210> 85
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 15 LC CDR1
<400> 85
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 86
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 15 LC CDR2
<400> 86
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 87
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No.15 LC CDR3
<400> 87
Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val
1 5 10
<210> 88
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 15 HC CDR1
<400> 88
Arg Gly Asp Tyr Trp Gly
1 5
<210> 89
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No.15 HC CDR2
<400> 89
Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 90
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 15 HC CDR3
<400> 90
His Gly Thr Ser Gly Tyr Tyr Tyr Pro Asn Trp Phe Asp Pro
1 5 10
<210> 91
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 16 LC CDR1
<400> 91
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 92
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 16 LC CDR2
<400> 92
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 93
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.16 LC CDR3
<400> 93
Ala Ala Trp Asp Asp Ser Leu Asn Ala Ser Leu
1 5 10
<210> 94
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 16 HC CDR1
<400> 94
Gly Tyr Tyr Trp Ser
1 5
<210> 95
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No.16 HC CDR2
<400> 95
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 96
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 16 HC CDR3
<400> 96
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 97
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 17 LC CDR1
<400> 97
Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 98
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 17 LC CDR2
<400> 98
Thr Asp Asn Arg Arg Pro Ser
1 5
<210> 99
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.17 LC CDR3
<400> 99
Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val
1 5 10
<210> 100
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 17 HC CDR1
<400> 100
Gly Tyr Tyr Trp Ser
1 5
<210> 101
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No.17 HC CDR2
<400> 101
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 102
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 17 HC CDR3
<400> 102
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 103
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 18 LC CDR1
<400> 103
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 104
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 18 LC CDR2
<400> 104
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 105
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.18 LC CDR3
<400> 105
Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val
1 5 10
<210> 106
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 18 HC CDR1
<400> 106
Gly Tyr Tyr Trp Ser
1 5
<210> 107
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No.18 HC CDR2
<400> 107
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 108
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 18 HC CDR3
<400> 108
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 109
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 19 LC CDR1
<400> 109
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 110
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 19 LC CDR2
<400> 110
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 111
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.19 LC CDR3
<400> 111
Ala Ala Arg Asp Asp Ser Leu Asn Gly Ala Val
1 5 10
<210> 112
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 19 HC CDR1
<400> 112
Gly Tyr Tyr Trp Ser
1 5
<210> 113
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No.19 HC CDR2
<400> 113
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 114
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 19 HC CDR3
<400> 114
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 115
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 20 LC CDR1
<400> 115
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 116
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 20 LC CDR2
<400> 116
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 117
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.20 LC CDR3
<400> 117
Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Pro
1 5 10
<210> 118
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 20 HC CDR1
<400> 118
Thr Ser Gly Val Gly Val Gly
1 5
<210> 119
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No.20 HC CDR2
<400> 119
Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr
1 5 10 15
<210> 120
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> No.20 HC CDR3
<400> 120
Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met
1 5 10 15
Asp Val
<210> 121
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 21 LC CDR1
<400> 121
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 122
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 21 LC CDR2
<400> 122
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 123
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.21 LC CDR3
<400> 123
Gln Glu Tyr Gly Ser Ser Pro Arg Arg Val Thr
1 5 10
<210> 124
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 21 HC CDR1
<400> 124
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 125
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No.21 HC CDR2
<400> 125
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 126
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No.21 HC CDR3
<400> 126
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 127
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 22 LC CDR1
<400> 127
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 128
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 22 LC CDR2
<400> 128
Asp Ala Ser Thr Arg Ala Thr
1 5
<210> 129
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No.22 LC CDR3
<400> 129
Gln Gln Tyr Tyr Gln Val Pro Leu Thr
1 5
<210> 130
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 22 HC CDR1
<400> 130
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 131
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No.22 HC CDR2
<400> 131
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 132
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 22 HC CDR3
<400> 132
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 133
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 23 LC CDR1
<400> 133
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 134
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 23 LC CDR2
<400> 134
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 135
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.23 LC CDR3
<400> 135
Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val
1 5 10
<210> 136
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 23 HC CDR1
<400> 136
Asp Tyr Gly Met His
1 5
<210> 137
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No.23 HC CDR2
<400> 137
Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 138
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 23 HC CDR3
<400> 138
Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala
1 5 10 15
Met Asp Val
<210> 139
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 24 LC CDR1
<400> 139
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 140
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 24 LC CDR2
<400> 140
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 141
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No.24 LC CDR3
<400> 141
Ser Ser Tyr Thr Ser Ser Ser Thr Tyr Val
1 5 10
<210> 142
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 24 HC CDR1
<400> 142
Glu Leu Ser Ile His
1 5
<210> 143
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 24 HC CDR2
<400> 143
Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 144
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 24 HC CDR3
<400> 144
Ser Pro Ala Val Thr Thr Ala Gly Trp Phe Asp Pro
1 5 10
<210> 145
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 25 LC CDR1
<400> 145
Ser Gly Ser Ser Ser Asn Ile Gly Thr Asn Thr Val Asn
1 5 10
<210> 146
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 25 LC CDR2
<400> 146
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 147
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.25 LC CDR3
<400> 147
Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Leu
1 5 10
<210> 148
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 25 HC CDR1
<400> 148
Gly Tyr Tyr Trp Ser
1 5
<210> 149
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 25 HC CDR2
<400> 149
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 150
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 25 HC CDR3
<400> 150
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 151
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 26 LC CDR1
<400> 151
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 152
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 26 LC CDR2
<400> 152
Asp Val Gly Lys Arg Pro Ser
1 5
<210> 153
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No.26 LC CDR3
<400> 153
Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val
1 5 10
<210> 154
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 26 HC CDR1
<400> 154
Phe Tyr Ala Ile Ser
1 5
<210> 155
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 26 HC CDR2
<400> 155
Gly Ile Ile Pro Leu Phe Gly Thr Ala Lys Tyr Ala Gln Arg Phe Gln
1 5 10 15
Asp
<210> 156
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 26 HC CDR3
<400> 156
Gly Gly Trp Ile Tyr Arg Gly Asn Trp Phe Asp Pro
1 5 10
<210> 157
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 27 LC CDR1
<400> 157
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 158
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 27 LC CDR2
<400> 158
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 159
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.27 LC CDR3
<400> 159
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val
1 5 10
<210> 160
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 27 HC CDR1
<400> 160
Asn Tyr Gly Ile Ser
1 5
<210> 161
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 27 HC CDR2
<400> 161
Gly Ile Ser Ser His Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln
1 5 10 15
Gly
<210> 162
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 27 HC CDR3
<400> 162
Glu Gly Gly Tyr Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Arg Phe
1 5 10 15
Ala Phe Asp Ile
20
<210> 163
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 28 LC CDR1
<400> 163
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 164
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 28 LC CDR2
<400> 164
Glu Val Ser Lys Arg Pro Ser
1 5
<210> 165
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No.28 LC CDR3
<400> 165
Ser Ser Tyr Ala Gly Ser Asn Tyr Val Val
1 5 10
<210> 166
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 28 HC CDR1
<400> 166
Ser Tyr Ala Met Ser
1 5
<210> 167
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 28 HC CDR2
<400> 167
Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 168
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 28 HC CDR3
<400> 168
Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr
1 5 10 15
Tyr Phe Asp Tyr
20
<210> 169
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 29 LC CDR1
<400> 169
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 170
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 29 LC CDR2
<400> 170
Asp Val Ser Asn Arg Pro Ser
1 5
<210> 171
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.29 LC CDR3
<400> 171
Ser Ser Tyr Thr Ser Ser Ser Thr Leu Gly Val
1 5 10
<210> 172
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 29 HC CDR1
<400> 172
Ser Tyr Ala Met Ser
1 5
<210> 173
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 29 HC CDR2
<400> 173
Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 174
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 29 HC CDR3
<400> 174
Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr
1 5 10 15
Tyr Phe Asp Tyr
20
<210> 175
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 30 LC CDR1
<400> 175
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 176
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 30 LC CDR2
<400> 176
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 177
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.30 LC CDR3
<400> 177
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 178
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 30 HC CDR1
<400> 178
Gly Tyr Tyr Met His
1 5
<210> 179
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 30 HC CDR2
<400> 179
Val Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 180
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 30 HC CDR3
<400> 180
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 181
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 31 LC CDR1
<400> 181
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 182
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 31 LC CDR2
<400> 182
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 183
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 31 LC CDR3
<400> 183
Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Val
1 5 10
<210> 184
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 31 HC CDR1
<400> 184
Ser Tyr Trp Ile Val
1 5
<210> 185
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 31 HC CDR2
<400> 185
Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 186
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 31 HC CDR3
<400> 186
Gly Pro Asn Ile Tyr Asn Trp Phe Asp Ser
1 5 10
<210> 187
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 32 LC CDR1
<400> 187
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 188
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 32 LC CDR2
<400> 188
Ala Ala Ser Ser Leu Gln Ser
1 5
<210> 189
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 32 LC CDR3
<400> 189
Gln Gln Ser Tyr Ser Thr Pro Leu Thr
1 5
<210> 190
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 32 HC CDR1
<400> 190
Ser Asn Tyr Met Thr
1 5
<210> 191
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 32 HC CDR2
<400> 191
Ile Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 192
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 32 HC CDR3
<400> 192
Asp Leu Pro Leu Thr Gly Thr Thr Leu Asp Tyr
1 5 10
<210> 193
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 33 LC CDR1
<400> 193
Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His
1 5 10
<210> 194
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 33 LC CDR2
<400> 194
Asp Asp Ser Asp Arg Pro Ser
1 5
<210> 195
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 33 LC CDR3
<400> 195
Gln Val Trp Asp Ser Ser Ser Asp His Val Val
1 5 10
<210> 196
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 33 HC CDR1
<400> 196
Asp Tyr Gly Met His
1 5
<210> 197
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 33 HC CDR2
<400> 197
Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 198
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 33 HC CDR3
<400> 198
Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala
1 5 10 15
Met Asp Val
<210> 199
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 34 LC CDR1
<400> 199
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 200
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 34 LC CDR2
<400> 200
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 201
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 34 LC CDR3
<400> 201
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val
1 5 10
<210> 202
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 34 HC CDR1
<400> 202
Asn Tyr Pro Leu Thr
1 5
<210> 203
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 34 HC CDR2
<400> 203
Gly Ile Ile Pro Ile Ile Gly Ala Thr Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 204
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 34 HC CDR3
<400> 204
Gly Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp Tyr
1 5 10 15
<210> 205
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 35 LC CDR1
<400> 205
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 206
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 35 LC CDR2
<400> 206
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 207
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 35 LC CDR3
<400> 207
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Trp Val
1 5 10
<210> 208
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 35 HC CDR1
<400> 208
Arg Tyr Ala Ile Ser
1 5
<210> 209
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 35 HC CDR2
<400> 209
Gly Ile Ile Pro Ile Phe Gly Thr Gly Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 210
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 35 HC CDR3
<400> 210
Ser Leu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Pro Ile Ser Glu Asp Tyr
1 5 10 15
Phe Asp Tyr
<210> 211
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 36 LC CDR1
<400> 211
Arg Ala Ser Gln Ser Val Gly Ser Ser Tyr Leu Ala
1 5 10
<210> 212
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 36 LC CDR2
<400> 212
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 213
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 36 LC CDR3
<400> 213
Gln Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<210> 214
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 36 HC CDR1
<400> 214
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 215
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 36 HC CDR2
<400> 215
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 216
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 36 HC CDR3
<400> 216
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 217
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 37 LC CDR1
<400> 217
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 218
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 37 LC CDR2
<400> 218
Thr Asn Asn Arg Arg Pro Ser
1 5
<210> 219
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 37 LC CDR3
<400> 219
Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Val
1 5 10
<210> 220
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 37 HC CDR1
<400> 220
Ser His Trp Ile Ala
1 5
<210> 221
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 37 HC CDR2
<400> 221
Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 222
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 37 HC CDR3
<400> 222
Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser
1 5 10
<210> 223
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 38 LC CDR1
<400> 223
Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His
1 5 10
<210> 224
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 38 LC CDR2
<400> 224
Tyr Asp Ser Asp Arg Pro Ser
1 5
<210> 225
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 38 LC CDR3
<400> 225
Gln Val Trp Asp Ser Ser Ser Asp His Trp Val
1 5 10
<210> 226
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 38 HC CDR1
<400> 226
Asp Tyr Ala Met Ser
1 5
<210> 227
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 38 HC CDR2
<400> 227
Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 228
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 38 HC CDR3
<400> 228
Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro Gly Asp
1 5 10 15
Ala Phe Asp Ile
20
<210> 229
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 39 LC CDR1
<400> 229
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 230
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 39 LC CDR2
<400> 230
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 231
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 39 LC CDR3
<400> 231
Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Trp Val
1 5 10
<210> 232
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 39 HC CDR1
<400> 232
Asp Tyr Gly Met His
1 5
<210> 233
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 39 HC CDR2
<400> 233
Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 234
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 39 HC CDR3
<400> 234
Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala
1 5 10 15
Met Asp Val
<210> 235
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 40 LC CDR1
<400> 235
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 236
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 40 LC CDR2
<400> 236
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 237
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 40 LC CDR3
<400> 237
Gln Gln Tyr Gly Ser Ser Pro Gln Thr
1 5
<210> 238
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 40 HC CDR1
<400> 238
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 239
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 40 HC CDR2
<400> 239
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 240
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 40 HC CDR3
<400> 240
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 241
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 41 LC CDR1
<400> 241
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 242
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 41 LC CDR2
<400> 242
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 243
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 41 LC CDR3
<400> 243
Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val
1 5 10
<210> 244
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 41 HC CDR1
<400> 244
Gly Tyr Tyr Trp Ser
1 5
<210> 245
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 41 HC CDR2
<400> 245
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 246
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 41 HC CDR3
<400> 246
Gly Arg Tyr Tyr Ser Ser Trp Tyr Gly Pro Arg Thr Trp Phe Asp Pro
1 5 10 15
<210> 247
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 42 LC CDR1
<400> 247
Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln
1 5 10
<210> 248
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 42 LC CDR2
<400> 248
Glu Asp Asn Gln Arg Pro Ser
1 5
<210> 249
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 42 LC CDR3
<400> 249
Gln Ser Tyr Asp Ser Ser Asn Trp Val
1 5
<210> 250
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 42 HC CDR1
<400> 250
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 251
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 42 HC CDR2
<400> 251
Asn Phe Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 252
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 42 HC CDR3
<400> 252
Gln Glu Trp Leu Arg Gly Gly Phe Asp Asp
1 5 10
<210> 253
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 43 LC CDR1
<400> 253
Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn Tyr Val His
1 5 10
<210> 254
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 43 LC CDR2
<400> 254
Ser Asn Asp Gln Arg Pro Ser
1 5
<210> 255
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 43 LC CDR3
<400> 255
Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val
1 5 10
<210> 256
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 43 HC CDR1
<400> 256
Ser Tyr Ala Ile Ser
1 5
<210> 257
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 43 HC CDR2
<400> 257
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Arg Phe Gln
1 5 10 15
Gly
<210> 258
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 43 HC CDR3
<400> 258
Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr
1 5 10 15
Tyr Tyr Gly Met Asp Val
20
<210> 259
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 44 LC CDR1
<400> 259
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 260
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 44 LC CDR2
<400> 260
Asp Ala Ser Ser Arg Ala Thr
1 5
<210> 261
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 44 LC CDR3
<400> 261
Gln Gln Tyr Gly Ser Ser Pro Ser Ile Thr
1 5 10
<210> 262
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 44 HC CDR1
<400> 262
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 263
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 44 HC CDR2
<400> 263
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 264
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 44 HC CDR3
<400> 264
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 265
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 45 LC CDR1
<400> 265
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 266
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 45 LC CDR2
<400> 266
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 267
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 45 LC CDR3
<400> 267
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Val
1 5 10
<210> 268
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 45 HC CDR1
<400> 268
Ser Tyr Asp Ile Ser
1 5
<210> 269
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 45 HC CDR2
<400> 269
Gly Ile Ile Pro Ile Leu Gly Ile Pro Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 270
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 45 HC CDR3
<400> 270
Ser Arg Gly Tyr Ser Gly Tyr Gly Ala Asn Trp Tyr Phe Asp Leu
1 5 10 15
<210> 271
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 46 LC CDR1
<400> 271
Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln
1 5 10
<210> 272
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 46 LC CDR2
<400> 272
Glu Asp Asn Gln Arg Pro Ser
1 5
<210> 273
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 46 LC CDR3
<400> 273
Gln Ser Tyr Asp Ser Ser Asn Trp Val
1 5
<210> 274
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 46 HC CDR1
<400> 274
Arg Tyr Gly Ile Ser
1 5
<210> 275
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 46 HC CDR2
<400> 275
Trp Ile Ser Ala Tyr Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln
1 5 10 15
Gly
<210> 276
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 46 HC CDR3
<400> 276
Val Leu Gly Ile Ala Val Ala Gly Thr Pro Ile
1 5 10
<210> 277
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 47 LC CDR1
<400> 277
Arg Ala Ser Gln Ser Val Arg Ser Asp Ile Ala
1 5 10
<210> 278
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 47 LC CDR2
<400> 278
Asp Thr Ser Thr Arg Ala Thr
1 5
<210> 279
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 47 LC CDR3
<400> 279
Gln Gln Tyr Tyr Thr Thr Pro Phe Thr
1 5
<210> 280
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 47 HC CDR1
<400> 280
Asp Tyr Tyr Ile Gln
1 5
<210> 281
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 47 HC CDR2
<400> 281
Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln
1 5 10 15
Gly
<210> 282
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 47 HC CDR3
<400> 282
Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro
1 5 10
<210> 283
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 48 LC CDR1
<400> 283
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 284
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 48 LC CDR2
<400> 284
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 285
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 48 LC CDR3
<400> 285
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Leu Trp Val
1 5 10
<210> 286
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 48 HC CDR1
<400> 286
Ser Asn Tyr Met Ser
1 5
<210> 287
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 48 HC CDR2
<400> 287
Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln Gly
1 5 10 15
<210> 288
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 48 HC CDR3
<400> 288
Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile
1 5 10
<210> 289
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 49 LC CDR1
<400> 289
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 290
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 49 LC CDR2
<400> 290
Asp Val Ser Asn Arg Pro Ser
1 5
<210> 291
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 49 LC CDR3
<400> 291
Ser Ser Tyr Thr Ser Ser Ser Pro Trp Val
1 5 10
<210> 292
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 49 HC CDR1
<400> 292
Ser Tyr Ala Met Ser
1 5
<210> 293
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 49 HC CDR2
<400> 293
Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 294
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 49 HC CDR3
<400> 294
Gly Val Val Thr Ala Asp Trp Tyr Phe Asp Leu
1 5 10
<210> 295
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 50 LC CDR1
<400> 295
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 296
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 50 LC CDR2
<400> 296
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 297
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 50 LC CDR3
<400> 297
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Trp Val
1 5 10
<210> 298
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 50 HC CDR1
<400> 298
Arg Tyr Ala Ile Asn
1 5
<210> 299
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 50 HC CDR2
<400> 299
Gly Ile Ile Pro Leu Leu Gly Thr Ala Asp Tyr Pro Gln Lys Phe Gln
1 5 10 15
Gly
<210> 300
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 50 HC CDR3
<400> 300
Thr Leu Tyr Tyr Tyr Asp Arg Ser Gly Asn Ala Arg Thr Asp Asp Tyr
1 5 10 15
Phe Asp His
<210> 301
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 51 LC CDR1
<400> 301
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 302
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 51 LC CDR2
<400> 302
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 303
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 51 LC CDR3
<400> 303
Gln Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<210> 304
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 51 HC CDR1
<400> 304
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 305
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 51 HC CDR2
<400> 305
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 306
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 51 HC CDR3
<400> 306
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 307
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 52 LC CDR1
<400> 307
Arg Ala Ser Gln Ser Val Asn Ser Asn Leu Ala
1 5 10
<210> 308
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 52 LC CDR2
<400> 308
Asp Ala Ser Thr Arg Ala Thr
1 5
<210> 309
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 52 LC CDR3
<400> 309
Gln Gln Tyr Asn Asn Trp Pro Leu Thr
1 5
<210> 310
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 52 HC CDR1
<400> 310
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 311
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 52 HC CDR2
<400> 311
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 312
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 52 HC CDR3
<400> 312
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 313
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 53 LC CDR1
<400> 313
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 314
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 53 LC CDR2
<400> 314
Ala Ala Ser Ser Leu Gln Ser
1 5
<210> 315
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 53 LC CDR3
<400> 315
Gln Gln Ser Tyr Ser Thr Pro Leu Thr
1 5
<210> 316
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 53 HC CDR1
<400> 316
Ser Asn Tyr Met Ser
1 5
<210> 317
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 53 HC CDR2
<400> 317
Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln Gly
1 5 10 15
<210> 318
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 53 HC CDR3
<400> 318
Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile
1 5 10
<210> 319
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 54 LC CDR1
<400> 319
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 320
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 54 LC CDR2
<400> 320
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 321
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 54 LC CDR3
<400> 321
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val
1 5 10
<210> 322
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 54 HC CDR1
<400> 322
Asp Tyr Ala Met His
1 5
<210> 323
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 54 HC CDR2
<400> 323
Gly Ile Ser Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 324
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 54 HC CDR3
<400> 324
Glu Glu Leu Gly Pro Tyr Ser Asn Arg Trp Tyr Ser Ser Ser Asp Gly
1 5 10 15
Met Asp Val
<210> 325
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 55 LC CDR1
<400> 325
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 326
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 55 LC CDR2
<400> 326
Ala Ala Ser Ser Leu Gln Ser
1 5
<210> 327
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 55 LC CDR3
<400> 327
Gln Gln Ser Tyr Ser Thr Pro Leu Thr
1 5
<210> 328
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 55 HC CDR1
<400> 328
Ser Ser Ala Ile Asn
1 5
<210> 329
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 55 HC CDR2
<400> 329
Gly Ile Ile Pro Ile Phe Gly Thr Val Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 330
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 55 HC CDR3
<400> 330
Asp His Ile Val Ser Pro Leu Tyr Gly Met Asp Val
1 5 10
<210> 331
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 56 LC CDR1
<400> 331
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 332
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 56 LC CDR2
<400> 332
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 333
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 56 LC CDR3
<400> 333
Gln Ser Tyr Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 334
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 56 HC CDR1
<400> 334
Ser Asn Tyr Met Ser
1 5
<210> 335
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 56 HC CDR2
<400> 335
Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln Gly
1 5 10 15
<210> 336
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 56 HC CDR3
<400> 336
Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile
1 5 10
<210> 337
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 57 LC CDR1
<400> 337
Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala
1 5 10
<210> 338
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 57 LC CDR2
<400> 338
Asp Ala Ser Asn Leu Glu Thr
1 5
<210> 339
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 57 LC CDR3
<400> 339
Gln Gln Tyr Tyr Ser Thr Pro Ile Thr
1 5
<210> 340
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 57 HC CDR1
<400> 340
Asp Tyr Tyr Ile Gln
1 5
<210> 341
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 57 HC CDR2
<400> 341
Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln
1 5 10 15
Gly
<210> 342
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 57 HC CDR3
<400> 342
Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro
1 5 10
<210> 343
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 58 LC CDR1
<400> 343
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Ser His Val Ser
1 5 10
<210> 344
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 58 LC CDR2
<400> 344
Glu Val Ser Asp Arg Pro Ser
1 5
<210> 345
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 58 LC CDR3
<400> 345
Asn Ser Tyr Thr Ser Ser Ser Thr Trp Val
1 5 10
<210> 346
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 58 HC CDR1
<400> 346
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 347
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 58 HC CDR2
<400> 347
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 348
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 58 HC CDR3
<400> 348
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 349
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 59 LC CDR1
<400> 349
Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala
1 5 10
<210> 350
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 59 LC CDR2
<400> 350
Asp Ala Ser Thr Arg Ala Thr
1 5
<210> 351
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 59 LC CDR3
<400> 351
Gln Gln Tyr Asn Asn Trp Pro Leu Thr
1 5
<210> 352
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 59 HC CDR1
<400> 352
Gly Ser Ser Tyr Tyr Trp Gly
1 5
<210> 353
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 59 HC CDR2
<400> 353
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 354
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 59 HC CDR3
<400> 354
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 355
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 60 LC CDR1
<400> 355
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 356
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 60 LC CDR2
<400> 356
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 357
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 60 LC CDR3
<400> 357
Gln Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr
1 5 10
<210> 358
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 60 HC CDR1
<400> 358
Ser Tyr Ala Ile Ile
1 5
<210> 359
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 60 HC CDR2
<400> 359
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 360
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 60 HC CDR3
<400> 360
Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr
1 5 10
<210> 361
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 61 LC CDR1
<400> 361
Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp
1 5 10
<210> 362
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 61 LC CDR2
<400> 362
Asp Asp Ser Asp Arg Pro Ser
1 5
<210> 363
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 61 LC CDR3
<400> 363
Gln Val Trp Asp Ser Ser Ser Asp Arg Val Val
1 5 10
<210> 364
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 61 HC CDR1
<400> 364
Asp Tyr Ala Met His
1 5
<210> 365
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 61 HC CDR2
<400> 365
Gly Thr Thr Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 366
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 61 HC CDR3
<400> 366
Asp Ile Gly Ser Gly Asp Arg Pro Asp Ala Phe His Leu
1 5 10
<210> 367
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 62 LC CDR1
<400> 367
Ser Gly Ser Ser Ser Asn Ile Glu Asn Asn Tyr Val Ser
1 5 10
<210> 368
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 62 LC CDR2
<400> 368
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 369
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 62 LC CDR3
<400> 369
Gly Thr Trp Asp Asn Ser Leu Ser Ala Trp Val
1 5 10
<210> 370
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 62 HC CDR1
<400> 370
Ser Tyr Tyr Met His
1 5
<210> 371
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 62 HC CDR2
<400> 371
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 372
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 62 HC CDR3
<400> 372
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 373
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 63 LC CDR1
<400> 373
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 374
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 63 LC CDR2
<400> 374
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 375
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 63 LC CDR3
<400> 375
Gln Gln Tyr Gly Ser Ser Pro Tyr Thr
1 5
<210> 376
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 63 HC CDR1
<400> 376
Ser Ser Pro Met His
1 5
<210> 377
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 63 HC CDR2
<400> 377
Val Ile Ser Tyr Gly Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 378
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 63 HC CDR3
<400> 378
Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val
1 5 10
<210> 379
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 64 LC CDR1
<400> 379
Thr Gly Asn Arg Ser Asp Ile Gly Gly Tyr Asn Ser Leu Ser
1 5 10
<210> 380
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 64 LC CDR2
<400> 380
Asp Val Asn Asn Arg Pro Ser
1 5
<210> 381
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 64 LC CDR3
<400> 381
Asn Ser Tyr Thr Ser Lys Asn Thr Trp Val
1 5 10
<210> 382
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 64 HC CDR1
<400> 382
Ser Ser Pro Met His
1 5
<210> 383
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 64 HC CDR2
<400> 383
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 384
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 64 HC CDR3
<400> 384
Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val
1 5 10
<210> 385
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 65 LC CDR1
<400> 385
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 386
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 65 LC CDR2
<400> 386
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 387
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 65 LC CDR3
<400> 387
Gln Gln Tyr Gly Ser Ser Pro Phe Thr
1 5
<210> 388
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 65 HC CDR1
<400> 388
Ser Ser Pro Met His
1 5
<210> 389
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 65 HC CDR2
<400> 389
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 390
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 65 HC CDR3
<400> 390
Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val
1 5 10
<210> 391
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 66 LC CDR1
<400> 391
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 392
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 66 LC CDR2
<400> 392
Asp Val Ser Asn Arg Pro Ser
1 5
<210> 393
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 66 LC CDR3
<400> 393
Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val
1 5 10
<210> 394
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 66 HC CDR1
<400> 394
Ser Ser Pro Met His
1 5
<210> 395
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 66 HC CDR2
<400> 395
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 396
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 66 HC CDR3
<400> 396
Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val
1 5 10
<210> 397
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 67 LC CDR1
<400> 397
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 398
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 67 LC CDR2
<400> 398
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 399
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 67 LC CDR3
<400> 399
Gln Gln Tyr Gly Ser Ser Pro Ala Leu Thr
1 5 10
<210> 400
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 67 HC CDR1
<400> 400
Ser Ser Pro Met His
1 5
<210> 401
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 67 HC CDR2
<400> 401
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 402
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 67 HC CDR3
<400> 402
Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val
1 5 10
<210> 403
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 68 LC CDR1
<400> 403
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 404
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 68 LC CDR2
<400> 404
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 405
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 68 LC CDR3
<400> 405
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 406
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 68 HC CDR1
<400> 406
Arg Lys Val Ile Ala
1 5
<210> 407
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 68 HC CDR2
<400> 407
Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Arg Lys Phe Gln
1 5 10 15
Gly
<210> 408
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 68 HC CDR3
<400> 408
Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Asn
1 5 10
<210> 409
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 69 LC CDR1
<400> 409
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Asn Val Ser
1 5 10
<210> 410
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 69 LC CDR2
<400> 410
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 411
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 69 LC CDR3
<400> 411
Ser Ser Tyr Thr Ser Ser Ser Pro Trp Val
1 5 10
<210> 412
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 69 HC CDR1
<400> 412
Ser Tyr Ala Ile Ser
1 5
<210> 413
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 69 HC CDR2
<400> 413
Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 414
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 69 HC CDR3
<400> 414
Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser Tyr Tyr
1 5 10 15
Pro
<210> 415
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 70 LC CDR1
<400> 415
Thr Gly Thr Ser Thr Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 416
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 70 LC CDR2
<400> 416
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 417
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 70 LC CDR3
<400> 417
Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val
1 5 10
<210> 418
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 70 HC CDR1
<400> 418
Asn Tyr Gly Met His
1 5
<210> 419
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 70 HC CDR2
<400> 419
Val Met Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 420
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 70 HC CDR3
<400> 420
Pro Asp Asp Ser Ser Gly Tyr Tyr Pro Asp Tyr
1 5 10
<210> 421
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 71 LC CDR1
<400> 421
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 422
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 71 LC CDR2
<400> 422
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 423
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 71 LC CDR3
<400> 423
Ser Ser Tyr Thr Ser Ser Arg Thr Trp Val
1 5 10
<210> 424
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 71 HC CDR1
<400> 424
Gly Tyr Ala Met His
1 5
<210> 425
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 71 HC CDR2
<400> 425
Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 426
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 71 HC CDR3
<400> 426
Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val
1 5 10
<210> 427
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 72 LC CDR1
<400> 427
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Ala Val Asn
1 5 10
<210> 428
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 72 LC CDR2
<400> 428
Ser Asn Ser Tyr Arg Pro Ser
1 5
<210> 429
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 72 LC CDR3
<400> 429
Gln Ser Tyr Asp Ser Ala Leu Arg Gly Pro Leu
1 5 10
<210> 430
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 72 HC CDR1
<400> 430
Ser Tyr Gly Ile Ser
1 5
<210> 431
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 72 HC CDR2
<400> 431
Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 432
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 72 HC CDR3
<400> 432
Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe Asp Pro
1 5 10 15
<210> 433
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 73 LC CDR1
<400> 433
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 434
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 73 LC CDR2
<400> 434
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 435
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 73 LC CDR3
<400> 435
Gln Ser Tyr Asp Ser Ser Leu Ser Asp Val Val
1 5 10
<210> 436
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 73 HC CDR1
<400> 436
Ser Tyr Gly Ile Ser
1 5
<210> 437
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 73 HC CDR2
<400> 437
Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 438
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 73 HC CDR3
<400> 438
Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe Asp Pro
1 5 10 15
<210> 439
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 74 LC CDR1
<400> 439
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 440
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 74 LC CDR2
<400> 440
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 441
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 74 LC CDR3
<400> 441
Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val
1 5 10
<210> 442
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 74 HC CDR1
<400> 442
Ser Tyr Ala Met His
1 5
<210> 443
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 74 HC CDR2
<400> 443
Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 444
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 74 HC CDR3
<400> 444
Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val
1 5 10
<210> 445
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 75 LC CDR1
<400> 445
Ser Ser Ser Thr Gly Ala Val Thr Arg Gly His Phe Pro Asn
1 5 10
<210> 446
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 75 LC CDR2
<400> 446
Ser Thr Ser Asn Lys His Ser
1 5
<210> 447
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 75 LC CDR3
<400> 447
Leu Leu Tyr Asp Ala Gly Ala Pro Gly Trp Val
1 5 10
<210> 448
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 75 HC CDR1
<400> 448
Ser Tyr Pro Met His
1 5
<210> 449
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 75 HC CDR2
<400> 449
Val Ile Ser Tyr Asp Gly Ser Leu Lys Tyr Tyr Val Asp Ser Val Lys
1 5 10 15
Gly
<210> 450
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 75 HC CDR3
<400> 450
Asp Ser Ser Cys Ser Gly Gly Ser Cys Phe Asp Tyr
1 5 10
<210> 451
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 76 LC CDR1
<400> 451
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 452
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 76 LC CDR2
<400> 452
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 453
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 76 LC CDR3
<400> 453
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val
1 5 10
<210> 454
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 76 HC CDR1
<400> 454
Ser Tyr Gly Ile Ser
1 5
<210> 455
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 76 HC CDR2
<400> 455
Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 456
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 76 HC CDR3
<400> 456
Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe Asp Pro
1 5 10 15
<210> 457
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 77 LC CDR1
<400> 457
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 458
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 77 LC CDR2
<400> 458
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 459
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 77 LC CDR3
<400> 459
Gly Ala Trp Asp Ser Ser Leu Ser Thr Pro Asn Trp Val
1 5 10
<210> 460
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 77 HC CDR1
<400> 460
Ser Tyr Pro Met His
1 5
<210> 461
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 77 HC CDR2
<400> 461
Val Ile Ser Tyr Asp Gly Ser Leu Lys Tyr Tyr Val Asp Ser Val Lys
1 5 10 15
Gly
<210> 462
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 77 HC CDR3
<400> 462
Asp Ser Ser Cys Ser Gly Gly Ser Cys Phe Asp Tyr
1 5 10
<210> 463
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 78 LC CDR1
<400> 463
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 464
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 78 LC CDR2
<400> 464
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 465
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 78 LC CDR3
<400> 465
Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val
1 5 10
<210> 466
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 78 HC CDR1
<400> 466
Ser Asn Trp Ile Ala
1 5
<210> 467
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 78 HC CDR2
<400> 467
Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Asn Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 468
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 78 HC CDR3
<400> 468
Leu Ala Tyr Phe His Pro Gln Arg Asn Gly Gly Tyr Glu Tyr Tyr Phe
1 5 10 15
Asp Tyr
<210> 469
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 79 LC CDR1
<400> 469
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 470
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 79 LC CDR2
<400> 470
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 471
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 79 LC CDR3
<400> 471
Gln Ser Tyr Asp Ser Arg Leu Arg Ala Val Val
1 5 10
<210> 472
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 79 HC CDR1
<400> 472
Thr Gln Tyr Leu His
1 5
<210> 473
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 79 HC CDR2
<400> 473
Ile Ile Asn Pro Tyr Gly Gly Ser Thr Thr Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 474
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 79 HC CDR3
<400> 474
Ser Pro Ser Gly Tyr Tyr Gly Asp Tyr Glu Gly Asp Ala Phe Asp Ile
1 5 10 15
<210> 475
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 80 LC CDR1
<400> 475
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 476
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 80 LC CDR2
<400> 476
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 477
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 80 LC CDR3
<400> 477
Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val
1 5 10
<210> 478
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 80 HC CDR1
<400> 478
Ser Tyr Val Ile Ser
1 5
<210> 479
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 80 HC CDR2
<400> 479
Arg Ile Ile Pro Ile Phe Gly Thr Val Lys Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 480
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 80 HC CDR3
<400> 480
Asp Leu Pro Gly Asp Ser Arg Asp Gly Tyr Asn Tyr Asp Ala Phe Asp
1 5 10 15
Ile
<210> 481
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 81 LC CDR1
<400> 481
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 482
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 81 LC CDR2
<400> 482
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 483
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 81 LC CDR3
<400> 483
Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val
1 5 10
<210> 484
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 81 HC CDR1
<400> 484
Ser Phe Ala Met His
1 5
<210> 485
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 81 HC CDR2
<400> 485
Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 486
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 81 HC CDR3
<400> 486
Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe
1 5 10 15
Asp Tyr
<210> 487
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 82 LC CDR1
<400> 487
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr
1 5 10
<210> 488
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 82 LC CDR2
<400> 488
Arg Asn Asn Gln Arg Pro Ser
1 5
<210> 489
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 82 LC CDR3
<400> 489
Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val
1 5 10
<210> 490
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 82 HC CDR1
<400> 490
Ser Tyr Ala Ile Ser
1 5
<210> 491
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 82 HC CDR2
<400> 491
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 492
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 82 HC CDR3
<400> 492
Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr
1 5 10 15
Tyr Tyr Gly Met Asp Val
20
<210> 493
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 83 LC CDR1
<400> 493
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 494
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 83 LC CDR2
<400> 494
Asn Asn Asn Gln Arg Pro Ser
1 5
<210> 495
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 83 LC CDR3
<400> 495
Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val
1 5 10
<210> 496
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 83 HC CDR1
<400> 496
Ser Tyr Trp Ile Gly
1 5
<210> 497
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 83 HC CDR2
<400> 497
Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 498
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 83 HC CDR3
<400> 498
Gly Pro Asn Ile Tyr Asn Trp Phe Asp Ser
1 5 10
<210> 499
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 84 LC CDR1
<400> 499
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 500
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 84 LC CDR2
<400> 500
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 501
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 84 LC CDR3
<400> 501
Gln Gln Arg Arg Asn Trp Pro Pro Val Leu Thr
1 5 10
<210> 502
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 84 HC CDR1
<400> 502
Ser Tyr Ala Ile Ser
1 5
<210> 503
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 84 HC CDR2
<400> 503
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 504
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 84 HC CDR3
<400> 504
Val Glu Gly Tyr Asp Ser Ser Gly Tyr Tyr Leu Asp Tyr
1 5 10
<210> 505
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 85 LC CDR1
<400> 505
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 506
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 85 LC CDR2
<400> 506
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 507
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 85 LC CDR3
<400> 507
Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val
1 5 10
<210> 508
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 85 HC CDR1
<400> 508
Asp Tyr Gly Met His
1 5
<210> 509
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 85 HC CDR2
<400> 509
Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 510
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 85 HC CDR3
<400> 510
Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala
1 5 10 15
Met Asp Val
<210> 511
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 86 LC CDR1
<400> 511
Arg Ala Ser Gln Ser Val Ser Thr Phe Leu Ala
1 5 10
<210> 512
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 86 LC CDR2
<400> 512
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 513
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 86 LC CDR3
<400> 513
Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr
1 5 10
<210> 514
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 86 HC CDR1
<400> 514
Ser Tyr Ala Ile Ser
1 5
<210> 515
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 86 HC CDR2
<400> 515
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 516
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 86 HC CDR3
<400> 516
Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr
1 5 10
<210> 517
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 87 LC CDR1
<400> 517
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 518
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 87 LC CDR2
<400> 518
Ala Ala Ser Ser Leu Gln Ser
1 5
<210> 519
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 87 LC CDR3
<400> 519
Gln Gln Ser Tyr Ser Thr Pro Phe Thr
1 5
<210> 520
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 87 HC CDR1
<400> 520
Ser Tyr Ala Met His
1 5
<210> 521
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 87 HC CDR2
<400> 521
Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 522
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 87 HC CDR3
<400> 522
Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val
1 5 10
<210> 523
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 88 LC CDR1
<400> 523
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 524
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 88 LC CDR2
<400> 524
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 525
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 88 LC CDR3
<400> 525
Gln Gln Arg Ser Asn Trp Pro Pro Lys Tyr Thr
1 5 10
<210> 526
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 88 HC CDR1
<400> 526
Ser Tyr Ala Ile Ser
1 5
<210> 527
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 88 HC CDR2
<400> 527
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 528
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 88 HC CDR3
<400> 528
Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Glu Tyr
1 5 10
<210> 529
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 89 LC CDR1
<400> 529
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 530
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 89 LC CDR2
<400> 530
Lys Ala Ser Ser Leu Glu Ser
1 5
<210> 531
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 89 LC CDR3
<400> 531
Gln Gln Ser Tyr Ser Thr Trp Thr
1 5
<210> 532
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 89 HC CDR1
<400> 532
Ser Tyr Ala Met His
1 5
<210> 533
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 89 HC CDR2
<400> 533
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 534
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 89 HC CDR3
<400> 534
Ala Arg Gly Gly Ser Tyr Leu Tyr Gly Met Asp Val
1 5 10
<210> 535
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 90 LC CDR1
<400> 535
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 536
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 90 LC CDR2
<400> 536
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 537
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 90 LC CDR3
<400> 537
Gln Gln Arg Arg Asn Trp Pro Pro Arg Ile Thr
1 5 10
<210> 538
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 90 HC CDR1
<400> 538
Ser Tyr Ala Ile Ser
1 5
<210> 539
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 90 HC CDR2
<400> 539
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 540
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 90 HC CDR3
<400> 540
Val Glu Gly Tyr Asp Ser Ser Gly Tyr Tyr Leu Asp Tyr
1 5 10
<210> 541
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 91 LC CDR1
<400> 541
Ser Gly Ser Ser Ser Asn Ile Gly Asn Ser Tyr Val Ser
1 5 10
<210> 542
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 91 LC CDR2
<400> 542
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 543
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 91 LC CDR3
<400> 543
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 544
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 91 HC CDR1
<400> 544
Ser Tyr Tyr Met His
1 5
<210> 545
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 91 HC CDR2
<400> 545
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 546
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 91 HC CDR3
<400> 546
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 547
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 92 LC CDR1
<400> 547
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 548
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 92 LC CDR2
<400> 548
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 549
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 92 LC CDR3
<400> 549
Ala Ala Trp Asp Asp Ser Leu Gly Gly Pro Val
1 5 10
<210> 550
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 92 HC CDR1
<400> 550
Thr Tyr Gly Met His
1 5
<210> 551
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 92 HC CDR2
<400> 551
Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 552
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 92 HC CDR3
<400> 552
Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val
1 5 10
<210> 553
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 93 LC CDR1
<400> 553
Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala
1 5 10
<210> 554
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 93 LC CDR2
<400> 554
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 555
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 93 LC CDR3
<400> 555
Gln Gln Arg Ser Asn Trp Pro Pro Lys Leu Thr
1 5 10
<210> 556
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 93 HC CDR1
<400> 556
Ser Tyr Ala Ile Ser
1 5
<210> 557
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 93 HC CDR2
<400> 557
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 558
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 93 HC CDR3
<400> 558
Val Ser Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr
1 5 10
<210> 559
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 94 LC CDR1
<400> 559
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 560
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 94 LC CDR2
<400> 560
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 561
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 94 LC CDR3
<400> 561
Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val
1 5 10
<210> 562
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 94 HC CDR1
<400> 562
Thr Tyr Gly Met His
1 5
<210> 563
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 94 HC CDR2
<400> 563
Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 564
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 94 HC CDR3
<400> 564
Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val
1 5 10
<210> 565
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 95 LC CDR1
<400> 565
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Ser
1 5 10
<210> 566
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 95 LC CDR2
<400> 566
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 567
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 95 LC CDR3
<400> 567
Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val
1 5 10
<210> 568
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 95 HC CDR1
<400> 568
Gly Tyr Tyr Trp Ser
1 5
<210> 569
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 95 HC CDR2
<400> 569
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 570
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 95 HC CDR3
<400> 570
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 571
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 96 LC CDR1
<400> 571
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 572
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 96 LC CDR2
<400> 572
Ala Ala Ser Ser Leu Gln Ser
1 5
<210> 573
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 96 LC CDR3
<400> 573
Gln Gln Ser Tyr Ser Thr Trp Thr
1 5
<210> 574
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 96 HC CDR1
<400> 574
Ser Tyr Ala Met His
1 5
<210> 575
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 96 HC CDR2
<400> 575
Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 576
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 96 HC CDR3
<400> 576
Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val
1 5 10
<210> 577
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 97 LC CDR1
<400> 577
Gln Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 578
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 97 LC CDR2
<400> 578
Ala Ala Ser Ser Leu Gln Ser
1 5
<210> 579
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 97 LC CDR3
<400> 579
Gln Gln Ser Tyr Ser Thr Trp Thr
1 5
<210> 580
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 97 HC CDR1
<400> 580
Ser Tyr Ala Met His
1 5
<210> 581
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 97 HC CDR2
<400> 581
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 582
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 97 HC CDR3
<400> 582
Ala Arg Gly Gly Ser Tyr Leu Tyr Gly Met Asp Val
1 5 10
<210> 583
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 98 LC CDR1
<400> 583
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210> 584
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 98 LC CDR2
<400> 584
Ala Ala Ser Ser Leu Gln Ser
1 5
<210> 585
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 98 LC CDR3
<400> 585
Gln Gln Ser Tyr Ser Asn Pro Phe Thr
1 5
<210> 586
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 98 HC CDR1
<400> 586
Ser Tyr Ala Met His
1 5
<210> 587
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 98 HC CDR2
<400> 587
Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 588
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 98 HC CDR3
<400> 588
Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val
1 5 10
<210> 589
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 99 LC CDR1
<400> 589
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 590
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 99 LC CDR2
<400> 590
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 591
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 99 LC CDR3
<400> 591
Gln Gln Arg Ser Asn Trp Pro Pro Met Tyr Thr
1 5 10
<210> 592
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 99 HC CDR1
<400> 592
Ser Tyr Ala Ile Ile
1 5
<210> 593
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 99 HC CDR2
<400> 593
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 594
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 99 HC CDR3
<400> 594
Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr
1 5 10
<210> 595
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 100 LC CDR1
<400> 595
Thr Gly Ser Arg Ser Asn Ile Gly Ile Asn Ser Val Asn
1 5 10
<210> 596
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 100 LC CDR2
<400> 596
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 597
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 100 LC CDR3
<400> 597
Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val
1 5 10
<210> 598
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 100 HC CDR1
<400> 598
Gly Tyr Tyr Trp Ser
1 5
<210> 599
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 100 HC CDR2
<400> 599
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 600
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 100 HC CDR3
<400> 600
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 601
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 101 LC CDR1
<400> 601
Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 602
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 101 LC CDR2
<400> 602
Ala Val Ser Lys Arg Pro Ser
1 5
<210> 603
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 101 LC CDR3
<400> 603
Ser Ser Tyr Thr Ser Ser Ser Gly Thr Leu Asn Val
1 5 10
<210> 604
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 101 HC CDR1
<400> 604
Thr Tyr Gly Met His
1 5
<210> 605
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 101 HC CDR2
<400> 605
Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 606
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 101 HC CDR3
<400> 606
Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val
1 5 10
<210> 607
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 102 LC CDR1
<400> 607
Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Phe Val Ser
1 5 10
<210> 608
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 102 LC CDR2
<400> 608
Asp Asn Asn Val Arg Pro Ser
1 5
<210> 609
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 102 LC CDR3
<400> 609
Ala Ala Trp Asp Thr Ser Leu Ser Ser Trp Val
1 5 10
<210> 610
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 102 HC CDR1
<400> 610
Ser Tyr Tyr Met His
1 5
<210> 611
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 102 HC CDR2
<400> 611
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 612
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 102 HC CDR3
<400> 612
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 613
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 103 LC CDR1
<400> 613
Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala
1 5 10
<210> 614
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 103 LC CDR2
<400> 614
Arg Ala Ser Thr Leu Gln Ser
1 5
<210> 615
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 103 LC CDR3
<400> 615
Gln Gln Tyr Lys Thr Tyr Pro Leu Thr
1 5
<210> 616
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 103 HC CDR1
<400> 616
Ser Tyr Gly Met His
1 5
<210> 617
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 103 HC CDR2
<400> 617
Ala Ile Trp His Asp Gly Tyr Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 618
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 103 HC CDR3
<400> 618
Gly Ser Lys Ala Ala Asp Tyr
1 5
<210> 619
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.104 LC CDR1
<400> 619
Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His
1 5 10
<210> 620
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No.104 LC CDR2
<400> 620
Gln Asp Ser Lys Arg Pro Ser
1 5
<210> 621
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No.104 LC CDR3
<400> 621
Gln Ala Trp Asp Ser Ser Thr Val
1 5
<210> 622
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No.104 HC CDR1
<400> 622
Thr Tyr Gly Met His
1 5
<210> 623
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No.104 HC CDR2
<400> 623
Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 624
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No.104 HC CDR3
<400> 624
Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val
1 5 10
<210> 625
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.105 LC CDR1
<400> 625
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 626
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No.105 LC CDR2
<400> 626
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 627
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.105 LC CDR3
<400> 627
Gln Gln Arg Ser Asn Trp Pro Pro Met Tyr Thr
1 5 10
<210> 628
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No.105 HC CDR1
<400> 628
Ser Tyr Ala Ile Ser
1 5
<210> 629
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No.105 HC CDR2
<400> 629
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 630
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No.105 HC CDR3
<400> 630
Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Glu Tyr
1 5 10
<210> 631
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No.106 LC CDR1
<400> 631
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 632
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No.106 LC CDR2
<400> 632
Asp Val Ser Asn Arg Pro Ser
1 5
<210> 633
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.106 LC CDR3
<400> 633
Ser Ser Tyr Thr Ser Ser Ser Thr Arg Tyr Val
1 5 10
<210> 634
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No.106 HC CDR1
<400> 634
Ser Tyr Ala Met Asn
1 5
<210> 635
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No.106 HC CDR2
<400> 635
Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 636
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No.106 HC CDR3
<400> 636
Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr
1 5 10 15
Tyr Phe Asp Tyr
20
<210> 637
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No.107 LC CDR1
<400> 637
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 638
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No.107 LC CDR2
<400> 638
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 639
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No.107 LC CDR3
<400> 639
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val
1 5 10
<210> 640
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No.107 HC CDR1
<400> 640
Asn Tyr Gly Ile Ser
1 5
<210> 641
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No.107 HC CDR2
<400> 641
Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln
1 5 10 15
Gly
<210> 642
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No.107 HC CDR3
<400> 642
Pro Arg Gly Tyr Ser Gly Tyr Gly Ser Asn Trp Tyr Phe Asp Leu
1 5 10 15
<210> 643
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 108 LC CDR1
<400> 643
Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala
1 5 10
<210> 644
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 108 LC CDR2
<400> 644
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 645
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 108 LC CDR3
<400> 645
Gln Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr
1 5 10
<210> 646
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 108 HC CDR1
<400> 646
Ser Tyr Ala Ile Ser
1 5
<210> 647
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 108 HC CDR2
<400> 647
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 648
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 108 HC CDR3
<400> 648
Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr
1 5 10
<210> 649
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 109 LC CDR1
<400> 649
Arg Thr Thr Gln Asn Ile Asn Thr Tyr Leu Asn
1 5 10
<210> 650
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 109 LC CDR2
<400> 650
Ala Ala Ser Arg Leu Gln Ser
1 5
<210> 651
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 109 LC CDR3
<400> 651
Gln Arg Ser Tyr Ser Thr Pro Tyr Thr
1 5
<210> 652
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 109 HC CDR1
<400> 652
Ser Tyr Ala Met His
1 5
<210> 653
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 109 HC CDR2
<400> 653
Leu Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 654
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 109 HC CDR3
<400> 654
Ala Thr Tyr Gly Ser Tyr Tyr Tyr Gly Met Asp Ala
1 5 10
<210> 655
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 110 LC CDR1
<400> 655
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 656
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 110 LC CDR2
<400> 656
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 657
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 110 LC CDR3
<400> 657
Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val
1 5 10
<210> 658
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 110 HC CDR1
<400> 658
Asn Tyr Ala Met Asn
1 5
<210> 659
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 110 HC CDR2
<400> 659
Thr Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 660
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 110 HC CDR3
<400> 660
Gly Tyr Ala Leu Asn Pro
1 5
<210> 661
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 111 LC CDR1
<400> 661
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Ser
1 5 10
<210> 662
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 111 LC CDR2
<400> 662
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 663
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 111 LC CDR3
<400> 663
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 664
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 111 HC CDR1
<400> 664
Ser Tyr Tyr Met His
1 5
<210> 665
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 111 HC CDR2
<400> 665
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 666
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 111 HC CDR3
<400> 666
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 667
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 112 LC CDR1
<400> 667
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 668
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 112 LC CDR2
<400> 668
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 669
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 112 LC CDR3
<400> 669
Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val
1 5 10
<210> 670
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 112 HC CDR1
<400> 670
Ser Tyr Tyr Met His
1 5
<210> 671
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 112 HC CDR2
<400> 671
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 672
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 112 HC CDR3
<400> 672
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 673
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 113 LC CDR1
<400> 673
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 674
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 113 LC CDR2
<400> 674
Asp Asn Ser Arg Arg Pro Ser
1 5
<210> 675
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 113 LC CDR3
<400> 675
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 676
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 113 HC CDR1
<400> 676
Ser Tyr Tyr Met His
1 5
<210> 677
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 113 HC CDR2
<400> 677
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 678
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 113 HC CDR3
<400> 678
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 679
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 114 LC CDR1
<400> 679
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 680
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 114 LC CDR2
<400> 680
Arg Asn Asn Gln Arg Pro Ser
1 5
<210> 681
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 114 LC CDR3
<400> 681
Ala Ala Trp Asp Asp Ser Leu Ser Ala Trp Val
1 5 10
<210> 682
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 114 HC CDR1
<400> 682
Ser Tyr Tyr Met His
1 5
<210> 683
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 114 HC CDR2
<400> 683
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 684
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 114 HC CDR3
<400> 684
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 685
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 115 LC CDR1
<400> 685
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 686
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 115 LC CDR2
<400> 686
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 687
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 115 LC CDR3
<400> 687
Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Trp Val
1 5 10
<210> 688
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 115 HC CDR1
<400> 688
Ser Tyr Tyr Met His
1 5
<210> 689
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 115 HC CDR2
<400> 689
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 690
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 115 HC CDR3
<400> 690
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 691
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 116 LC CDR1
<400> 691
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 692
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 116 LC CDR2
<400> 692
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 693
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 116 LC CDR3
<400> 693
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 694
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 116 HC CDR1
<400> 694
Ser Tyr Tyr Met His
1 5
<210> 695
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 116 HC CDR2
<400> 695
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Ser
<210> 696
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 116 HC CDR3
<400> 696
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 697
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 117 LC CDR1
<400> 697
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 698
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 117 LC CDR2
<400> 698
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 699
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 117 LC CDR3
<400> 699
Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val
1 5 10
<210> 700
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 117 HC CDR1
<400> 700
Arg Tyr Ala Met Ser
1 5
<210> 701
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 117 HC CDR2
<400> 701
Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 702
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 117 HC CDR3
<400> 702
Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp Val
1 5 10 15
<210> 703
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 118 LC CDR1
<400> 703
Ser Gly Ser Ser Ser Ser Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 704
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 118 LC CDR2
<400> 704
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 705
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 118 LC CDR3
<400> 705
Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val
1 5 10
<210> 706
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 118 HC CDR1
<400> 706
Ser Tyr Tyr Met His
1 5
<210> 707
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 118 HC CDR2
<400> 707
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 708
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 118 HC CDR3
<400> 708
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 709
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 119 LC CDR1
<400> 709
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 710
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 119 LC CDR2
<400> 710
Asp Asn Asn Val Arg Pro Ser
1 5
<210> 711
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 119 LC CDR3
<400> 711
Ala Ala Trp Asp Thr Ser Leu Ser Ser Trp Val
1 5 10
<210> 712
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 119 HC CDR1
<400> 712
Ser Tyr Tyr Met His
1 5
<210> 713
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 119 HC CDR2
<400> 713
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 714
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 119 HC CDR3
<400> 714
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 715
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 120 LC CDR1
<400> 715
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 716
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 120 LC CDR2
<400> 716
Asp Asn Asn Gln Arg Pro Ser
1 5
<210> 717
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 120 LC CDR3
<400> 717
Gly Thr Trp Asp Thr Ser Leu Ser Ala Trp Val
1 5 10
<210> 718
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 120 HC CDR1
<400> 718
Ser Tyr Tyr Met His
1 5
<210> 719
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 120 HC CDR2
<400> 719
Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln
1 5 10 15
Gly
<210> 720
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 120 HC CDR3
<400> 720
Gly Gly Arg His Ser Leu Asp Val
1 5
<210> 721
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 121 LC CDR1
<400> 721
Ser Gly Ser Ser Ser Asn Ile Gly Arg Asn Tyr Val Ser
1 5 10
<210> 722
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 121 LC CDR2
<400> 722
Asp Asn Asn Arg Arg Pro Ser
1 5
<210> 723
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 121 LC CDR3
<400> 723
Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Ala
1 5 10
<210> 724
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 121 HC CDR1
<400> 724
Ser Tyr Tyr Met His
1 5
<210> 725
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 121 HC CDR2
<400> 725
Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 726
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 121 HC CDR3
<400> 726
Gly Gly Asp His Gly Met Asp Val
1 5
<210> 727
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 122 LC CDR1
<400> 727
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 728
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 122 LC CDR2
<400> 728
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 729
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 122 LC CDR3
<400> 729
Ala Ala Trp Asp Asp Ser Leu Asn Gly Thr Val
1 5 10
<210> 730
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 122 HC CDR1
<400> 730
Gly Tyr Tyr Trp Ser
1 5
<210> 731
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 122 HC CDR2
<400> 731
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 732
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 122 HC CDR3
<400> 732
Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile
1 5 10 15
Gly Met Asp Val
20
<210> 733
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 123 LC CDR1
<400> 733
Ser Gly Asp Val Leu Ala Lys Lys Tyr Ala Arg
1 5 10
<210> 734
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 123 LC CDR2
<400> 734
Lys Asp Ser Glu Arg Pro Ser
1 5
<210> 735
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 123 LC CDR3
<400> 735
Tyr Ser Ala Ala Asp Asn Asn Gly Val
1 5
<210> 736
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 123 HC CDR1
<400> 736
Ser Asp Ala Met His
1 5
<210> 737
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 123 HC CDR2
<400> 737
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 738
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 123 HC CDR3
<400> 738
Glu Ala Thr Tyr Asp Ser Ser Gly Arg Pro Thr Gly Asp Tyr Gly Met
1 5 10 15
Asp Val
<210> 739
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 124 LC CDR1
<400> 739
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 740
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 124 LC CDR2
<400> 740
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 741
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 124 LC CDR3
<400> 741
Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr
1 5 10
<210> 742
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 124 HC CDR1
<400> 742
Ser Tyr Ala Ile Ser
1 5
<210> 743
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 124 HC CDR2
<400> 743
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 744
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 124 HC CDR3
<400> 744
Val Thr Gly Tyr Asp Gly Ser Gly Tyr Tyr Gln Asp Tyr
1 5 10
<210> 745
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 125 LC CDR1
<400> 745
Ser Gly Ser Asn Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 746
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 125 LC CDR2
<400> 746
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 747
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 125 LC CDR3
<400> 747
Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val
1 5 10
<210> 748
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 125 HC CDR1
<400> 748
Gly Tyr Tyr Trp Ser
1 5
<210> 749
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 125 HC CDR2
<400> 749
Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 750
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 125 HC CDR3
<400> 750
Gly Arg Tyr Tyr Ser Ser Trp Tyr Gly Pro Arg Thr Trp Phe Asp Pro
1 5 10 15
<210> 751
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 126 LC CDR1
<400> 751
Arg Ala Ser Gln Ser Val Ser Thr Tyr Leu Ser
1 5 10
<210> 752
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 126 LC CDR2
<400> 752
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 753
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 126 LC CDR3
<400> 753
Leu Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr
1 5 10
<210> 754
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 126 HC CDR1
<400> 754
Ser Tyr Ala Ile Ser
1 5
<210> 755
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 126 HC CDR2
<400> 755
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 756
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 126 HC CDR3
<400> 756
Ala Ser Gly Tyr Asp Ser Ser Gly Tyr Tyr Ser Asp Tyr
1 5 10
<210> 757
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 127 LC CDR1
<400> 757
Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala
1 5 10
<210> 758
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 127 LC CDR2
<400> 758
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 759
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 127 LC CDR3
<400> 759
Gln Gln Arg Ser Asn Trp Pro Pro Ser Ile Thr
1 5 10
<210> 760
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 127 HC CDR1
<400> 760
Ser Tyr Ala Ile Ser
1 5
<210> 761
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 127 HC CDR2
<400> 761
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 762
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 127 HC CDR3
<400> 762
Val Gly Thr Tyr Asp Ser Ser Gly Tyr Ser Phe Asp Tyr
1 5 10
<210> 763
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 128 LC CDR1
<400> 763
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 764
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 128 LC CDR2
<400> 764
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 765
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 128 LC CDR3
<400> 765
Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val
1 5 10
<210> 766
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 128 HC CDR1
<400> 766
Arg Tyr Ala Met Ser
1 5
<210> 767
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 128 HC CDR2
<400> 767
Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 768
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 128 HC CDR3
<400> 768
Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr
1 5 10 15
<210> 769
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 129 LC CDR1
<400> 769
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asp
1 5 10
<210> 770
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 129 LC CDR2
<400> 770
Asn Asn Asn Gln Arg Pro Ser
1 5
<210> 771
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 129 LC CDR3
<400> 771
Ala Ala Trp Asp Asp Ser Leu Asn Ala Pro Trp Val
1 5 10
<210> 772
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 129 HC CDR1
<400> 772
Ser Tyr Ala Met His
1 5
<210> 773
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 129 HC CDR2
<400> 773
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 774
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 129 HC CDR3
<400> 774
Pro Arg Gly Gly Asn Tyr Arg Gly Ala Leu Asp Ile
1 5 10
<210> 775
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 130 LC CDR1
<400> 775
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 776
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 130 LC CDR2
<400> 776
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 777
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 130 LC CDR3
<400> 777
Gln Gln Tyr Gly Ser Ser Pro Pro Ile Thr
1 5 10
<210> 778
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 130 HC CDR1
<400> 778
Ser Tyr Ala Ile Ser
1 5
<210> 779
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 130 HC CDR2
<400> 779
Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 780
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 130 HC CDR3
<400> 780
Asp Pro Thr Gly Trp Tyr Ser Gly Tyr Phe Asp Tyr
1 5 10
<210> 781
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 131 LC CDR1
<400> 781
Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser
1 5 10
<210> 782
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 131 LC CDR2
<400> 782
Asp Val Ser Asn Arg Pro Ser
1 5
<210> 783
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 131 LC CDR3
<400> 783
Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val
1 5 10
<210> 784
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 131 HC CDR1
<400> 784
Asn Tyr Gly Met His
1 5
<210> 785
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 131 HC CDR2
<400> 785
Val Met Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 786
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 131 HC CDR3
<400> 786
Pro Asp Asp Ser Ser Gly Tyr Tyr Pro Asp Tyr
1 5 10
<210> 787
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 132 LC CDR1
<400> 787
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 788
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 132 LC CDR2
<400> 788
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 789
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 132 LC CDR3
<400> 789
Ser Ser Tyr Thr Thr Ser Ser Thr Trp Val
1 5 10
<210> 790
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 132 HC CDR1
<400> 790
Glu Leu Ser Ile His
1 5
<210> 791
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 132 HC CDR2
<400> 791
Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 792
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 132 HC CDR3
<400> 792
Ser Pro Ala Val Thr Thr Ala Gly Trp Phe Asp Pro
1 5 10
<210> 793
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 133 LC CDR1
<400> 793
Thr Gly Thr Arg Gly Asp Ile Gly Ala Tyr Asp Gly Val Ser
1 5 10
<210> 794
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 133 LC CDR2
<400> 794
Ala Val Thr Gln Arg Pro Ser
1 5
<210> 795
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 133 LC CDR3
<400> 795
Ser Ser Tyr Thr Ser Ser Ser Ser Trp Val
1 5 10
<210> 796
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 133 HC CDR1
<400> 796
Glu Leu Ser Met His
1 5
<210> 797
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 133 HC CDR2
<400> 797
Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 798
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 133 HC CDR3
<400> 798
Ser Pro Ala Ile Ile Arg Val Asp Trp Phe Asp Pro
1 5 10
<210> 799
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 134 LC CDR1
<400> 799
Thr Gly Thr Arg Gly Asp Ile Gly Ala Tyr Asp Gly Val Ser
1 5 10
<210> 800
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 134 LC CDR2
<400> 800
Ala Val Thr Gln Arg Pro Ser
1 5
<210> 801
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 134 LC CDR3
<400> 801
Ser Ser Tyr Thr Ser Ser Ser Ser Trp Val
1 5 10
<210> 802
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 134 HC CDR1
<400> 802
Arg Tyr Ala Met Ser
1 5
<210> 803
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 134 HC CDR2
<400> 803
Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 804
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 134 HC CDR3
<400> 804
Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr
1 5 10 15
<210> 805
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 135 LC CDR1
<400> 805
Ser Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 806
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 135 LC CDR2
<400> 806
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 807
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 135 LC CDR3
<400> 807
Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val
1 5 10
<210> 808
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 135 HC CDR1
<400> 808
Ser Tyr Ala Met His
1 5
<210> 809
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 135 HC CDR2
<400> 809
Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 810
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 135 HC CDR3
<400> 810
Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val
1 5 10
<210> 811
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 136 LC CDR1
<400> 811
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 812
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 136 LC CDR2
<400> 812
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 813
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 136 LC CDR3
<400> 813
Ser Ser Tyr Thr Ser Ser Ser Thr Pro Trp Val
1 5 10
<210> 814
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 136 HC CDR1
<400> 814
Ser Tyr Ala Met His
1 5
<210> 815
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 136 HC CDR2
<400> 815
Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 816
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 136 HC CDR3
<400> 816
Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val
1 5 10
<210> 817
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 137 LC CDR1
<400> 817
Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 818
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 137 LC CDR2
<400> 818
Asp Val Thr Lys Arg Pro Ser
1 5
<210> 819
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 137 LC CDR3
<400> 819
Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val
1 5 10
<210> 820
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 137 HC CDR1
<400> 820
Ser Tyr Ala Met His
1 5
<210> 821
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 137 HC CDR2
<400> 821
Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 822
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 137 HC CDR3
<400> 822
Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val
1 5 10
<210> 823
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 138 LC CDR1
<400> 823
Thr Gly Thr Ser Thr Asp Ile Gly Arg Tyr Asn Tyr Val Ser
1 5 10
<210> 824
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 138 LC CDR2
<400> 824
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 825
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 138 LC CDR3
<400> 825
Ser Ser Tyr Thr Ser Ser Ser Thr Tyr Ala
1 5 10
<210> 826
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 138 HC CDR1
<400> 826
Glu Val Ala Ile His
1 5
<210> 827
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 138 HC CDR2
<400> 827
Gly Phe Asp Pro Glu Asp Gly Glu Thr Ser Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 828
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 138 HC CDR3
<400> 828
Gly Pro Val Leu Gly Leu Ser Lys Trp Leu Glu Phe Asp Pro
1 5 10
<210> 829
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 139 LC CDR1
<400> 829
Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Asn Tyr Val Ser
1 5 10
<210> 830
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 139 LC CDR2
<400> 830
Asp Val Ser Lys Arg Pro Ser
1 5
<210> 831
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 139 LC CDR3
<400> 831
Asn Ser Tyr Thr Ser Ser Ser Thr Trp Val
1 5 10
<210> 832
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 139 HC CDR1
<400> 832
Glu Val Ala Ile His
1 5
<210> 833
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 139 HC CDR2
<400> 833
Gly Phe Asp Pro Glu Asp Gly Glu Thr Ser Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 834
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 139 HC CDR3
<400> 834
Gly Pro Val Leu Gly Leu Ser Lys Trp Leu Glu Phe Asp Pro
1 5 10
<210> 835
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 140 LC CDR1
<400> 835
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 836
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 140 LC CDR2
<400> 836
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 837
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 140 LC CDR3
<400> 837
Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val
1 5 10
<210> 838
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 140 HC CDR1
<400> 838
Arg Tyr Ala Met Ser
1 5
<210> 839
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 140 HC CDR2
<400> 839
Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 840
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 140 HC CDR3
<400> 840
Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr
1 5 10 15
<210> 841
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 141 LC CDR1
<400> 841
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 842
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 141 LC CDR2
<400> 842
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 843
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 141 LC CDR3
<400> 843
Glu Ala Trp Asp Ser Ser Leu Ser Ala Val Leu
1 5 10
<210> 844
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 141 HC CDR1
<400> 844
Arg Tyr Ala Met Ser
1 5
<210> 845
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 141 HC CDR2
<400> 845
Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 846
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 141 HC CDR3
<400> 846
Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr
1 5 10 15
<210> 847
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 142 LC CDR1
<400> 847
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 848
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 142 LC CDR2
<400> 848
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 849
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 142 LC CDR3
<400> 849
Gly Thr Trp Asp Thr Ser Leu Ser Ala Gly Val
1 5 10
<210> 850
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 142 HC CDR1
<400> 850
Arg Tyr Ala Met Ser
1 5
<210> 851
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 142 HC CDR2
<400> 851
Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 852
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 142 HC CDR3
<400> 852
Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr
1 5 10 15
<210> 853
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 143 LC CDR1
<400> 853
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 854
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 143 LC CDR2
<400> 854
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 855
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 143 LC CDR3
<400> 855
Gly Thr Trp Asp Ser Ser Leu Ser Asp Val Val
1 5 10
<210> 856
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 143 HC CDR1
<400> 856
Arg Tyr Ala Met Ser
1 5
<210> 857
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 143 HC CDR2
<400> 857
Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 858
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 143 HC CDR3
<400> 858
Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr
1 5 10 15
<210> 859
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 144 LC CDR1
<400> 859
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 860
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 144 LC CDR2
<400> 860
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 861
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 144 LC CDR3
<400> 861
Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val
1 5 10
<210> 862
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 144 HC CDR1
<400> 862
Arg Tyr Ala Met Ser
1 5
<210> 863
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 144 HC CDR2
<400> 863
Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 864
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 144 HC CDR3
<400> 864
Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr
1 5 10 15
<210> 865
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 145 LC CDR1
<400> 865
Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 866
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 145 LC CDR2
<400> 866
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 867
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 145 LC CDR3
<400> 867
Gln Gln Tyr Gly Ser Ser Pro Pro Thr
1 5
<210> 868
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 145 HC CDR1
<400> 868
Asn Tyr Val Ile Asn
1 5
<210> 869
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 145 HC CDR2
<400> 869
Gly Phe Ile Pro Val Phe Gly Ile Ala Asp Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 870
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 145 HC CDR3
<400> 870
Ser Gly Leu Phe Asp Trp Leu Leu Pro Arg Ser Arg His Arg Asp Tyr
1 5 10 15
Phe Asp Tyr
<210> 871
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 146 LC CDR1
<400> 871
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 872
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 146 LC CDR2
<400> 872
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 873
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 146 LC CDR3
<400> 873
Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val
1 5 10
<210> 874
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 146 HC CDR1
<400> 874
Ser Tyr Ala Ile Ser
1 5
<210> 875
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 146 HC CDR2
<400> 875
Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 876
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 146 HC CDR3
<400> 876
Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser Tyr Tyr
1 5 10 15
Pro
<210> 877
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 147 LC CDR1
<400> 877
Ser Gly Ser Gly Ser Asn Ile Gly Ser Asn Tyr Val His
1 5 10
<210> 878
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 147 LC CDR2
<400> 878
Arg Asn Ser Gln Arg Pro Ser
1 5
<210> 879
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 147 LC CDR3
<400> 879
Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val
1 5 10
<210> 880
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 147 HC CDR1
<400> 880
Ser Tyr Ala Ile Ser
1 5
<210> 881
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 147 HC CDR2
<400> 881
Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 882
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 147 HC CDR3
<400> 882
Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser Tyr Tyr
1 5 10 15
Pro
<210> 883
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 148 LC CDR1
<400> 883
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr
1 5 10
<210> 884
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 148 LC CDR2
<400> 884
Arg Asn Asn Gln Arg Pro Ser
1 5
<210> 885
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 148 LC CDR3
<400> 885
Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val
1 5 10
<210> 886
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 148 HC CDR1
<400> 886
Glu Leu Pro Ile His
1 5
<210> 887
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 148 HC CDR2
<400> 887
Arg Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Asn Phe Gln
1 5 10 15
Gly
<210> 888
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 148 HC CDR3
<400> 888
Asp Leu Thr Thr Val Thr Asn Pro Leu Asn Tyr Tyr Tyr Tyr Gly Met
1 5 10 15
Asp Val
<210> 889
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 149 LC CDR1
<400> 889
Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Tyr Val Tyr
1 5 10
<210> 890
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 149 LC CDR2
<400> 890
Arg Asn Ser Gln Arg Pro Ser
1 5
<210> 891
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 149 LC CDR3
<400> 891
Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Met
1 5 10
<210> 892
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 149 HC CDR1
<400> 892
Ser Tyr Gly Thr Thr
1 5
<210> 893
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 149 HC CDR2
<400> 893
Trp Ile Ser Gly Tyr Asn Glu Asn Ser Thr His Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 894
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 149 HC CDR3
<400> 894
Asp Ala Leu Arg Tyr Asp Ile Leu Thr Gly Phe Thr Gly Phe Asp Tyr
1 5 10 15
<210> 895
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 150 LC CDR1
<400> 895
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 896
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 150 LC CDR2
<400> 896
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 897
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 150 LC CDR3
<400> 897
Ala Ala Trp Asp Asp Ser Leu Ser Gly Pro Val
1 5 10
<210> 898
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 150 HC CDR1
<400> 898
Ser Tyr Ala Met Ser
1 5
<210> 899
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 150 HC CDR2
<400> 899
Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 900
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 150 HC CDR3
<400> 900
Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp Val
1 5 10 15
<210> 901
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 151 LC CDR1
<400> 901
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 902
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 151 LC CDR2
<400> 902
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 903
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 151 LC CDR3
<400> 903
Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val
1 5 10
<210> 904
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 151 HC CDR1
<400> 904
Ser Tyr Trp Met Ser
1 5
<210> 905
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 151 HC CDR2
<400> 905
Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys
1 5 10 15
Gly
<210> 906
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 151 HC CDR3
<400> 906
Gly Thr Tyr Tyr Tyr Asp Ser Ser Gly Pro Leu Asn Trp Phe Asp Pro
1 5 10 15
<210> 907
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 152 LC CDR1
<400> 907
Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 908
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 152 LC CDR2
<400> 908
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 909
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 152 LC CDR3
<400> 909
Gln Gln Gly Leu Thr
1 5
<210> 910
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 152 HC CDR1
<400> 910
Ser Tyr Ala Ile Ser
1 5
<210> 911
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 152 HC CDR2
<400> 911
Gly Ile Ile Pro Phe Leu Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 912
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 152 HC CDR3
<400> 912
Gly Lys Pro Tyr Tyr Cys Thr Gly Ser Thr Cys Tyr Gln Pro Leu Gly
1 5 10 15
Pro
<210> 913
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 153 LC CDR1
<400> 913
Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 914
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 153 LC CDR2
<400> 914
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 915
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 153 LC CDR3
<400> 915
Gln Gln Tyr Gly Ser Ser Pro Tyr Thr
1 5
<210> 916
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 153 HC CDR1
<400> 916
Ser Ser Pro Met His
1 5
<210> 917
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 153 HC CDR2
<400> 917
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 918
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 153 HC CDR3
<400> 918
Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val
1 5 10
<210> 919
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 154 LC CDR1
<400> 919
Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr Asn Tyr Val Ser
1 5 10
<210> 920
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 154 LC CDR2
<400> 920
Asp Val Ser Asn Arg Pro Ser
1 5
<210> 921
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 154 LC CDR3
<400> 921
Ser Ser Tyr Thr Ser Ser Gly Thr Leu Val
1 5 10
<210> 922
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 154 HC CDR1
<400> 922
Glu Leu Ser Ile His
1 5
<210> 923
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 154 HC CDR2
<400> 923
Gly Phe Asp Pro Glu Asn Gly Glu Thr Ile His Ala Gln Arg Phe Gln
1 5 10 15
Gly
<210> 924
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 154 HC CDR3
<400> 924
Ser Thr Pro Met Ile Arg Ala Ser Trp Phe Asp Pro
1 5 10
<210> 925
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 155 LC CDR1
<400> 925
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Asn
1 5 10
<210> 926
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 155 LC CDR2
<400> 926
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 927
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 155 LC CDR3
<400> 927
Ala Thr Trp Asp Asp Ser Leu Asn Gly Gln Val
1 5 10
<210> 928
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 155 HC CDR1
<400> 928
Asp Tyr Trp Met Ser
1 5
<210> 929
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 155 HC CDR2
<400> 929
Asn Ile Lys Glu Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys
1 5 10 15
Gly
<210> 930
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 155 HC CDR3
<400> 930
Gly Tyr Ser Gly Asn Phe
1 5
<210> 931
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 156 LC CDR1
<400> 931
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser
1 5 10
<210> 932
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 156 LC CDR2
<400> 932
Asp Asn Asn Lys Arg Pro Ser
1 5
<210> 933
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 156 LC CDR3
<400> 933
Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val
1 5 10
<210> 934
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 156 HC CDR1
<400> 934
Ser Tyr Ala Ile Ile
1 5
<210> 935
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 156 HC CDR2
<400> 935
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 936
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 156 HC CDR3
<400> 936
Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr
1 5 10
<210> 937
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 157 LC CDR1
<400> 937
Arg Ala Ser Gln Ser Val Gly Arg Asn Tyr Leu Ala
1 5 10
<210> 938
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 157 LC CDR2
<400> 938
Asp Ala Ser Thr Arg Ala Thr
1 5
<210> 939
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 157 LC CDR3
<400> 939
Gln Gln Tyr Gly Ser Ser Pro Ile Thr
1 5
<210> 940
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 157 HC CDR1
<400> 940
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 941
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 157 HC CDR2
<400> 941
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 942
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 157 HC CDR3
<400> 942
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 943
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 158 LC CDR1
<400> 943
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 944
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 158 LC CDR2
<400> 944
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 945
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 158 LC CDR3
<400> 945
His Gln Tyr Gly Thr Ser Pro Phe Thr
1 5
<210> 946
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 158 HC CDR1
<400> 946
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 947
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 158 HC CDR2
<400> 947
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 948
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 158 HC CDR3
<400> 948
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 949
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 159 LC CDR1
<400> 949
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 950
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 159 LC CDR2
<400> 950
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 951
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 159 LC CDR3
<400> 951
Gln Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<210> 952
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 159 HC CDR1
<400> 952
Ser Gly Gly Tyr Tyr Trp Ser
1 5
<210> 953
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 159 HC CDR2
<400> 953
Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 954
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 159 HC CDR3
<400> 954
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 955
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 160 LC CDR1
<400> 955
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 956
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 160 LC CDR2
<400> 956
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 957
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 160 LC CDR3
<400> 957
Gln Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<210> 958
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 160 HC CDR1
<400> 958
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 959
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 160 HC CDR2
<400> 959
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 960
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 160 HC CDR3
<400> 960
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 961
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 161 LC CDR1
<400> 961
Arg Ala Ser Gln Ser Val Asn Ser Tyr Ser Ala
1 5 10
<210> 962
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 161 LC CDR2
<400> 962
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 963
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 161 LC CDR3
<400> 963
Gln Gln Tyr His Thr Ser Pro Ile Thr
1 5
<210> 964
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 161 HC CDR1
<400> 964
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 965
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 161 HC CDR2
<400> 965
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 966
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 161 HC CDR3
<400> 966
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 967
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 162 LC CDR1
<400> 967
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 968
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 162 LC CDR2
<400> 968
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 969
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 162 LC CDR3
<400> 969
Gln Gln Tyr Gly Ser Ser Pro Ile Thr
1 5
<210> 970
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 162 HC CDR1
<400> 970
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 971
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 162 HC CDR2
<400> 971
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 972
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 162 HC CDR3
<400> 972
Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 973
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 163 LC CDR1
<400> 973
Thr Gly Thr Ser Ser Asn Val Gly Asp Tyr Asn Tyr Val Ser
1 5 10
<210> 974
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 163 LC CDR2
<400> 974
Asp Val Thr Asn Arg Pro Ser
1 5
<210> 975
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 163 LC CDR3
<400> 975
Ser Ser Tyr Thr Ser Gly Ser Thr Pro Val Val
1 5 10
<210> 976
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 163 HC CDR1
<400> 976
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 977
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 163 HC CDR2
<400> 977
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 978
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 163 HC CDR3
<400> 978
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 979
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 164 LC CDR1
<400> 979
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 980
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 164 LC CDR2
<400> 980
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 981
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 164 LC CDR3
<400> 981
Gln Gln Tyr Gly Thr Ser Pro Leu Thr
1 5
<210> 982
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 164 HC CDR1
<400> 982
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 983
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 164 HC CDR2
<400> 983
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 984
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 164 HC CDR3
<400> 984
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 985
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 165 LC CDR1
<400> 985
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 986
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 165 LC CDR2
<400> 986
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 987
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 165 LC CDR3
<400> 987
Gln Gln Tyr Gly Ser Ser Pro Leu Ala
1 5
<210> 988
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 165 HC CDR1
<400> 988
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 989
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 165 HC CDR2
<400> 989
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 990
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 165 HC CDR3
<400> 990
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 991
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 166 LC CDR1
<400> 991
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 992
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 166 LC CDR2
<400> 992
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 993
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 166 LC CDR3
<400> 993
Gln Gln Tyr Gly Ser Ser Pro Gln Thr
1 5
<210> 994
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 166 HC CDR1
<400> 994
Gly Ser Ser Tyr Tyr Trp Gly
1 5
<210> 995
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 166 HC CDR2
<400> 995
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 996
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 166 HC CDR3
<400> 996
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 997
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 167 LC CDR1
<400> 997
Arg Ala Ser Gln Ser Val Arg Asn Tyr Leu Ala
1 5 10
<210> 998
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 167 LC CDR2
<400> 998
Asp Ala Ser Thr Arg Ala Thr
1 5
<210> 999
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 167 LC CDR3
<400> 999
Gln Gln Tyr Gly Arg Ser Pro Leu Thr
1 5
<210> 1000
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 167 HC CDR1
<400> 1000
Gly Ser Ser Tyr Tyr Trp Gly
1 5
<210> 1001
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 167 HC CDR2
<400> 1001
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 1002
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 167 HC CDR3
<400> 1002
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 1003
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 168 LC CDR1
<400> 1003
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 1004
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 168 LC CDR2
<400> 1004
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 1005
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 168 LC CDR3
<400> 1005
Gln Gln His Gly Ser Ser Pro Phe Thr
1 5
<210> 1006
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 168 HC CDR1
<400> 1006
Gly Ser Ser Tyr Tyr Trp Gly
1 5
<210> 1007
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 168 HC CDR2
<400> 1007
Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 1008
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 168 HC CDR3
<400> 1008
Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly
1 5 10 15
Phe Asp Tyr
<210> 1009
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 169 LC CDR1
<400> 1009
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr
1 5 10
<210> 1010
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 169 LC CDR2
<400> 1010
Arg Asn Asn Gln Arg Pro Ser
1 5
<210> 1011
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 169 LC CDR3
<400> 1011
Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val
1 5 10
<210> 1012
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 169 HC CDR1
<400> 1012
Ser Tyr Ala Ile Ser
1 5
<210> 1013
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 169 HC CDR2
<400> 1013
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 1014
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 169 HC CDR3
<400> 1014
Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr
1 5 10 15
Tyr Tyr Gly Met Asp Val
20
<210> 1015
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 170 LC CDR1
<400> 1015
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1016
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 170 LC CDR2
<400> 1016
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1017
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 170 LC CDR3
<400> 1017
Ser Thr Trp Asp Asp Ser Leu Ser Gly Arg Val
1 5 10
<210> 1018
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 170 HC CDR1
<400> 1018
Ser Tyr Ala Ile Ser
1 5
<210> 1019
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 170 HC CDR2
<400> 1019
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 1020
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 170 HC CDR3
<400> 1020
Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr
1 5 10 15
Tyr Tyr Gly Met Asp Val
20
<210> 1021
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 171 LC CDR1
<400> 1021
Ser Gly Leu Thr Ser Asn Ile Gly Ser Asn Phe Val Tyr
1 5 10
<210> 1022
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 171 LC CDR2
<400> 1022
Arg Asn Asn Glu Arg Pro Ser
1 5
<210> 1023
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 171 LC CDR3
<400> 1023
Ala Ala Trp Asp Asp Thr Leu Val Gly Arg Val
1 5 10
<210> 1024
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 171 HC CDR1
<400> 1024
Ser Tyr Ala Ile Ser
1 5
<210> 1025
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 171 HC CDR2
<400> 1025
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Asp
<210> 1026
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 171 HC CDR3
<400> 1026
Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr
1 5 10 15
Tyr Tyr Gly Met Asp Val
20
<210> 1027
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 172 LC CDR1
<400> 1027
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1028
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 172 LC CDR2
<400> 1028
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1029
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 172 LC CDR3
<400> 1029
Ala Ala Trp Asp Asp Ser Leu Ser Gly Pro Val
1 5 10
<210> 1030
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 172 HC CDR1
<400> 1030
Ser His Trp Ile Ala
1 5
<210> 1031
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 172 HC CDR2
<400> 1031
Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 1032
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 172 HC CDR3
<400> 1032
Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser
1 5 10
<210> 1033
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 173 LC CDR1
<400> 1033
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1034
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 173 LC CDR2
<400> 1034
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1035
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 173 LC CDR3
<400> 1035
Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val
1 5 10
<210> 1036
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 173 HC CDR1
<400> 1036
Ser His Trp Ile Ala
1 5
<210> 1037
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 173 HC CDR2
<400> 1037
Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 1038
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 173 HC CDR3
<400> 1038
Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser
1 5 10
<210> 1039
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 174 LC CDR1
<400> 1039
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1040
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 174 LC CDR2
<400> 1040
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1041
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 174 LC CDR3
<400> 1041
Ala Ala Trp Asp Asp Ser Leu Asn Gly Ser Val Val
1 5 10
<210> 1042
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 174 HC CDR1
<400> 1042
Ser Tyr Trp Ile Ala
1 5
<210> 1043
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 174 HC CDR2
<400> 1043
Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 1044
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 174 HC CDR3
<400> 1044
Gly Pro Asn Leu Tyr Asn Trp Phe Asp Phe
1 5 10
<210> 1045
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 175 LC CDR1
<400> 1045
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1046
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 175 LC CDR2
<400> 1046
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1047
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 175 LC CDR3
<400> 1047
Ala Ala Trp Asp Asp Ser Leu Asn Gly His Val Val
1 5 10
<210> 1048
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 175 HC CDR1
<400> 1048
Ser Tyr Trp Ile Ala
1 5
<210> 1049
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 175 HC CDR2
<400> 1049
Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 1050
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 175 HC CDR3
<400> 1050
Gly Pro Asn Leu Tyr Asn Trp Phe Asp Phe
1 5 10
<210> 1051
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 176 LC CDR1
<400> 1051
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1052
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 176 LC CDR2
<400> 1052
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1053
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 176 LC CDR3
<400> 1053
Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val
1 5 10
<210> 1054
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 176 HC CDR1
<400> 1054
Ser His Trp Ile Ala
1 5
<210> 1055
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 176 HC CDR2
<400> 1055
Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 1056
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 176 HC CDR3
<400> 1056
Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser
1 5 10
<210> 1057
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 177 LC CDR1
<400> 1057
Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10
<210> 1058
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 177 LC CDR2
<400> 1058
Asp Ala Ser Asn Arg Ala Thr
1 5
<210> 1059
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 177 LC CDR3
<400> 1059
Gln Gln Tyr Tyr Ser Thr Pro Phe Thr
1 5
<210> 1060
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 177 HC CDR1
<400> 1060
Asp Tyr Tyr Ile Gln
1 5
<210> 1061
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 177 HC CDR2
<400> 1061
Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln
1 5 10 15
Gly
<210> 1062
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 177 HC CDR3
<400> 1062
Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro
1 5 10
<210> 1063
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 178 LC CDR1
<400> 1063
Arg Ala Ser Gln Gly Ile Ser Asn Ser Leu Ala
1 5 10
<210> 1064
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 178 LC CDR2
<400> 1064
Ala Ala Ser Arg Leu Glu Ser
1 5
<210> 1065
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 178 LC CDR3
<400> 1065
Gln Gln Tyr Tyr Ser Thr Pro Phe Thr
1 5
<210> 1066
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 178 HC CDR1
<400> 1066
Asp Tyr Tyr Ile Gln
1 5
<210> 1067
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 178 HC CDR2
<400> 1067
Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln
1 5 10 15
Gly
<210> 1068
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 178 HC CDR3
<400> 1068
Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro
1 5 10
<210> 1069
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 179 LC CDR1
<400> 1069
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1070
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 179 LC CDR2
<400> 1070
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1071
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 179 LC CDR3
<400> 1071
Ala Ala Trp Asp Asp Ser Leu Asn Ser Gly Val
1 5 10
<210> 1072
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 179 HC CDR1
<400> 1072
Ser Asn Trp Ile Gly
1 5
<210> 1073
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 179 HC CDR2
<400> 1073
Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 1074
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 179 HC CDR3
<400> 1074
Thr Tyr Gly Ser Gly Ser Tyr Ser Asp Phe Asp Tyr
1 5 10
<210> 1075
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 180 LC CDR1
<400> 1075
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1076
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 180 LC CDR2
<400> 1076
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1077
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 180 LC CDR3
<400> 1077
Ala Ala Trp Asp Asp Ser Leu Asn Gly Gly Val
1 5 10
<210> 1078
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 180 HC CDR1
<400> 1078
Ser Asn Trp Ile Gly
1 5
<210> 1079
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 180 HC CDR2
<400> 1079
Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 1080
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 180 HC CDR3
<400> 1080
Thr Tyr Gly Ser Gly Ser Tyr Ser Asp Phe Asp Tyr
1 5 10
<210> 1081
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 181 LC CDR1
<400> 1081
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 1082
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 181 LC CDR2
<400> 1082
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 1083
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 181 LC CDR3
<400> 1083
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val
1 5 10
<210> 1084
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 181 HC CDR1
<400> 1084
Asp Tyr Ala Met Ser
1 5
<210> 1085
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 181 HC CDR2
<400> 1085
Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 1086
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 181 HC CDR3
<400> 1086
Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro Gly Asp
1 5 10 15
Ala Phe Asp
<210> 1087
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 182 LC CDR1
<400> 1087
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 1088
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 182 LC CDR2
<400> 1088
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 1089
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 182 LC CDR3
<400> 1089
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val
1 5 10
<210> 1090
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 182 HC CDR1
<400> 1090
Asp Tyr Ala Met Ser
1 5
<210> 1091
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 182 HC CDR2
<400> 1091
Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 1092
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 182 HC CDR3
<400> 1092
Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro Gly Asp
1 5 10 15
Ala Phe Asp
<210> 1093
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 183 LC CDR1
<400> 1093
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1094
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 183 LC CDR2
<400> 1094
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1095
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 183 LC CDR3
<400> 1095
Ala Ala Trp Asp Asp Ser Leu Met Gln Gly Val
1 5 10
<210> 1096
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 183 HC CDR1
<400> 1096
Asn Tyr Trp Ile Ala
1 5
<210> 1097
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 183 HC CDR2
<400> 1097
Ile Ile Tyr Pro Tyr Asp Ser Asp Thr Arg Lys Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 1098
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 183 HC CDR3
<400> 1098
Gln Asp Ser Gly Thr Tyr Gly Trp Ile Asp Tyr
1 5 10
<210> 1099
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 184 LC CDR1
<400> 1099
Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln
1 5 10
<210> 1100
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 184 LC CDR2
<400> 1100
Glu Asp Asn Gln Arg Pro Ser
1 5
<210> 1101
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 184 LC CDR3
<400> 1101
Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val
1 5 10
<210> 1102
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 184 HC CDR1
<400> 1102
Ser Ser Ser Tyr Tyr Trp Gly
1 5
<210> 1103
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 184 HC CDR2
<400> 1103
Asn Phe Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 1104
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 184 HC CDR3
<400> 1104
Gln Glu Trp Leu Arg Gly Gly Phe Asp Asp
1 5 10
<210> 1105
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 185 LC CDR1
<400> 1105
Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Ile Val Asn
1 5 10
<210> 1106
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 185 LC CDR2
<400> 1106
Asn Asn Asn Gln Arg Pro Ser
1 5
<210> 1107
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 185 LC CDR3
<400> 1107
Ala Ala Trp Asp Asp Ser Leu Asn Ala Trp Val
1 5 10
<210> 1108
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 185 HC CDR1
<400> 1108
Asn His Trp Ile Ala
1 5
<210> 1109
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 185 HC CDR2
<400> 1109
Ile Ile Tyr Pro Tyr Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 1110
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 185 HC CDR3
<400> 1110
Asn Pro Thr Val Thr Asn Trp Phe Asp Ser
1 5 10
<210> 1111
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 186 LC CDR1
<400> 1111
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 1112
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 186 LC CDR2
<400> 1112
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 1113
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 186 LC CDR3
<400> 1113
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Asn Trp Val
1 5 10
<210> 1114
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 186 HC CDR1
<400> 1114
Ser Tyr Ala Ile Ser
1 5
<210> 1115
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 186 HC CDR2
<400> 1115
Gly Ile Ile Pro Phe Phe Gly Thr Ser Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 1116
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 186 HC CDR3
<400> 1116
Gly Gln Phe Ser Asp Ser Ser Gly Tyr Gln His Pro Tyr Tyr Asp Tyr
1 5 10 15
Gly Met Asp
<210> 1117
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 187 LC CDR1
<400> 1117
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
1 5 10
<210> 1118
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 187 LC CDR2
<400> 1118
Asp Val Ser Asn Arg Pro Ser
1 5
<210> 1119
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 187 LC CDR3
<400> 1119
Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val
1 5 10
<210> 1120
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 187 HC CDR1
<400> 1120
Thr His Ala Leu Ser
1 5
<210> 1121
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 187 HC CDR2
<400> 1121
Gly Ile Ile Pro Ile Phe Gly Pro Ala Asp Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 1122
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 187 HC CDR3
<400> 1122
Gly Leu Ser Leu Gly Phe Cys Ser Ala Gly Ser Cys Tyr Asp Tyr Leu
1 5 10 15
Asp Tyr
<210> 1123
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 188 LC CDR1
<400> 1123
Ser Gly Ser Ser Ser Asp Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 1124
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 188 LC CDR2
<400> 1124
Ser Asn Asn Gln Arg Pro Ser
1 5
<210> 1125
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 188 LC CDR3
<400> 1125
Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val
1 5 10
<210> 1126
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 188 HC CDR1
<400> 1126
Asn Tyr Ala Ile Asn
1 5
<210> 1127
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 188 HC CDR2
<400> 1127
Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 1128
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 188 HC CDR3
<400> 1128
Asp Arg Tyr Pro Gly Tyr Tyr Asp Ile Leu Thr Gly Gln Ile Gly Thr
1 5 10 15
Gly Glu Arg Asn Ala Met Asp Val
20
<210> 1129
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 189 LC CDR1
<400> 1129
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 1130
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 189 LC CDR2
<400> 1130
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 1131
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 189 LC CDR3
<400> 1131
Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val
1 5 10
<210> 1132
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 189 HC CDR1
<400> 1132
Asn Tyr Pro Leu Thr
1 5
<210> 1133
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 189 HC CDR2
<400> 1133
Gly Ile Ile Pro Ile Ile Gly Ala Thr Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 1134
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 189 HC CDR3
<400> 1134
Gly Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp Tyr
1 5 10 15
<210> 1135
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 190 LC CDR1
<400> 1135
Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His
1 5 10
<210> 1136
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 190 LC CDR2
<400> 1136
Tyr Asp Ser Asp Arg Pro Ser
1 5
<210> 1137
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 190 LC CDR3
<400> 1137
Gln Val Trp Asp Ser Ser Ser Asp His Trp Val
1 5 10
<210> 1138
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 190 HC CDR1
<400> 1138
Ser Tyr Tyr Ile His
1 5
<210> 1139
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 190 HC CDR2
<400> 1139
Phe Ile Asn Pro Ser Asp Val Thr Thr Tyr Tyr Ala Gln Lys Phe Gln
1 5 10 15
Gly
<210> 1140
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 190 HC CDR3
<400> 1140
Ser Arg Ile Ala Pro Thr Glu Asp Phe Phe Asp Tyr
1 5 10
<210> 1141
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.1 LC variable region
<400> 1141
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Ser Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Arg Leu
85 90 95
Ser Ala Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1142
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 1 HC variable region
<400> 1142
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Ser Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1143
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.2 LC variable region
<400> 1143
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Phe Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Glu Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1144
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 2 HC variable region
<400> 1144
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1145
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.3 LC variable region
<400> 1145
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1146
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 3 HC variable region
<400> 1146
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1147
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.4 LC variable region
<400> 1147
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1148
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 4 HC variable region
<400> 1148
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1149
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.5 LC variable region
<400> 1149
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1150
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 5 HC variable region
<400> 1150
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1151
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.6 LC variable region
<400> 1151
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1152
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 6 HC variable region
<400> 1152
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Ala Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1153
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.7 LC variable region
<400> 1153
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1154
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 7 HC variable region
<400> 1154
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Leu Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Pro Phe Glu Arg Lys
20 25 30
Val Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val
35 40 45
Gly Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Ala Asp Asp Ser Thr Ala Thr Ala Phe
65 70 75 80
Met Glu Leu Ser Ser Leu Gly Tyr Gly Asp Thr Gly Val Tyr Tyr Cys
85 90 95
Ala Thr Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Asn Trp Gly Gln
100 105 110
Gly Thr Leu Val Phe Val Ser Thr
115 120
<210> 1155
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No.8 LC variable region
<400> 1155
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Ser
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu
35 40 45
Tyr Ala Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1156
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 8 HC variable region
<400> 1156
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30
Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Arg Ile Lys Thr Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala
50 55 60
Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asn Asp Ser Lys Asn Met
65 70 75 80
Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Thr Thr His Ser Arg Pro Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
<210> 1157
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.9 LC variable region
<400> 1157
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1158
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 9 HC variable region
<400> 1158
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Pro Phe Glu Arg Lys
20 25 30
Val Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val
35 40 45
Gly Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Ala Asp Asp Ser Thr Ser Thr Ala Phe
65 70 75 80
Met Glu Leu Ser Thr Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Thr Trp Gly Gln
100 105 110
Gly Thr Leu Val Leu Val Ser Ala
115 120
<210> 1159
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No.10 LC variable region
<400> 1159
Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Leu
35 40 45
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Ala Ala Val Tyr Tyr Cys Leu Gln Tyr Phe Thr Ile Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1160
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 10 HC variable region
<400> 1160
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Glu Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn Ala
20 25 30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Arg Ile Lys Thr Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala
50 55 60
Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80
Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Thr Thr Phe Ser Thr Pro Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
<210> 1161
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.11 LC variable region
<400> 1161
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1162
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 11 HC variable region
<400> 1162
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Arg Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ile Arg Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Pro Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Lys Val Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Asn
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Gly Ser Thr Trp Tyr Gly Gly Asn Trp Phe Asp Pro Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1163
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> No.12 LC variable region
<400> 1163
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15
Thr Ala Arg Ile Thr Cys Ser Gly Asp Val Leu Ala Lys Lys Tyr Ala
20 25 30
Arg Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
35 40 45
Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Ala Gln Val Glu
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Ala Ala Asp Asn Asn Gly Val
85 90 95
Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105
<210> 1164
<211> 127
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 12 HC variable region
<400> 1164
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asp
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ala Thr Tyr Asp Ser Ser Gly Arg Pro Thr Gly Asp Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1165
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.13 LC variable region
<400> 1165
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1166
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 13 HC variable region
<400> 1166
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1167
<211> 112
<212> PRT
<213> Artificial Sequence
<220>
<223> No.14 LC variable region
<400> 1167
Glu Leu Ala Leu Asn Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala His Lys Leu
35 40 45
Met Met Tyr Asp Val Ser Asn Arg Pro Ser Gly Ala Tyr Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Ala Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Ser His Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1168
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 14 HC variable region
<400> 1168
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Ser Ser Tyr Ala
20 25 30
Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
35 40 45
Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu
100 105 110
Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1169
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.15 LC variable region
<400> 1169
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1170
<211> 123
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 15 HC variable region
<400> 1170
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Ser Arg Gly
20 25 30
Asp Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
35 40 45
Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu
50 55 60
Lys Ser Arg Val Thr Ile Ser Ala Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80
Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ala Tyr Tyr Cys
85 90 95
Ala Arg His Gly Thr Ser Gly Tyr Tyr Tyr Pro Asn Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1171
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.16 LC variable region
<400> 1171
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Ala Ser Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1172
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 16 HC variable region
<400> 1172
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1173
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.17 LC variable region
<400> 1173
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Thr Asp Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1174
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 17 HC variable region
<400> 1174
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1175
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.18 LC variable region
<400> 1175
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1176
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 18 HC variable region
<400> 1176
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1177
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No.19 LC variable region
<400> 1177
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Arg Asp Asp Ser Leu
85 90 95
Asn Gly Ala Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1178
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 19 HC variable region
<400> 1178
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1179
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No.20 LC variable region
<400> 1179
Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1180
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 20 HC variable region
<400> 1180
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser
50 55 60
Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1181
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 21 LC variable region
<400> 1181
Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Tyr Gly Ser Ser Pro Arg
85 90 95
Arg Val Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1182
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 21 HC variable region
<400> 1182
Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1183
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 22 LC variable region
<400> 1183
Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Gly Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Gln Val Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1184
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 22 HC variable region
<400> 1184
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1185
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 23 LC variable region
<400> 1185
Glu Leu Gly Gln Thr Gln Gln Leu Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1186
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 23 HC variable region
<400> 1186
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr
100 105 110
Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1187
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 24 LC variable region
<400> 1187
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1188
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 24 HC variable region
<400> 1188
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Ser Pro Ala Val Thr Thr Ala Gly Trp Phe Asp Pro Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1189
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 25 LC variable region
<400> 1189
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Thr Asn
20 25 30
Thr Val Asn Trp Tyr Gln His Leu Pro Gly Met Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Leu Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1190
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 25 HC variable region
<400> 1190
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1191
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 26 LC variable region
<400> 1191
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Gly Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1192
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 26 HC variable region
<400> 1192
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Phe Tyr
20 25 30
Ala Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Leu Phe Gly Thr Ala Lys Tyr Ala Gln Arg Phe
50 55 60
Gln Asp Arg Val Thr Phe Ile Ala Asp Asp Thr Ser Thr Ala Tyr Met
65 70 75 80
Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Gly Gly Trp Ile Tyr Arg Gly Asn Trp Phe Asp Pro Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1193
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 27 LC variable region
<400> 1193
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Trp Val Leu Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1194
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 27 HC variable region
<400> 1194
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Thr Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn Asn Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ser Ser His Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Gly Tyr Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro
100 105 110
Arg Phe Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser
115 120 125
Ser
<210> 1195
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 28 LC variable region
<400> 1195
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser
85 90 95
Asn Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1196
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 28 HC variable region
<400> 1196
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser
100 105 110
Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1197
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 29 LC variable region
<400> 1197
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Leu Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1198
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 29 HC variable region
<400> 1198
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser
100 105 110
Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1199
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 30 LC variable region
<400> 1199
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1200
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 30 HC variable region
<400> 1200
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1201
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 31 LC variable region
<400> 1201
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Leu Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1202
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 31 HC variable region
<400> 1202
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ile Ser Tyr
20 25 30
Trp Ile Val Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Gly Pro Asn Ile Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1203
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 32 LC variable region
<400> 1203
Glu Leu Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1204
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 32 HC variable region
<400> 1204
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Phe Ile Val Ser Ser Asn
20 25 30
Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ile Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Arg Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Leu Pro Leu Thr Gly Thr Thr Leu Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1205
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 33 LC variable region
<400> 1205
Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Val Ala Pro Gly Lys
1 5 10 15
Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr
35 40 45
Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His
85 90 95
Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105
<210> 1206
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 33 HC variable region
<400> 1206
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr
100 105 110
Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1207
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 34 LC variable region
<400> 1207
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1208
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 34 HC variable region
<400> 1208
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Asn Tyr
20 25 30
Pro Leu Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Gly Ile Ile Pro Ile Ile Gly Ala Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Phe
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1209
<211> 112
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 35 LC variable region
<400> 1209
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1210
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 35 HC variable region
<400> 1210
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Arg Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Gly Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Leu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Pro Ile Ser Glu
100 105 110
Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
115 120 125
<210> 1211
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 36 LC variable region
<400> 1211
Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1212
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 36 HC variable region
<400> 1212
Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Ala Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1213
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 37 LC variable region
<400> 1213
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Thr Asn Asn Arg Arg Pro Ser Gly Ala Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Leu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1214
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 37 HC variable region
<400> 1214
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His
20 25 30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1215
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 38 LC variable region
<400> 1215
Glu Leu Val Val Thr Gln Glu Pro Ser Val Ser Val Ala Pro Gly Lys
1 5 10 15
Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
35 40 45
Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His
85 90 95
Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu
100 105
<210> 1216
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 38 HC variable region
<400> 1216
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro
100 105 110
Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser
115 120 125
Ser
<210> 1217
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 39 LC variable region
<400> 1217
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Gly Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1218
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 39 HC variable region
<400> 1218
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr
100 105 110
Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1219
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 40 LC variable region
<400> 1219
Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1220
<211> 130
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 40 HC variable region
<400> 1220
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser
20 25 30
Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu
35 40 45
Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro
50 55 60
Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln
65 70 75 80
Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr
85 90 95
Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr
100 105 110
Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
115 120 125
Ser Ser
130
<210> 1221
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 41 LC variable region
<400> 1221
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1222
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 41 HC variable region
<400> 1222
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Tyr Ser Ser Trp Tyr Gly Pro Arg Thr Trp Phe Asp
100 105 110
Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1223
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 42 LC variable region
<400> 1223
Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys
1 5 10 15
Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn
20 25 30
Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val
35 40 45
Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly
65 70 75 80
Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser
85 90 95
Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1224
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 42 HC variable region
<400> 1224
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Phe Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Glu Trp Leu Arg Gly Gly Phe Asp Asp Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1225
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 43 LC variable region
<400> 1225
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn
20 25 30
Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1226
<211> 131
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 43 HC variable region
<400> 1226
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Arg Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp
100 105 110
Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
115 120 125
Val Ser Ser
130
<210> 1227
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 44 LC variable region
<400> 1227
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ser
85 90 95
Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1228
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 44 HC variable region
<400> 1228
Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1229
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 45 LC variable region
<400> 1229
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Glu Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1230
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 45 HC variable region
<400> 1230
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Asp Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Leu Gly Ile Pro Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Gly Tyr Ser Gly Tyr Gly Ala Asn Trp Tyr Phe Asp
100 105 110
Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1231
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 46 LC variable region
<400> 1231
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ser Pro Gly Lys
1 5 10 15
Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn
20 25 30
Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val
35 40 45
Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly
65 70 75 80
Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser
85 90 95
Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1232
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 46 HC variable region
<400> 1232
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Arg Ala Ser Gly Tyr Ala Phe Thr Arg Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Leu Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Leu Gly Ile Ala Val Ala Gly Thr Pro Ile Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Pro
115 120
<210> 1233
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 47 LC variable region
<400> 1233
Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Asp
20 25 30
Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Thr Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Val Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Thr Thr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
<210> 1234
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 47 HC variable region
<400> 1234
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1235
<211> 112
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 48 LC variable region
<400> 1235
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Gln
100 105 110
<210> 1236
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 48 HC variable region
<400> 1236
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn
20 25 30
Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile Trp
100 105 110
Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120
<210> 1237
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 49 LC variable region
<400> 1237
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Pro Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1238
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 49 HC variable region
<400> 1238
Glu Val Gln Leu Leu Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ser Gly Val Val Thr Ala Asp Trp Tyr Phe Asp Leu Trp Gly Arg
100 105 110
Gly Thr Leu Ala Thr Val Ser Ser
115 120
<210> 1239
<211> 112
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 50 LC variable region
<400> 1239
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Pro Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1240
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 50 HC variable region
<400> 1240
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Val Thr Phe Ser Arg Tyr
20 25 30
Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Leu Leu Gly Thr Ala Asp Tyr Pro Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Thr Asp Glu Ser Thr Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Thr Leu Tyr Tyr Tyr Asp Arg Ser Gly Asn Ala Arg Thr Asp
100 105 110
Asp Tyr Phe Asp His Trp Ala Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1241
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 51 LC variable region
<400> 1241
Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1242
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 51 HC variable region
<400> 1242
Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Val Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1243
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 52 LC variable region
<400> 1243
Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1244
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 52 HC variable region
<400> 1244
Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1245
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 53 LC variable region
<400> 1245
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1246
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 53 HC variable region
<400> 1246
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn
20 25 30
Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile Trp
100 105 110
Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120
<210> 1247
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 54 LC variable region
<400> 1247
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1248
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 54 HC variable region
<400> 1248
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Arg Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95
Ala Lys Glu Glu Leu Gly Pro Tyr Ser Asn Arg Trp Tyr Ser Ser Ser
100 105 110
Asp Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1249
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 55 LC variable region
<400> 1249
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1250
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 55 HC variable region
<400> 1250
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Thr Ser Ser
20 25 30
Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Val Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Phe Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ala Arg Asp His Ile Val Ser Pro Leu Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1251
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 56 LC variable region
<400> 1251
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1252
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 56 HC variable region
<400> 1252
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn
20 25 30
Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile Trp
100 105 110
Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120
<210> 1253
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 57 LC variable region
<400> 1253
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Ile
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1254
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 57 HC variable region
<400> 1254
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1255
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 58 LC variable region
<400> 1255
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Pro Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Ser His Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Ile Leu Tyr Glu Val Ser Asp Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1256
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 58 HC variable region
<400> 1256
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1257
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 59 LC variable region
<400> 1257
Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Gly Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1258
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 59 HC variable region
<400> 1258
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Pro Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1259
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 60 LC variable region
<400> 1259
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro
85 90 95
Ala Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1260
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 60 HC variable region
<400> 1260
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ile Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1261
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 61 LC variable region
<400> 1261
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys
1 5 10 15
Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr
35 40 45
Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Arg
85 90 95
Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105
<210> 1262
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 61 HC variable region
<400> 1262
Glu Val Gln Leu Leu Glu Ser Gly Gly Ala Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Gly Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Thr Thr Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Glu Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95
Ala Lys Asp Ile Gly Ser Gly Asp Arg Pro Asp Ala Phe His Leu Trp
100 105 110
Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120
<210> 1263
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 62 LC variable region
<400> 1263
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Glu Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1264
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 62 HC variable region
<400> 1264
Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1265
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 63 LC variable region
<400> 1265
Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1266
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 63 HC variable region
<400> 1266
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
20 25 30
Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Gly Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1267
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 64 LC variable region
<400> 1267
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Asn Arg Ser Asp Ile Gly Gly Tyr
20 25 30
Asn Ser Leu Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Ile Ile Tyr Asp Val Asn Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Ala Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Lys
85 90 95
Asn Thr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1268
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 64 HC variable region
<400> 1268
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
20 25 30
Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1269
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 65 LC variable region
<400> 1269
Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1270
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 65 HC variable region
<400> 1270
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
20 25 30
Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1271
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 66 LC variable region
<400> 1271
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1272
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 66 HC variable region
<400> 1272
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Ser Ser
20 25 30
Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1273
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 67 LC variable region
<400> 1273
Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys
100 105
<210> 1274
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 67 HC variable region
<400> 1274
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
20 25 30
Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1275
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 68 LC variable region
<400> 1275
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1276
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 68 HC variable region
<400> 1276
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Pro Phe Glu Arg Lys
20 25 30
Val Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val
35 40 45
Gly Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Arg Lys Phe
50 55 60
Gln Gly Arg Val Thr Leu Thr Ala Asp Asp Ser Thr Ser Thr Ala Phe
65 70 75 80
Met Glu Phe Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys
85 90 95
Ala Thr Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Asn Trp Gly Gln
100 105 110
Gly Thr Leu Val Phe Val Ser Ala
115 120
<210> 1277
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 69 LC variable region
<400> 1277
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Asn Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Pro Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1278
<211> 126
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 69 HC variable region
<400> 1278
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser
100 105 110
Tyr Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1279
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 70 LC variable region
<400> 1279
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Thr Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Ser Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1280
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 70 HC variable region
<400> 1280
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Met Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Pro Asp Asp Ser Ser Gly Tyr Tyr Pro Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1281
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 71 LC variable region
<400> 1281
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Arg Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1282
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 71 HC variable region
<400> 1282
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp
100 105 110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1283
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 72 LC variable region
<400> 1283
Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Ser Tyr Arg Pro Ser Gly Val Ser Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Arg
65 70 75 80
Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ala Leu
85 90 95
Arg Gly Pro Leu Phe Gly Gly Gly Thr Lys Val Asp Ile Lys
100 105 110
<210> 1284
<211> 125
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 72 HC variable region
<400> 1284
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Gly Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe
100 105 110
Asp Pro Trp Gly Leu Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1285
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 73 LC variable region
<400> 1285
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Asp Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1286
<211> 125
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 73 HC variable region
<400> 1286
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Gly Ser Tyr
20 25 30
Gly Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe
100 105 110
Asp Pro Trp Gly Leu Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1287
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 74 LC variable region
<400> 1287
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu
100 105 110
<210> 1288
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 74 HC variable region
<400> 1288
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp
100 105 110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1289
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 75 LC variable region
<400> 1289
Glu Leu Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15
Thr Val Thr Leu Thr Cys Ser Ser Ser Thr Gly Ala Val Thr Arg Gly
20 25 30
His Phe Pro Asn Trp Leu Gln Gln Lys Pro Gly Gln Thr Pro Arg Ala
35 40 45
Leu Ile His Ser Thr Ser Asn Lys His Ser Trp Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Asp Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80
Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Tyr Asp Ala Gly
85 90 95
Ala Pro Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1290
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 75 HC variable region
<400> 1290
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Leu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ser Ser Cys Ser Gly Gly Ser Cys Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1291
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 76 LC variable region
<400> 1291
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu
85 90 95
Ser Gly Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1292
<211> 125
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 76 HC variable region
<400> 1292
Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Gly Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe
100 105 110
Asp Pro Trp Gly Leu Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1293
<211> 112
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 77 LC variable region
<400> 1293
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Phe Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Ser Ser Leu
85 90 95
Ser Thr Pro Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1294
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 77 HC variable region
<400> 1294
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Leu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ser Ser Cys Ser Gly Gly Ser Cys Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1295
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 78 LC variable region
<400> 1295
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1296
<211> 127
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 78 HC variable region
<400> 1296
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Ser Ser Asn
20 25 30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Asn Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Met Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Ser Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Leu Ala Tyr Phe His Pro Gln Arg Asn Gly Gly Tyr Glu Tyr
100 105 110
Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Pro
115 120 125
<210> 1297
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 79 LC variable region
<400> 1297
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Ala Ser Lys Asp Ala Ala Ser Ala Tyr Leu Thr Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Gly Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Arg
85 90 95
Leu Arg Ala Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1298
<211> 125
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 79 HC variable region
<400> 1298
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Gln
20 25 30
Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Asn Pro Tyr Gly Gly Ser Thr Thr Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Pro Ser Gly Tyr Tyr Gly Asp Tyr Glu Gly Asp Ala Phe
100 105 110
Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120 125
<210> 1299
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 80 LC variable region
<400> 1299
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1300
<211> 126
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 80 HC variable region
<400> 1300
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val
35 40 45
Gly Arg Ile Ile Pro Ile Phe Gly Thr Val Lys Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Leu Pro Gly Asp Ser Arg Asp Gly Tyr Asn Tyr Asp Ala
100 105 110
Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Leu
115 120 125
<210> 1301
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 81 LC variable region
<400> 1301
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1302
<211> 127
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 81 HC variable region
<400> 1302
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro
100 105 110
Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1303
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 82 LC variable region
<400> 1303
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1304
<211> 131
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 82 HC variable region
<400> 1304
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp
100 105 110
Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
115 120 125
Val Ser Ser
130
<210> 1305
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 83 LC variable region
<400> 1305
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1306
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 83 HC variable region
<400> 1306
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Gly Pro Asn Ile Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1307
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 84 LC variable region
<400> 1307
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Arg Asn Trp Pro Pro
85 90 95
Val Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1308
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 84 HC variable region
<400> 1308
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Glu Gly Tyr Asp Ser Ser Gly Tyr Tyr Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1309
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 85 LC variable region
<400> 1309
Glu Leu Gly Gln Thr Gln Gln Leu Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1310
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 85 HC variable region
<400> 1310
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr
100 105 110
Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1311
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 86 LC variable region
<400> 1311
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Phe
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro
85 90 95
Arg Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1312
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 86 HC variable region
<400> 1312
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1313
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 87 LC variable region
<400> 1313
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1314
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 87 HC variable region
<400> 1314
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1315
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 88 LC variable region
<400> 1315
Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro
85 90 95
Lys Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1316
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 88 HC variable region
<400> 1316
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Arg Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Glu Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Pro
115 120
<210> 1317
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 89 LC variable region
<400> 1317
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Trp Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1318
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 89 HC variable region
<400> 1318
Glu Val Gln Leu Leu Glu Ser Gly Gly Ser Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ala Arg Gly Gly Ser Tyr Leu Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1319
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 90 LC variable region
<400> 1319
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Arg Asn Trp Pro Pro
85 90 95
Arg Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1320
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 90 HC variable region
<400> 1320
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Glu Gly Tyr Asp Ser Ser Gly Tyr Tyr Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1321
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 91 LC variable region
<400> 1321
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Ser
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1322
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 91 HC variable region
<400> 1322
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1323
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 92 LC variable region
<400> 1323
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu
65 70 75 80
Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser
85 90 95
Leu Gly Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1324
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 92 HC variable region
<400> 1324
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1325
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 93 LC variable region
<400> 1325
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro
85 90 95
Lys Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1326
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 93 HC variable region
<400> 1326
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Ser Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1327
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 94 LC variable region
<400> 1327
Glu Leu Gln Met Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 1328
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 94 HC variable region
<400> 1328
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1329
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 95 LC variable region
<400> 1329
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1330
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 95 HC variable region
<400> 1330
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Asp Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1331
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 96 LC variable region
<400> 1331
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Trp Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1332
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 96 HC variable region
<400> 1332
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Glu Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1333
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 97 LC variable region
<400> 1333
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Trp Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1334
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 97 HC variable region
<400> 1334
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ala Arg Gly Gly Ser Tyr Leu Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1335
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 98 LC variable region
<400> 1335
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1336
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 98 HC variable region
<400> 1336
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Glu Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1337
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 99 LC variable region
<400> 1337
Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro
85 90 95
Met Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1338
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 99 HC variable region
<400> 1338
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ile Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1339
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 100 LC variable region
<400> 1339
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Arg Ser Asn Ile Gly Ile Asn
20 25 30
Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Leu Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Glu Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1340
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 100 HC variable region
<400> 1340
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1341
<211> 112
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 101 LC variable region
<400> 1341
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Ala Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Gly Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Gly Thr Leu Asn Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1342
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 101 HC variable region
<400> 1342
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1343
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 102 LC variable region
<400> 1343
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn
20 25 30
Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Val Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Thr Ser Leu
85 90 95
Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1344
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 102 HC variable region
<400> 1344
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1345
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 103 LC variable region
<400> 1345
Glu Leu Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Arg Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Lys Thr Tyr Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1346
<211> 116
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 103 HC variable region
<400> 1346
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Trp His Asp Gly Tyr Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Ser Lys Ala Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Ile Val Ser Ser
115
<210> 1347
<211> 105
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 104 LC variable region
<400> 1347
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys
1 5 10 15
Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr
35 40 45
Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Phe
85 90 95
Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<210> 1348
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 104 HC variable region
<400> 1348
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1349
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 105 LC variable region
<400> 1349
Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Thr Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro
85 90 95
Met Tyr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1350
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 105 HC variable region
<400> 1350
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Glu Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1351
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 106 LC variable region
<400> 1351
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Arg Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1352
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 106 HC variable region
<400> 1352
Gln Ile Thr Leu Lys Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Gly Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser
100 105 110
Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1353
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 107 LC variable region
<400> 1353
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1354
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 107 HC variable region
<400> 1354
Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Pro Arg Gly Tyr Ser Gly Tyr Gly Ser Asn Trp Tyr Phe Asp
100 105 110
Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1355
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 108 LC variable region
<400> 1355
Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe
20 25 30
Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro
85 90 95
Ala Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1356
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 108 HC variable region
<400> 1356
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1357
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 109 LC variable region
<400> 1357
Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Thr Gln Asn Ile Asn Thr Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Gln Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Thr Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Val Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Arg Ser Tyr Ser Thr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1358
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 109 HC variable region
<400> 1358
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Pro Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Ala Leu Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ala Thr Tyr Gly Ser Tyr Tyr Tyr Gly Met Asp Ala Trp Gly
100 105 110
Leu Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1359
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 110 LC variable region
<400> 1359
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1360
<211> 115
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 110 HC variable region
<400> 1360
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Tyr Ala Leu Asn Pro Trp Gly Gln Gly Thr Leu Val Thr
100 105 110
Val Ser Ser
115
<210> 1361
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 111 LC variable region
<400> 1361
Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1362
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 111 HC variable region
<400> 1362
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1363
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 112 LC variable region
<400> 1363
Glu Leu Val Val Thr Gln Pro Pro Pro Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1364
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 112 HC variable region
<400> 1364
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1365
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 113 LC variable region
<400> 1365
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Ser Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1366
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 113 HC variable region
<400> 1366
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1367
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 114 LC variable region
<400> 1367
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Arg
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1368
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 114 HC variable region
<400> 1368
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1369
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 115 LC variable region
<400> 1369
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Tyr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1370
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 115 HC variable region
<400> 1370
Glu Val Gln Leu Met Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1371
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 116 LC variable region
<400> 1371
Glu Leu Val Met Thr Gln Ser Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 1372
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 116 HC variable region
<400> 1372
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Ser Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1373
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 117 LC variable region
<400> 1373
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1374
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 117 HC variable region
<400> 1374
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr
20 25 30
Ala Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1375
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 118 LC variable region
<400> 1375
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Ser Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1376
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 118 HC variable region
<400> 1376
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1377
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 119 LC variable region
<400> 1377
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Val Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Arg Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Thr Ser Leu
85 90 95
Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1378
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 119 HC variable region
<400> 1378
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1379
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 120 LC variable region
<400> 1379
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Gln Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Thr Ser Leu
85 90 95
Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1380
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 120 HC variable region
<400> 1380
Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1381
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 121 LC variable region
<400> 1381
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Arg Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Val Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1382
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 121 HC variable region
<400> 1382
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Asp His Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 1383
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 122 LC variable region
<400> 1383
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Thr Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1384
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 122 HC variable region
<400> 1384
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly
100 105 110
Ile Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1385
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 123 LC variable region
<400> 1385
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15
Thr Ala Arg Ile Thr Cys Ser Gly Asp Val Leu Ala Lys Lys Tyr Ala
20 25 30
Arg Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
35 40 45
Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Ala Gln Val Glu
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Ala Ala Asp Asn Asn Gly Val
85 90 95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<210> 1386
<211> 127
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 123 HC variable region
<400> 1386
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asp
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ala Thr Tyr Asp Ser Ser Gly Arg Pro Thr Gly Asp Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1387
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 124 LC variable region
<400> 1387
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro
85 90 95
Arg Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1388
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 124 HC variable region
<400> 1388
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Thr Gly Tyr Asp Gly Ser Gly Tyr Tyr Gln Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1389
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 125 LC variable region
<400> 1389
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1390
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 125 HC variable region
<400> 1390
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Gly Arg Tyr Tyr Ser Ser Trp Tyr Gly Pro Arg Thr Trp Phe Asp
100 105 110
Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1391
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 126 LC variable region
<400> 1391
Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Tyr
20 25 30
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln Arg Ser Asn Trp Pro Pro
85 90 95
Ala Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1392
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 126 HC variable region
<400> 1392
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ala Ser Gly Tyr Asp Ser Ser Gly Tyr Tyr Ser Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1393
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 127 LC variable region
<400> 1393
Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro
85 90 95
Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1394
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 127 HC variable region
<400> 1394
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr His Cys
85 90 95
Val Arg Val Gly Thr Tyr Asp Ser Ser Gly Tyr Ser Phe Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1395
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 128 LC variable region
<400> 1395
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1396
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 128 HC variable region
<400> 1396
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr
20 25 30
Ala Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1397
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 129 LC variable region
<400> 1397
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asp Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Asp Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Ala Pro Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1398
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 129 HC variable region
<400> 1398
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Pro Arg Gly Gly Asn Tyr Arg Gly Ala Leu Asp Ile Trp Gly
100 105 110
Gln Gly Thr Met Val Thr Val Ser Ser
115 120
<210> 1399
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 130 LC variable region
<400> 1399
Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Val Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro
85 90 95
Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1400
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 130 HC variable region
<400> 1400
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Ala Met Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Pro Thr Gly Trp Tyr Ser Gly Tyr Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1401
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 131 LC variable region
<400> 1401
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr
20 25 30
Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1402
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 131 HC variable region
<400> 1402
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Met Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Pro Asp Asp Ser Ser Gly Tyr Tyr Pro Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1403
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 132 LC variable region
<400> 1403
Glu Leu Lys Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Ser
85 90 95
Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1404
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 132 HC variable region
<400> 1404
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Ser Pro Ala Val Thr Thr Ala Gly Trp Phe Asp Pro Cys Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1405
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 133 LC variable region
<400> 1405
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Asp
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Arg Gly Asp Ile Gly Ala Tyr
20 25 30
Asp Gly Val Ser Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu
35 40 45
Ile Ile Tyr Ala Val Thr Gln Arg Pro Ser Gly Ile Ser Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1406
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 133 HC variable region
<400> 1406
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu
20 25 30
Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ile Ser Pro Ala Ile Ile Arg Val Asp Trp Phe Asp Pro Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1407
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 134 LC variable region
<400> 1407
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Asp
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Arg Gly Asp Ile Gly Ala Tyr
20 25 30
Asp Gly Val Ser Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu
35 40 45
Ile Ile Tyr Ala Val Thr Gln Arg Pro Ser Gly Ile Ser Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1408
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 134 HC variable region
<400> 1408
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1409
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 135 LC variable region
<400> 1409
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Ser Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu
100 105 110
<210> 1410
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 135 HC variable region
<400> 1410
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp
100 105 110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1411
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 136 LC variable region
<400> 1411
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Lys Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Pro Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu
100 105 110
<210> 1412
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 136 HC variable region
<400> 1412
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp
100 105 110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1413
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 137 LC variable region
<400> 1413
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Thr Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1414
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 137 HC variable region
<400> 1414
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Phe Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp
100 105 110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1415
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 138 LC variable region
<400> 1415
Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Thr Asp Ile Gly Arg Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Tyr Ala Phe Gly Thr Gly Thr Lys Val Asp Ile Lys
100 105 110
<210> 1416
<211> 123
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 138 HC variable region
<400> 1416
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Val
20 25 30
Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ser Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Gly Pro Val Leu Gly Leu Ser Lys Trp Leu Glu Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1417
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 139 LC variable region
<400> 1417
Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Val Asp Ile Lys
100 105 110
<210> 1418
<211> 123
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 139 HC variable region
<400> 1418
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Val
20 25 30
Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ser Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Gly Pro Val Leu Gly Leu Ser Lys Trp Leu Glu Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1419
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 140 LC variable region
<400> 1419
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1420
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 140 HC variable region
<400> 1420
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1421
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 141 LC variable region
<400> 1421
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Glu Ala Trp Asp Ser Ser Leu
85 90 95
Ser Ala Val Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1422
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 141 HC variable region
<400> 1422
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1423
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 142 LC variable region
<400> 1423
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Thr Ser Leu
85 90 95
Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1424
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 142 HC variable region
<400> 1424
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1425
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 143 LC variable region
<400> 1425
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1426
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 143 HC variable region
<400> 1426
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1427
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 144 LC variable region
<400> 1427
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Arg
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1428
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 144 HC variable region
<400> 1428
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1429
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 145 LC variable region
<400> 1429
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1430
<211> 128
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 145 HC variable region
<400> 1430
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Asn Tyr
20 25 30
Val Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Ile Pro Val Phe Gly Ile Ala Asp Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Leu Phe Asp Trp Leu Leu Pro Arg Ser Arg His Arg
100 105 110
Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1431
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 146 LC variable region
<400> 1431
Glu Leu Gly Gln Thr Gln Gln Leu Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1432
<211> 126
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 146 HC variable region
<400> 1432
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser
100 105 110
Tyr Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1433
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 147 LC variable region
<400> 1433
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Gly Ser Asn Ile Gly Ser Asn
20 25 30
Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Arg Asn Ser Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Ser Gly Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu
100 105 110
<210> 1434
<211> 126
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 147 HC variable region
<400> 1434
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser
100 105 110
Tyr Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1435
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 148 LC variable region
<400> 1435
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Arg Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1436
<211> 127
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 148 HC variable region
<400> 1436
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu
20 25 30
Pro Ile His Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Arg Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Asn Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Asp Leu Thr Thr Val Thr Asn Pro Leu Asn Tyr Tyr Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
<210> 1437
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 149 LC variable region
<400> 1437
Glu Leu Glu Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn
20 25 30
Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Arg Asn Ser Gln Arg Pro Ser Gly Val Pro Ala Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Val Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Ser Gly Trp Met Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1438
<211> 125
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 149 HC variable region
<400> 1438
Gln Val Gln Leu Val Gln Ser Gly Ala Asp Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr
20 25 30
Gly Thr Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Glu Asn Ser Thr His Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ala Leu Arg Tyr Asp Ile Leu Thr Gly Phe Thr Gly Phe
100 105 110
Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120 125
<210> 1439
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 150 LC variable region
<400> 1439
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Ser Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1440
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 150 HC variable region
<400> 1440
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Asp Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Thr Lys Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1441
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 151 LC variable region
<400> 1441
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu
65 70 75 80
Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser
85 90 95
Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1442
<211> 125
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 151 HC variable region
<400> 1442
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Thr Tyr Tyr Tyr Asp Ser Ser Gly Pro Leu Asn Trp Phe
100 105 110
Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1443
<211> 103
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 152 LC variable region
<400> 1443
Glu Leu Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Ser Leu Ser Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Leu Thr Phe Gly Gly
85 90 95
Gly Thr Lys Val Glu Ile Lys
100
<210> 1444
<211> 126
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 152 HC variable region
<400> 1444
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Phe Leu Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Arg Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Thr Gly Lys Pro Tyr Tyr Cys Thr Gly Ser Thr Cys Tyr Gln Pro
100 105 110
Leu Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1445
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 153 LC variable region
<400> 1445
Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys
100 105
<210> 1446
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 153 HC variable region
<400> 1446
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
20 25 30
Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 1447
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 154 LC variable region
<400> 1447
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Asp Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Gly Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1448
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 154 HC variable region
<400> 1448
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu
20 25 30
Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Gly Phe Asp Pro Glu Asn Gly Glu Thr Ile His Ala Gln Arg Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Thr Ser Thr Pro Met Ile Arg Ala Ser Trp Phe Asp Pro Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1449
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 155 LC variable region
<400> 1449
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Tyr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Phe Cys Ala Thr Trp Asp Asp Ser Leu
85 90 95
Asn Gly Gln Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1450
<211> 115
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 155 HC variable region
<400> 1450
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Asn Ile Lys Glu Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Tyr Ser Gly Asn Phe Trp Gly Gln Gly Thr Leu Val Thr
100 105 110
Val Ser Ser
115
<210> 1451
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 156 LC variable region
<400> 1451
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1452
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 156 HC variable region
<400> 1452
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ile Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1453
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 157 LC variable region
<400> 1453
Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Arg Asn
20 25 30
Tyr Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Asp Ala Ser Thr Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1454
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 157 HC variable region
<400> 1454
Gln Ile Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1455
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 158 LC variable region
<400> 1455
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys His Gln Tyr Gly Thr Ser Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
<210> 1456
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 158 HC variable region
<400> 1456
Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1457
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 159 LC variable region
<400> 1457
Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys
100 105
<210> 1458
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 159 HC variable region
<400> 1458
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Gly
20 25 30
Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1459
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 160 LC variable region
<400> 1459
Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1460
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 160 HC variable region
<400> 1460
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1461
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 161 LC variable region
<400> 1461
Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Tyr
20 25 30
Ser Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr His Thr Ser Pro Ile
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1462
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 161 HC variable region
<400> 1462
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1463
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 162 LC variable region
<400> 1463
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ile
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 1464
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 162 HC variable region
<400> 1464
Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser
115 120 125
Ser
<210> 1465
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 163 LC variable region
<400> 1465
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asn Val Gly Asp Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Thr Asn Arg Pro Ser Gly Val Ser Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Gly
85 90 95
Ser Thr Pro Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1466
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 163 HC variable region
<400> 1466
Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1467
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 164 LC variable region
<400> 1467
Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1468
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 164 HC variable region
<400> 1468
Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1469
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 165 LC variable region
<400> 1469
Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1470
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 165 HC variable region
<400> 1470
Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1471
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 166 LC variable region
<400> 1471
Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 1472
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 166 HC variable region
<400> 1472
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1473
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 167 LC variable region
<400> 1473
Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Met
35 40 45
Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 1474
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 167 HC variable region
<400> 1474
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1475
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 168 LC variable region
<400> 1475
Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Gly Ser Ser Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
<210> 1476
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 168 HC variable region
<400> 1476
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser
100 105 110
Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
115 120 125
Ser
<210> 1477
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 169 LC variable region
<400> 1477
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Ser Gly Lys Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu
100 105 110
<210> 1478
<211> 131
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 169 HC variable region
<400> 1478
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp
100 105 110
Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
115 120 125
Val Ser Ser
130
<210> 1479
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 170 LC variable region
<400> 1479
Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu
85 90 95
Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1480
<211> 131
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 170 HC variable region
<400> 1480
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp
100 105 110
Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
115 120 125
Val Ser Ser
130
<210> 1481
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 171 LC variable region
<400> 1481
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Gly Val Thr Ile Ser Cys Ser Gly Leu Thr Ser Asn Ile Gly Ser Asn
20 25 30
Phe Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Arg Asn Asn Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Gly Glu Tyr Phe Cys Ala Ala Trp Asp Asp Thr Leu
85 90 95
Val Gly Arg Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1482
<211> 131
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 171 HC variable region
<400> 1482
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp
100 105 110
Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
115 120 125
Val Pro Ser
130
<210> 1483
<211> 109
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 172 LC variable region
<400> 1483
Glu Leu Val Val Thr Gln Glu Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Ser Gly Pro Val Phe Gly Gly Thr Gln Leu Thr Val Leu
100 105
<210> 1484
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 172 HC variable region
<400> 1484
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His
20 25 30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1485
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 173 LC variable region
<400> 1485
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1486
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 173 HC variable region
<400> 1486
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His
20 25 30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1487
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 174 LC variable region
<400> 1487
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1488
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 174 HC variable region
<400> 1488
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Ser Ser Gly Tyr Ser Phe Ile Ser Tyr
20 25 30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Glu Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Phe Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1489
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 175 LC variable region
<400> 1489
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly His Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu
100 105 110
<210> 1490
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 175 HC variable region
<400> 1490
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ile Ser Tyr
20 25 30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Glu Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Phe Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1491
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 176 LC variable region
<400> 1491
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1492
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 176 HC variable region
<400> 1492
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His
20 25 30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1493
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 177 LC variable region
<400> 1493
Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
<210> 1494
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 177 HC variable region
<400> 1494
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1495
<211> 107
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 178 LC variable region
<400> 1495
Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Ser
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu
35 40 45
Tyr Ala Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
<210> 1496
<211> 122
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 178 HC variable region
<400> 1496
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1497
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 179 LC variable region
<400> 1497
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Ser Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1498
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 179 HC variable region
<400> 1498
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Asn
20 25 30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Thr Tyr Gly Ser Gly Ser Tyr Ser Asp Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1499
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 180 LC variable region
<400> 1499
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1500
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 180 HC variable region
<400> 1500
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Asn
20 25 30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Thr Tyr Gly Ser Gly Ser Tyr Ser Asp Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1501
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 181 LC variable region
<400> 1501
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Arg Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1502
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 181 HC variable region
<400> 1502
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro
100 105 110
Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser
115 120 125
Ser
<210> 1503
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 182 LC variable region
<400> 1503
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1504
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 182 HC variable region
<400> 1504
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro
100 105 110
Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser
115 120 125
Ser
<210> 1505
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 183 LC variable region
<400> 1505
Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Met Gln Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1506
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 183 HC variable region
<400> 1506
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Asn Tyr
20 25 30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Tyr Asp Ser Asp Thr Arg Lys Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Met Ser Ala Asp Lys Ser Ile Thr Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Thr Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Gln Asp Ser Gly Thr Tyr Gly Trp Ile Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1507
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 184 LC variable region
<400> 1507
Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys
1 5 10 15
Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn
20 25 30
Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val
35 40 45
Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly
65 70 75 80
Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser
85 90 95
Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1508
<211> 120
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 184 HC variable region
<400> 1508
Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Asn Phe Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe
85 90 95
Cys Ala Arg Gln Glu Trp Leu Arg Gly Gly Phe Asp Asp Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1509
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 185 LC variable region
<400> 1509
Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn
20 25 30
Ile Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Ala Trp Val Phe Gly Gly Gly Thr Lys Val Asp Ile Lys
100 105 110
<210> 1510
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 185 HC variable region
<400> 1510
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Asn His
20 25 30
Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Tyr Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Val Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Asn Pro Thr Val Thr Asn Trp Phe Asp Ser Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 1511
<211> 113
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 186 LC variable region
<400> 1511
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Pro Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val
100 105 110
Leu
<210> 1512
<211> 129
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 186 HC variable region
<400> 1512
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Phe Phe Gly Thr Ser Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Val Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gln Phe Ser Asp Ser Ser Gly Tyr Gln His Pro Tyr Tyr
100 105 110
Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
115 120 125
Ser
<210> 1513
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 187 LC variable region
<400> 1513
Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1514
<211> 127
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 187 HC variable region
<400> 1514
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr His
20 25 30
Ala Leu Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Pro Ala Asp Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Leu Ser Leu Gly Phe Cys Ser Ala Gly Ser Cys Tyr Asp
100 105 110
Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 1515
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 188 LC variable region
<400> 1515
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asp Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110
<210> 1516
<211> 133
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 188 HC variable region
<400> 1516
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr
20 25 30
Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Arg Tyr Pro Gly Tyr Tyr Asp Ile Leu Thr Gly Gln Ile
100 105 110
Gly Thr Gly Glu Arg Asn Ala Met Asp Val Trp Gly Gln Gly Thr Thr
115 120 125
Val Thr Val Ser Ser
130
<210> 1517
<211> 111
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 189 LC variable region
<400> 1517
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 1518
<211> 124
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 189 HC variable region
<400> 1518
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Asn Tyr
20 25 30
Pro Leu Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Gly Ile Ile Pro Ile Ile Gly Ala Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Phe
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp
100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 1519
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 190 LC variable region
<400> 1519
Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys
1 5 10 15
Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
35 40 45
Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His
85 90 95
Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105
<210> 1520
<211> 121
<212> PRT
<213> Artificial Sequence
<220>
<223> No. 190 HC variable region
<400> 1520
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Phe Ile Asn Pro Ser Asp Val Thr Thr Tyr Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys
85 90 95
Ala Arg Ser Arg Ile Ala Pro Thr Glu Asp Phe Phe Asp Tyr Trp Gly
100 105 110
Gln Gly Ser Leu Val Thr Val Ser Ser
115 120
Claims (21)
- 코로나바이러스(Coronavirus) 표면의 스파이크 단백질(Spike protein, S protein)에 결합하는 중화 결합 분자.
- 제1항에 있어서,
상기 코로나바이러스는 사스-코로나바이러스-2(SARS-CoV-2), 사스-코로나바이러스(SARS-CoV) 및 중동호흡기증후군 코로나바이러스(MERS-CoV)로 이루어진 군으로부터 선택되는 어느 하나 이상임을 특징으로 하는, 결합 분자.
- 제1항에 있어서,
상기 코로나바이러스는
i) 사스-코로나바이러스-2(SARS-CoV-2) 및 사스-코로나바이러스(SARS-CoV);
ii) 사스-코로나바이러스-2(SARS-CoV-2) 및 중동호흡기증후군 코로나바이러스(MERS-CoV); 또는
iii) 사스-코로나바이러스-2(SARS-CoV-2), 사스-코로나바이러스(SARS-CoV) 및 중동호흡기증후군 코로나바이러스(MERS-CoV)
임을 특징으로 하는, 결합 분자.
- 제1항에 있어서,
상기 결합 분자는 표 1의 결합 분자로 이루어진 군으로부터 선택되는 어느 하나임을 특징으로 하는, 결합 분자.
- 제1항에 있어서,
상기 결합 분자는 표 2의 결합 분자로 이루어진 군으로부터 선택되는 어느 하나임을 특징으로 하는, 결합 분자.
- 제1항 내지 제5항 중 어느 한 항에 있어서,
상기 결합 분자는 scFv 절편, scFv-Fc 절편, Fab 절편, Fv 절편, 디아바디(diabody), 키메라 항체, 인간화 항체 또는 인간 항체임을 특징으로 하는, 결합 분자.
- 제1항 내지 제5항 중 어느 한 항에 있어서,
상기 결합 분자는 사스-코로나바이러스-2의 스파이크 단백질에 돌연변이가 생긴 변이 바이러스에 중화능이 있음을 특징으로 하는, 결합 분자.
- 제1항 내지 제5항 중 어느 한 항에 있어서,
상기 결합 분자는 사스-코로나바이러스-2 S형, L형, V형, G형, GH형 또는 GR형에 중화능이 있음을 특징으로 하는, 결합 분자.
- 제1항 내지 제5항 중 어느 한 항에 있어서,
상기 결합 분자는 하기 1) 내지 20)으로 이루어진 군으로부터 선택되는 어느 하나 이상의 변이 바이러스에 중화능이 있음을 특징으로 하는, 결합 분자:
1) 사스-코로나바이러스-2의 스파이크 단백질의 614번 아미노산 위치에서 A222V 변이가 생긴 변이 바이러스;
2) 사스-코로나바이러스-2의 스파이크 단백질의 234번 아미노산 위치에서 N234Q 변이가 생긴 변이 바이러스;
3) 사스-코로나바이러스-2의 스파이크 단백질의 406번 아미노산 위치에서 E406Q 변이가 생긴 변이 바이러스;
4) 사스-코로나바이러스-2의 스파이크 단백질의 439번 아미노산 위치에서 N439K 변이가 생긴 변이 바이러스;
5) 사스-코로나바이러스-2의 스파이크 단백질의 444번 아미노산 위치에서 K444Q 변이가 생긴 변이 바이러스;
6) 사스-코로나바이러스-2의 스파이크 단백질의 445번 아미노산 위치에서 V445A 변이가 생긴 변이 바이러스;
7) 사스-코로나바이러스-2의 스파이크 단백질의 449번 아미노산 위치에서 Y449N 변이가 생긴 변이 바이러스;
8) 사스-코로나바이러스-2의 스파이크 단백질의 452번 아미노산 위치에서 L452R 변이가 생긴 변이 바이러스;
9) 사스-코로나바이러스-2의 스파이크 단백질의 453번 아미노산 위치에서 Y453F 변이가 생긴 변이 바이러스;
10) 사스-코로나바이러스-2의 스파이크 단백질의 455번 아미노산 위치에서 L455F 변이가 생긴 변이 바이러스;
11) 사스-코로나바이러스-2의 스파이크 단백질의 456번 아미노산 위치에서 F456L 변이가 생긴 변이 바이러스;
12) 사스-코로나바이러스-2의 스파이크 단백질의 475번 아미노산 위치에서 A475V 변이가 생긴 변이 바이러스;
13) 사스-코로나바이러스-2의 스파이크 단백질의 477번 아미노산 위치에서 S477N 변이가 생긴 변이 바이러스;
14) 사스-코로나바이러스-2의 스파이크 단백질의 484번 아미노산 위치에서 E484K 변이가 생긴 변이 바이러스;
15) 사스-코로나바이러스-2의 스파이크 단백질의 490번 아미노산 위치에서 F490S 변이가 생긴 변이 바이러스;
16) 사스-코로나바이러스-2의 스파이크 단백질의 493번 아미노산 위치에서 Q493K 변이가 생긴 변이 바이러스;
17) 사스-코로나바이러스-2의 스파이크 단백질의 494번 아미노산 위치에서 S494P 변이가 생긴 변이 바이러스;
18) 사스-코로나바이러스-2의 스파이크 단백질의 614번 아미노산 위치에서 D614G 변이가 생긴 변이 바이러스;
19) 사스-코로나바이러스-2의 스파이크 단백질의 685번 아미노산 위치에서 R685H 변이가 생긴 변이 바이러스; 및
20) 사스-코로나바이러스-2의 스파이크 단백질의 1176번 아미노산 위치에서 V1176F 변이가 생긴 변이 바이러스.
- 제1항 내지 제5항 중 어느 한 항의 결합 분자에 추가적으로 하나 이상의 태그가 결합된 이뮤노컨쥬게이트.
- 제1항 내지 제5항 중 어느 한 항의 결합 분자를 암호화하는 핵산 분자.
- 제11항의 핵산 분자가 삽입된 발현 벡터.
- 제12항의 발현 벡터로 형질전환된 세포주.
- 제13항에 있어서,
상기 세포주는 CHO 세포, F2N 세포, COS 세포, BHK 세포, 바우스(Bowes) 흑색종 세포, HeLa 세포, 911 세포, HT1080 세포, A549 세포, HEK 293 세포 및 HEK293T 세포로 이루어진 군으로부터 선택된 어느 하나임을 특징으로 하는 세포주.
- 제1항 내지 제5항 중 어느 한 항의 결합 분자를 포함하는, 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료용 조성물.
- 제15항에 있어서,
상기 코로나바이러스로 인하여 발생하는 질환은 코로나바이러스 감염증 2019 (COVID-19), 중증 급성 호흡기 증후군 (Severe acute respiratory syndrome), 또는 중동 호흡기 증후군 (Middle East Respiratory Syndrome)임을 특징으로 하는, 조성물.
- 제15항에 있어서,
상기 조성물은 멸균 주사용액, 동결건조(lyophilized) 제형, 사전 충전식 주사(pre-filled syringe) 용액제, 경구형 제형, 외용제 또는 좌제임을 특징으로 하는 조성물.
- 제1항 내지 제5항 중 어느 한 항의 결합 분자를 포함하는 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료용 키트.
- 제18항에 있어서,
상기 코로나바이러스로 인하여 발생하는 질환은 코로나바이러스 감염증 2019 (COVID-19), 중증 급성 호흡기 증후군 (Severe acute respiratory syndrome), 또는 중동 호흡기 증후군 (Middle East Respiratory Syndrome)임을 특징으로 하는, 키트.
- 코로나바이러스로 인하여 발생하는 질환을 가진 대상에 제15항 또는 제16항의 조성물을 치료학적으로 유효한 양으로 투여하는 단계를 포함하는, 코로나바이러스로 인하여 발생하는 질환의 진단, 예방 또는 치료 방법.
- 제20항에 있어서,
상기 코로나바이러스로 인하여 발생하는 질환은 코로나바이러스 감염증 2019 (COVID-19), 중증 급성 호흡기 증후군 (Severe acute respiratory syndrome), 또는 중동 호흡기 증후군 (Middle East Respiratory Syndrome)임을 특징으로 하는, 진단, 예방 또는 치료 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210097373A KR20220013344A (ko) | 2020-07-24 | 2021-07-23 | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 |
EP21845495.7A EP4186922A1 (en) | 2020-07-24 | 2021-07-23 | Binding molecule having neutralizing activity against coronavirus superfamily |
PCT/KR2021/009567 WO2022019711A1 (ko) | 2020-07-24 | 2021-07-23 | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 |
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200092285 | 2020-07-24 | ||
KR1020200092285 | 2020-07-24 | ||
KR1020200116817 | 2020-09-11 | ||
KR20200116817 | 2020-09-11 | ||
KR1020200152158A KR20220013287A (ko) | 2020-07-24 | 2020-11-13 | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 |
KR1020200152158 | 2020-11-13 | ||
KR1020200171999 | 2020-12-10 | ||
KR1020200171999A KR20220013289A (ko) | 2020-07-24 | 2020-12-10 | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 |
KR1020210019481 | 2021-02-10 | ||
KR1020210019481A KR20220013297A (ko) | 2020-07-24 | 2021-02-10 | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 |
KR1020210036902A KR20220013302A (ko) | 2020-07-24 | 2021-03-22 | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 |
KR1020210036902 | 2021-03-22 | ||
KR1020210041251 | 2021-03-30 | ||
KR1020210041251A KR20220013303A (ko) | 2020-07-24 | 2021-03-30 | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220013311A true KR20220013311A (ko) | 2022-02-04 |
Family
ID=80268220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210075095A KR20220013311A (ko) | 2020-07-24 | 2021-06-09 | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20220013311A (ko) |
-
2021
- 2021-06-09 KR KR1020210075095A patent/KR20220013311A/ko unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102205028B1 (ko) | 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자 | |
KR102229225B1 (ko) | 사스-코로나바이러스-2 표면의 스파이크 단백질에 결합하는 사스-코로나바이러스 감염증의 진단용 결합 분자 | |
US11345741B2 (en) | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
EP1476468B9 (en) | Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity | |
IL183723A (en) | Molecular-binding molecules that can neutralize West Nile virus, and their uses | |
US20230279079A1 (en) | Novel monoclonal antibodies against sars-cov-2 and uses thereof | |
WO2013043125A1 (en) | Enterovirus 71 specific antibodies and uses thereof | |
KR20220012810A (ko) | 사스-코로나바이러스-2 s 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자 | |
KR20220012826A (ko) | 사스-코로나바이러스-2 스파이크 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자 | |
US20220177552A1 (en) | Binding Molecule Having Neutralizing Activity Against Middle East Respiratory Syndrome-Coronavirus | |
KR20220136945A (ko) | 사스-코로나바이러스-2 스파이크 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자 | |
TW202140542A (zh) | 重組抗體、包含該重組抗體之套組、以及其用途 | |
KR20220012800A (ko) | 사스-코로나바이러스-2 s 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자 | |
KR20220013311A (ko) | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 | |
KR20220013303A (ko) | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 | |
Cao et al. | Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies | |
KR20220013302A (ko) | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 | |
KR20220013297A (ko) | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 | |
EP4186922A1 (en) | Binding molecule having neutralizing activity against coronavirus superfamily | |
KR20220013289A (ko) | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 | |
KR20220013287A (ko) | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 | |
KR20210118350A (ko) | 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자 | |
KR20210118344A (ko) | 사스-코로나바이러스-2 결합 분자 | |
KR20220012771A (ko) | 사스-코로나바이러스-2 s 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자 | |
KR20220012792A (ko) | 사스-코로나바이러스-2 s 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자 |